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Abstract 
As an obligate intracellular parasite, human adenovirus (HAdV) must utilize host factors 
for survival and replication.  Early during infection, its multifunctional E1A protein 
interacts with an impressive range of cellular target proteins to exert control over the 
cellular environment.  Through these virus-host interactions, E1A massively reprograms 
both viral and cellular transcription to activate the other HAdV genes, downregulate the 
host’s immune response, and induce the cell cycle.  Consequently, E1A converts the 
infected cell into a compliant state more amenable for HAdV replication, resulting from 
its numerous protein-protein interactions.  I sought to examine E1A’s interaction with 
cellular protein kinase A (PKA), a well-studied component of host cAMP signaling that 
plays a critical role in cellular transcription.  While characterizing the molecular 
determinants of the E1A-PKA interaction, I showed that E1A uses mimicry of cellular A-
kinase anchoring proteins (AKAPs) to usurp PKA for the benefit of HAdV.  This 
mechanism allowed E1A to outcompete endogenous AKAPs and induce an E1A-
mediated relocalization of PKA into the nucleus of infected cells.  Here, PKA was 
recruited to viral gene promoters.  This ultimately resulted in increased viral transcription 
from these loci as well as enhanced protein synthesis and higher levels of viral 
replication.  This mechanism of mimicry was conserved in E1A proteins across various, 
distinct species of HAdV, indicating its evolutionary importance.  Interestingly, different 
E1A proteins displayed a preference for manipulating one type of PKA isoform over 
another.  Despite mechanistic differences, all species of HAdV that commandeered PKA 
via their E1A proteins required this action for wild-type levels of both viral genome 
replication and infectious progeny production.  Additionally, these E1A proteins could 
induce transcription from a cAMP- and PKA-regulated reporter gene suggesting that this 
interaction may modulate host genes in a manner similar to viral ones.  Together, these 
studies show that manipulation of PKA by E1A is a conserved feature of diverse HAdVs.  
This allows these viruses to subvert cellular cAMP signaling and use a host factor to 
enhance multiple aspects of their replication cycles.  Furthermore, this mechanistically 
demonstrates HAdV E1A as the first known viral AKAP – a unique form of viral 
mimicry. 
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Chapter 1  
1 Introduction 
“Not explaining science seems to me perverse. When you're in love, you want to tell the 
world.” 
 – Carl Sagan 
1.1 General Introduction 
As obligate intracellular parasites, all viruses are critically dependent on their infected 
hosts for survival.  Due to physical constraints and limited coding capacity, no known 
viruses are capable of independently producing either their own protein or metabolic 
energy.  As a result of coevolution with their hosts, viruses have instead adapted to take 
advantage of machinery and factors from within the cell by engaging in a wide array of 
virus-host interactions (Rozenblatt-Rosen et al., 2012).  Infected cells will typically be 
drastically altered into environments more favourable for viral progeny production.  By 
teasing out the virus-host interactions that drive these changes, we gain greater 
understanding of not only viral pathogenesis, but also basic cellular functions such as 
gene expression, cell division, or immunological responses (Ferrari et al., 2014, 2008; 
Fonseca et al., 2012; Miyake-Stoner and O’Shea, 2014; Shah and O’Shea, 2015; Soria et 
al., 2010). 
Human adenovirus (HAdV) has served as a prime example of the utility for using viruses 
to study the molecular biology of eukaryotic cells (Berk, 2005; Cohen et al., 2013; Pelka 
et al., 2008).  Scientific breakthroughs related to cell cycle control, DNA replication, 
mRNA splicing, gene expression, interferon (IFN) signaling, and cancer can all be 
attributed to studies involving HAdV (Bayley and Mymryk, 1994; Berget et al., 1977; 
Chow et al., 1977; Flint and Shenk, 1997; Gallimore and Turnell, 2001).  The virus was 
originally discovered and characterized in 1953 as a causative agent for respiratory 
infections (Hillerman and Werner, 1954; Rowe et al., 1953).  HAdVs are non-enveloped 
viruses containing a linear double-stranded DNA (dsDNA) genome of approximately 36 
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Figure 1.1.  Schematic representation of the HAdV-5 double-stranded DNA genome. 
The HAdV-5 genome is approximately 36kbp in length and composed of both early (E) 
and late (L) transcription units.  Arrows depict the directionality of individual transcripts 
with their protein products labelled accordingly.  Early genes are depicted in green while 
late genes are displayed in red.  VA RNA is shown in yellow.  Adapted from NCBI 
sequence NC_001405.1. 
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kilobase pairs (kbp) (Davison et al., 2003) (Figure 1.1).  There are at least 57 distinct 
HAdV types which are divided across 7 unique species (A-G) based on various biological 
properties (Aoki et al., 2011; Jones et al., 2007; Walsh et al., 2011) (Figure 1.2).  While 
broadly similar, these species have evolved molecular differences that confer specific 
tissue and organ tropisms including the respiratory tract, gastrointestinal tract, ocular 
tissue, and blood (Ghebremedhin, 2014).  Clinically, most HAdV infections result in mild 
symptoms that resolve without treatment; however, disease can occasionally progress 
beyond a subclinical presentation, especially in immunocompromised hosts (Lion, 2014). 
HAdVs are considered part of the genetically-distinct but functionally-similar family of 
DNA tumour viruses, which include other well-studied pathogens such as human 
papillomavirus (HPV) and polyomavirus (HPyV) (Howley and Livingston, 2009; Yaniv, 
2009).  All of these viruses can cause cancer in either animal or human systems (DiMaio 
and Fan, 2013).  Indeed, in 1962 HAdV type 12 was the first human virus ever shown to 
be tumourigenic, albeit in a rodent model (Trentin et al., 1962).  Research interest in the 
DNA tumour viruses exploded after this seminal discovery, with particular focus on the 
activities of the viral oncoproteins produced by these pathogens.  Although not all species 
of HAdV can cause tumours in rodents, all viruses tested can transform cells in tissue 
culture (Berk, 2013; Freeman et al., 1967; Gallimore, 1972; McBride and Wiener, 1964) 
(Figure 1.2).  Differences in pathogenicity and tumourigenicity between various HAdV 
types can largely be attributed to the radical changes to the cellular environment 
conferred by virus-host interactions.  For HAdV, its early region 1A (E1A) protein is 
largely responsible for these pathophysiological changes and is the primary focus of this 
thesis. 
1.2 Adenovirus 
1.2.1 Physical properties of adenoviruses 
Adenoviruses are composed of a non-enveloped, icosahedral protein capsid that houses a 
linear, dsDNA genome (Ginsberg et al., 1966; Russell, 2009).  The capsid shell ranges in 
size between 60-90 nm in diameter, depending on the species.  It consists of 252 
capsomeres, 240 of which are hexons while 12 are pentons.  Pentons form the base for a 
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protruding fiber protein and together these capsid components mediate attachment and 
entry of HAdV particles into targeted cells (Norrby, 1966; Norrby and Skaaret, 1967; San 
Martín, 2012).  For some HAdV species, the fiber interacts with the coxsakievirus and 
adenovirus receptor (CAR) which is commonly found on the surface of epithelial cells 
(Bergelson et al., 1997; Devaux et al., 1987; Roelvink et al., 1998; Tomko et al., 1997).  
This is followed by an interaction of the arginine-glycine-aspartic acid (RGD) motif in 
the penton base with cell surface integrins (αvβ3 and αvβ5 for HAdV-5), resulting in 
endocytic uptake of the viral particle (Meier and Greber, 2003; Wickham et al., 1993).  
Notably, not all HAdV bind CAR (species B and D HAdVs can bind cellular CD46 
instead) or contain an RGD motif, contributing to altered specificity for cellular receptors 
(Albinsson and Kidd, 1999; Gaggar et al., 2003; Lenman et al., 2015; Segerman et al., 
2003; Sirena et al., 2004; Wickham et al., 1995; Wu et al., 2004). 
The genomes of HAdVs are linear, dsDNA ranging in size between 30-36 kbp (Davison 
et al., 2003; Roberts et al., 1984) (Figure 1.1).  Genomic organization is highly conserved 
and contains inverted terminal repeats (ITRs) at each end, as well as a covalently-
attached 55 kilo Dalton (kDa) terminal protein (TP) which functions as a primer for viral 
genome replication (Challberg et al., 1980; Rekosh et al., 1977; Steenbergh et al., 1977).  
TP may also shield viral genomes from being recognized as free, damaged DNA by the 
host’s DNA damage response machinery (Karen et al., 2009; Stracker et al., 2002; 
Weitzman and Ornelles, 2005).  HAdV genomes have been assigned arbitrary 
directionality, the ‘left’ end of which contains repeats of cis-acting packaging sequences 
that direct proper packaging of viral DNA into infectious progeny virions (Gräble and 
Hearing, 1992; Hearing et al., 1987; Ostapchuk and Hearing, 2003).  Viral genes are 
encoded on both strands of the genome and are broadly separated into two classes, early 
or late (Berk, 2013; Fessler and Young, 1998; Tollefson et al., 2007).  Early genes are 
transcribed before the onset of viral genome replication and serve to reorganize the cell 
into a suitable environment for virus replication and suppress host immune responses.  
Late genes are expressed after viral genome replication and encode the structural proteins 
that make up the HAdV capsid.  Depending on the species, HAdVs also encode one or 
two virus-associated RNAs (VA RNA) (Reich et al., 1966; Weinmann et al., 1974).  
These do not encode for viral proteins but instead act to antagonize the host’s IFN-
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Figure 1.2.  Classification and properties of HAdV species. 
Human adenoviruses are separated into 7 distinct species comprising over 50 unique 
types based on sequence similarity of their variable hexon epitopes.  Various 
characteristics are shown here, including hemagglutination group, tumourigenicity, 
transformation in tissue culture, percent of G-C in genome, and tissue tropisms.  Figure 
adapted from Field’s Virology, 7th edition with additional information from 
(Ghebremedhin, 2014). 
6 
 
 
induced activation of protein kinase R (PKR) (Andersson et al., 2005; Reichel et al., 
1985.; Schneider et al., 1984).  Both early and late HAdV transcripts are produced by the 
host RNA polymerase II (RNAPII) with the exception of VA RNA (transcribed by 
RNAPIII) (Mathews and Shenk, 1991; Weinmann et al., 1974). 
1.2.2 HAdV life cycle 
Internalization of HAdV occurs after viral attachment to a host cell receptor via the knob 
of the fiber protein (Devaux et al., 1987).  Following binding of the RGD sequence 
within the penton base to αvβ3 and αvβ5 integrins, receptor-mediated endocytosis ensues 
(Meier and Greber, 2003; Wickham et al., 1993).  Acidification of the endosome causes 
partial disassembly of the viral capsid and release of the core viral particle into the 
cytosol through an undefined mechanism (Greber et al., 1993; Mellman, 1992; Svensson, 
1985; Varga et al., 1991).  Partially-uncoated virions are subsequently trafficked to the 
nucleus via an interaction between hexon and the host microtubule network (Dales and 
Chardonnet, 1973; Leopold et al., 2000; Mabit et al., 2002).  At nuclear pore complexes 
(NPC), final uncoating occurs, allowing viral DNA bound by HAdV protein VII to be 
actively transported into the nucleus (Greber et al., 1997, 1996; Karen and Hearing, 2011; 
Spector et al., 2003).  The attachment, entry, and subcellular trafficking phase of HAdV 
infection is rapid, taking place in under two hours (Martin-Fernandez et al., 2004; 
Trotman et al., 2001).  In the nucleus, the viral genome becomes decorated by cellular 
histones and the transcription of early genes begins (Chen et al., 2007; Komatsu et al., 
2011; Trotman et al., 2001).  It is this early transcriptional phase of the viral life cycle 
that is a molecular focus of the thesis and will be discussed in more detail in subsequent 
sections. 
As HAdV gene products encoding viral genome replication machinery accumulate, the 
infection enters its late phase (Berk, 2013; Nevins et al., 1979).  This can begin as soon as 
six hours post-infection, depending on the type of infected cells and multiplicity of 
infection (MOI).  The ITRs of the HAdV genome serve as the origin of replication for the 
virally-encoded DNA polymerase (Lechner and Kelly, 1977).  New genomes are 
replicated via a strand-displacement mechanism not involving Okazaki fragments as 
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present in cellular DNA replication intermediates.  This is concomitant with the 
production of viral capsid proteins and the assembly of capsomeres in the cytoplasm 
(Horwitz et al., 1969; Velicer and Ginsberg, 1970).  These are subsequently transported 
into the nucleus where the assembly of progeny virions occurs.  An association between 
the HAdV late proteins and the packaging signal in newly-synthesized genomes 
facilitates the assembly of infectious particles (Daniell, 1976; Hearing et al., 1987; 
Ostapchuk and Hearing, 2005).  Final release of potentially 10,000 – 100,000 mature 
HAdV progeny occurs as the infected cell lyses (Green and Daesch, 1961; Tollefson et 
al., 1996a). 
1.2.3 HAdV transcripts 
Once an incoming viral genome reaches the cell nucleus, the first gene transcribed is the 
early region 1A gene (E1A), driven by a strong enhancer upstream of the E1A promoter 
(Hearing and Shenk, 1983; Nevins et al., 1979) (Figure 1.1).  E1A is the main focus of 
this thesis and will be discussed later in more detail.  Briefly, E1A performs key 
functions that suppress the cell’s immune response, push the infected cell into S-phase, 
and drive expression of other HAdV genes (Bayley and Mymryk, 1994; Berk, 2005; 
Ferrari et al., 2014, 2008; Flint and Shenk, 1997; Fonseca et al., 2012; Gallimore and 
Turnell, 2001; Pelka et al., 2008; Schaack et al., 2004).  Transcription of the other early 
genes follows closely after E1A and includes E1B, E2, E3, and E4.  The rest of the late 
proteins are encoded mainly by the Major Late transcription unit (Ahi and Mittal, 2016; 
Shaw and Ziff, 1980; Tollefson et al., 2007).  Most HAdV transcripts undergo extensive 
splicing, increasing the potential number of protein products upon translation (Berget et 
al., 1977; Berk, 2013). 
Along with E1A, the E1 region of HAdV-5 includes the E1B gene encoding for two 
proteins named for their molecular weights: E1B-55k and E1B-19k, both of which are 
anti-apoptotic (Cuconati and White, 2002; Yew and Berk, 1992).  E1B-55k functions as 
an E3 ubiquitin-ligase complex promoting the ubiquitination and subsequent degradation 
of the p53 tumour suppressor (Blanchette et al., 2004; Harada et al., 2002; Querido et al., 
2001).  E1B-19k functions as a viral mimic of cellular Bcl-2 by binding to BAK and 
BAX, blocking apoptosis via the release of mitochondrial cytochrome-c (Chiou et al., 
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1994; Farrow et al., 1995; Rao et al., 1992).  E1B-55k also functions as a SUMO (small 
ubiquitin-like modifier) ligase to modify p53 and force its nuclear export through an 
interaction with promyelocytic leukemia nuclear bodies (PML) and works in conjunction 
with HAdV open reading frame (ORF) E4-ORF6 to export viral mRNA into the 
cytoplasm via recruitment of the Nxf1/Tap export machinery (Gonzalez et al., 2006; 
Gonzalez and Flint, 2002; Muller and Dobner, 2008; Pennella et al., 2010; Yatherajam et 
al., 2011).  The combination of both HAdV E1A and E1B is also capable of transforming 
primary cells in culture, demonstrating E1B’s functionality as an oncoprotein (Bayley 
and Mymryk, 1994; Subramanian et al., 1991; Van den Elsen et al., 1983). 
The E2 region contains three genes encoding proteins required for viral genome 
replication.  These include a DNA-dependent DNA polymerase (Ad Pol), terminal 
protein (TP), and a single-stranded DNA binding protein (DBP) (Challberg and Kelly, 
1979; Levine et al., 1976; van der Vliet and Levine, 1973).  As mentioned earlier, TP 
serves as a protein primer for viral genome replication (Kelly and Lechner, 1979).  DNA 
replication occurs in the standard 5’ to 3’ direction by Ad Pol, which contains 
exonuclease activity for proofreading capability (Field et al., 1984; King et al., 1997).  As 
single-stranded intermediates are produced by strand displacement, they are bound by 
DBP to prevent hairpin formation and/or destruction.  Newly-synthesized genomes, 
whether double or single stranded, serve as templates for additional rounds of replication 
(Challberg and Kelly, 1981; Kelly and Lechner, 1979; van Breukelen et al., 2003; van der 
Vliet and Levine, 1973).   
The E3 region encodes for one transcript that is differentially spliced to code for several 
unique protein products, including receptor internalization and degradation complex αβ 
(RIDαβ), gp19k, 14.7k, 12.5k, 6.7k, and adenovirus death protein (ADP) (Berk, 2013; 
Lichtenstein et al., 2004).  E3 proteins are all involved in modulating cell death and 
immune signaling.  In conjunction with other E3 proteins, RIDαβ blocks extrinsic death 
signal ligands such as TNF (tumour necrosis factor), Fas ligand, and TRAIL (TNF-
related apoptosis-inducing ligand) (Benedict et al., 2001; Friedman and Horwitz, 2002; 
Shisler et al., 1997; Tollefson et al., 2001).  RIDαβ downregulates the proapoptotic 
receptors of these ligands by promoting internalization and subsequent lysosomal 
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degradation.  E3-gp19k is a transmembrane glycoprotein that inhibits the cell-surface 
function of major histocompatibility complex class I (MHC I) (Burgert et al., 1987; 
Burgert and Kvist, 1985; Wold et al., 1985).  It promotes immune evasion by binding and 
retaining MHC I molecules in the endoplasmic reticulum (ER) and also blocks the 
tapasin-mediated peptide loading of MHC (Bennett et al., 1999).  E3-14.7k binds and 
inhibits the apoptotic signaling activities of TNF, NF-κB, and Caspase 8 (Carmody et al., 
2006; Gooding et al., 1990, 1988; Kim and Foster, 2002).  E3-6.7k works with RIDαβ to 
downregulate TRAIL and TNF signaling via blockage of arachidonic acid release 
(Benedict et al., 2001; Moise et al., 2002).  Despite its genomic locus, ADP is 
predominantly produced later during infection and serves a proapoptotic role mediating 
release of progeny virus via cell lysis (Tollefson et al., 1996b, 1992).  Lastly, E3-12.5k 
has no known function and is not required for viral replication, yet its presence is highly 
conserved among various HAdV species suggesting it may play an important, yet 
undiscovered, role (Hawkins and Wold, 1992). 
Similar to E3, the HAdV E4 region encodes one mRNA that is differentially-spliced to 
encode many protein products.  These include E4ORF1, E4ORF3, E4ORF4, E4ORF6, 
and E4ORF6/7 and are involved in a wide array of biological functions (Berk, 2013; 
Täuber and Dobner, 2001).  Sequences encoding for additional ORFs have also been 
predicted but have either no known function or are undetectable during infection.  
Furthermore, the deletion of these ORFs via mutagenesis does not impair HAdV 
replication.  Both E4ORF1 and E4ORF4 enhance viral replication by modulating 
metabolism.  E4ORF1 activates the mechanistic target of rapamycin (mTOR) pathway by 
activating phosphatidylinositol 3-kinase (PI3K) (Frese et al., 2003; O’Shea et al., 2005).  
It also modulates glycolysis through an interaction with MYC resulting in cellular 
metabolites being rerouted for nucleotide biosynthesis (Miyake-Stoner and O’Shea, 2014; 
Thai et al., 2014).  E4ORF4 also activates mTOR independently of E4ORF1, by binding 
cellular phosphatase PP2A (O’Shea et al., 2005; Zhang et al., 2011).  Though the 
mechanistic details are unclear, this function increases viral replication under nutrient-
limiting conditions.  E4ORF3 inhibits the cell’s DNA double-stranded break response 
(DSBR) by sequestering the MRN DNA damage complex (MRE11/RAD50/NBS1) 
(Araujo et al., 2005; Evans and Hearing, 2005; Sohn and Hearing, 2012; Stracker et al., 
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2002).  It also inhibits antiviral functions of PML bodies mediated through the PML-
associated protein, Daxx, and inhibits p53 (in an E1B-independent manner) by inducing 
heterochromatin at p53-targeted promoters (Soria et al., 2010; Ullman and Hearing, 
2008).  E4ORF6 works mainly in a complex with E1B-55k to either degrade p53 
(described earlier) (Dobner et al., 1996; Harada et al., 2002; Querido et al., 2001) or 
perform various other tasks to enhance viral DNA replication, nuclear export of viral 
mRNA, and blocking host protein synthesis (Bridge and Ketner, 1990; Halbert et al., 
1985; Yatherajam et al., 2011).  Finally, E4ORF6/7 binds cellular E2F transcription 
factors (TFs) and recruits them to the HAdV E2 promoter, inducing transcription of the 
aforementioned E2 genes (Hardy et al., 1989; Helin and Harlow, 1994; Huang and 
Hearing, 1989). 
Overall, the early gene products serve to reprogram/reorganize the cell into an optimal 
environment for HAdV replication, by inducing DNA replication, and protecting progeny 
from destruction by immune responses (Berk, 2013).  The late products then form the 
basis for assembling and egressing mature virions for infecting new hosts.  Along with 
the U-exon protein (UXP), the major late transcription unit codes for both the structural 
and non-structural proteins required for virion assembly and packaging (Ahi and Mittal, 
2016; Shaw and Ziff, 1980; Tollefson et al., 2007).  These arise from differential splicing 
of the major late mRNA into a plethora of products, which are further classified into 5 
regions (L1-L5).  Penton, hexon, and fiber (described earlier) are encoded on L2, L3, and 
L5 respectively.   
1.2.4 HAdV diversity and virulence 
Historically, HAdV types were categorized into various serotypes by their resistance or 
sensitivity to neutralization by antisera against other HAdV types (Wold and Ison, 2013).  
More recently, molecular techniques utilizing amino acid or nucleotide sequence 
similarities within the main neutralizing epitopes (the hexon capsid protein) have been 
adopted to classify different types (Aoki et al., 2011; Jones et al., 2007; Madisch et al., 
2005).  Consequently, there are currently seven accepted HAdV species (A-G) 
encompassing over 50 distinct HAdV types (Adams et al., 2017) (Figure 1.2).  All 
HAdVs are quite species-specific in their ability to infect and replicate within hosts, as is 
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the case for non-human adenoviruses as well.  Even nonhuman primates make typically 
poor hosts for HAdV and these viruses are generally non-pathogenic in animals (Wold 
and Ison, 2013).  In cell culture models, modest replication will occur in cells from rats, 
mice, dogs, pigs, and hamsters (Jogler et al., 2006; Ternovoi et al., 2005; Thomas et al., 
2006; Toth et al., 2005).  However, human-derived immortalized cell lines (such as 
HEK293, HeLa, and A549) are by far the best culture system for abundant production of 
HAdV. 
Epidemiologically, HAdVs are ubiquitous in the human population (Ghebremedhin, 
2014; Lion, 2014; Wold and Ison, 2013).  The lower-numbered HAdV types (such as 
HAdV-5) are especially seroprevalent, particularly in children and adolescents.  
Transmission occurs via the fecal-oral route or aerosols, leading to viral entry through the 
mouth, nasopharynx, and ocular tissues (Couch et al., 1966; Fox et al., 1977; Russell et 
al., 2006).  Most HAdVs share similar cellular receptors (discussed earlier), however the 
mechanisms underlying preferred organ/tissue tropisms are not well understood.  HAdVs 
primarily infect a wide array of tissue sites, depending on the species (Ghebremedhin, 
2014; Law and Davidson, 2005; Lenman et al., 2015; Nicklin et al., 2005; Wold and Ison, 
2013; Zhang and Bergelson, 2005).  These include respiratory tissues (species A, B, C, 
E), gastrointestinal tract (species A, B, C, D, and especially F and G), and eye (B, D, E). 
As human pathogens, HAdVs are well-adapted to their hosts and typically cause 
asymptomatic or mild infections (Ghebremedhin, 2014; Lion, 2014; Wold and Ison, 
2013).  However, these infections can also cause acute respiratory disease (ARD), most 
commonly in children and military recruits.  HAdV is thought to contribute to 
approximately 8% of the global viral disease burden, including 10% of all febrile 
illnesses in children.  More severe disease can include pharyngitis, gastroenteritis, and 
conjunctivitis depending on the site of infection and HAdV species responsible (Binder et 
al., 2017).  In young children or immunocompromised individuals, HAdV infection can 
cause pneumonia, fulminant hepatitis, or encephalitis (Krilov, 2005; Walls et al., 2003).  
Occasionally, severe outbreaks have occurred, such as the emergence of fatal pneumonia 
cases linked to HAdV-14 across multiple American states in 2005 (Kajon et al., 2010; 
Lewis et al., 2009; Metzgar et al., 2007; Seto et al., 2009). 
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Figure 1.3.  Comparison of human and simian adenoviruses. 
Phylogenetic analysis of HAdVs and SAdVs based on the amino acid sequence of the 
viral E1A proteins. E1A sequences were imported into the PHYLIP suite of software to 
calculate phylogenetic distance using the programs PROTDIST.EXE and 
NEIGHBOR.EXE (Dr. Joe Felsentein, University of Washington, Seattle, WA) and 
visualized with TreeView (Page, 1996).  Branch lengths are proportional to genetic 
distance and some regions are magnified by the indicated factor for better visualization. 
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At the cellular level, HAdV infection causes characteristic cytopathic effects (CPE), such 
as enlarged cell nuclei and formation of inclusion bodies, eventually leading to cell death 
(Boyer et al., 1959; Kasel, 1979; Wold and Ison, 2013).  Host cell synthesis of DNA, 
RNA, and protein are also broadly inhibited.  The viral replication cycle in primary sites 
of infection is typically rapid and cytolytic; however, virus can be shed at low levels for 
months after visible symptoms have passed, often from secondary tissue sites (King et al., 
2016c; Lion, 2014).  HAdV can sometimes establish persistent-style infections in humans 
(Abken et al., 1987; Garnett et al., 2009; Rowe et al., 1953).  While some recent studies 
have revealed molecular details on how HAdV can re-task the host cell’s own antiviral 
response to establish persistence, these have been difficult to reproduce in cell culture and 
are poorly understood (Zheng et al., 2016). Persistent infections are characterized as 
long-term with occasional and low-level shedding of progeny virus that may cause little 
or no harm to host tissue (Zhang et al., 2010).  Persistence is an effective and common 
strategy for maintaining virus production beyond the primary infection, while 
simultaneously avoiding immune surveillance.  This alternative lifestyle likely benefits 
the virus by allowing the continuous production of new progeny at intermediate levels 
over a vastly extended timeframe.  It also partially explains why HAdV was originally 
isolated from the secondary lymphoid tissues (adenoids and tonsils) of visibly healthy 
individuals in 1953 (Rowe et al., 1953). 
Despite the label of being a DNA tumour virus, HAdV does not cause cancer in humans 
(Mackey et al., 1976; Mende et al., 2004).  Some HAdVs are, however, tumourigenic in 
rodent species and can stably transform primary rodent or human cells in culture (Berk, 
2013; Freeman et al., 1967; Gallimore, 1972; McBride and Wiener, 1964).  These 
oncogenic properties were initially observed in 1962 when injection of HAdV-12 into 
newborn hamsters induced malignant and aggressive tumours (Trentin et al., 1962).  This 
was the first demonstration of a human virus causing cancer (albeit in a rodent model) 
and caused a burgeoning interest in the field of adenovirology research.  Transformation 
by HAdV requires the activities of both its major oncoproteins, E1A and E1B, a process 
driven largely by the many protein-protein interactions made by these viral antigens with 
host target proteins (Graham et al., 1977; Houweling et al., 1980; Subramanian et al., 
1991; Van den Elsen et al., 1983; Whittaker et al., 1984).  Following these initial 
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discoveries, researchers have used HAdV as a model for uncoupling the molecular 
pathways that lead to cancer when dysregulated.  The E1A protein itself has undoubtedly 
had the largest impact on these findings and continues to be utilized as a molecular tool 
today. 
While considered rare, cross-species transmission events of HAdV have evidently 
occurred between humans and nonhuman primates (Ersching et al., 2010; Hoppe et al., 
2015; Robinson et al., 2013; Roy et al., 2009; Wevers et al., 2011).  Adenovirus zoonosis 
(the ability to transmit from human to non-human and vice versa) has given rise to 
multiple HAdV types now endemic in humans.  HAdV-4 (the only member of species E) 
is a recombinant virus comprised of hexon epitopes of HAdV-16 (encompassing 2.5% of 
the whole genome) within the backbone of simian adenovirus-26 (SAdV) (Dehghan et 
al., 2013).  The newly-classified and lone member of species G (HAdV-52) has 
extremely low detection rates in humans and is most closely related to SAdV-1, 
suggesting the virus has recently crossed into the human population (Jones et al., 2007; 
Lenman et al., 2015).  The closest HAdV relatives to HAdV-52 are those of species F 
(HAdV-40 and -41) as they have the highest amino acid similarity (Figure 1.3).  Species 
F and G contain the only HAdV types with two distinct fiber genes, and all readily infect 
the GI tract (Kidd et al., 1993).  Cross-talk between adenoviruses of humans and 
nonhuman primates is still ongoing, as recently a novel titi monkey adenovirus (TMAdV) 
caused a deadly pneumonia outbreak in a New World monkey colony in California (Chen 
et al., 2011).  Most of the monkeys died, one of the human workers became seriously ill, 
and the virus was also transmitted to a family member of this worker.  The fact that 
TMAdV could readily transmit between both monkeys and humans demonstrates that 
zoonotic adenoviruses need to be monitored as potentially deadly causes of viral disease 
outbreaks. 
1.3 HAdV Early Region 1A (E1A) 
1.3.1 E1A gene, transcripts, and protein products 
The HAdV E1A gene is found at the very left end of the viral genome, downstream of a 
strong transcriptional enhancer and the left ITR (Hearing and Shenk, 1983; Nevins et al., 
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Figure 1.4.  HAdV-5 E1A splice products. 
(A) The E1A transcript is differentially spliced into 5 products, each named for their 
sedimentation coefficients (13S, 12S, 11S, 10S, and 9S).  Black bars represent coding 
RNA while the lines represent excised sequence.  All splicing events maintain the same 
translational reading frame except for the C-terminus of the 9S mRNA (denoted by the 
checkered bar).  (B)  Diagram of the E1A protein products resulting from differential 
splicing.  Conserved regions 1 – 4 are denoted as is each protein’s length in amino acid 
residues.  The unique sequence in the 55R product is denoted by the checkered bar. 
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1979) (Figure 1.1).  E1A is the first viral gene expressed upon HAdV infection and is 
essential for productive viral replication unless extremely high multiplicities of infection 
are used (Jones and Shenk, 1979).  Broadly, E1A-encoded products function to activate 
expression of the other HAdV early genes (Berk et al., 1979; Montell et al., 1984, 1982; 
Winberg and Shenk, 1984) and condition the cellular environment into a compliant state 
amenable to an efficient and successful HAdV infection (Bayley and Mymryk, 1994; 
Berk, 2005; Flint and Shenk, 1997; Gallimore and Turnell, 2001; Pelka et al., 2008).  The 
E1A transcript is differentially spliced into five isoforms, denoted by their sedimentation 
coefficients (13S, 12S, 11S, 10S, and 9S in HAdV-5) (Berk, 2013) (Figure 1.4A).  All 
splicing events preserve the reading frame except for the 9S product, which has a unique 
29 amino acid stretch in its C-terminus (Virtanen and Pettersson, 1983) (Figure 1.4B).  
The two largest mRNAs yield proteins of 289 and 243 amino acids respectively and are 
expressed highly during the early phase of infection (Perricaudet et al., 1979).  These 
differ only by the absence of an internal 46 amino acid stretch in the smaller isoform.  
Both localize to the nucleus and the cytoplasm and carry out the majority of E1A’s 
known functions (Rowe et al., 1983; Turnell et al., 2000).  The three smaller isoforms 
(encoding proteins of 217, 171, and 55 amino acids) are produced at later times post-
infection (Spector et al., 1978; Stephens and Harlow, 1987; Svensson et al., 1983; 
Ulfendahl et al., 1987).  While they can enhance the HAdV life cycle, their precise roles 
are far less-characterized than their larger and more highly-expressed counterparts (Miller 
et al., 2012).  Sequence comparisons of the largest E1A protein across different HAdV 
species revealed four regions of sequence similarity termed conserved region (CR) 1 
through 4 (Avvakumov et al., 2004, 2002b; Kimelman et al., 1985; van Ormondt and 
Hesper, 1983) (Figure 1.5).  The highly conserved nature of these sequences suggests 
they play crucial roles in the viral life cycle. 
1.3.2 E1A is a viral hub protein 
E1A’s crucial biological role is a direct result of its numerous protein-protein interactions 
within the host cell.  In contrast to other well-studied viral hub proteins, E1A has no 
intrinsic DNA-binding or enzymatic activities (Avvakumov et al., 2002a; Chatterjee et 
al., 1988; Zu et al., 1992); instead it acts in a modular fashion by binding to and altering 
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Figure 1.5.  Alignment of E1A proteins from representative members of each HAdV 
species. 
The amino acid sequences of the largest E1A isoforms from HAdV-3, -4, -5, -9, -12, -40, 
and -52 (representing species B, E, C, D, A, F, and G respectively) are shown.  Sequence 
alignment was performed using CLUSTAL W (Thompson et al., 1994). Alignments were 
edited manually using GeneDoc as previously described (Avvakumov et al., 2004) and 
shaded to four levels of conservation using the Dayhoff PAM 250 score table.  The 
positions of the conserved regions are indicated as solid bars. 
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the functions of over 50 distinct cellular targets (Pelka et al., 2008) (Figure 1.6).  Indeed, 
many of these targets are highly-connected hub proteins themselves.  By embedding itself 
so deeply within the cell’s protein interaction network, E1A exerts tremendous control 
over both viral and host gene expression (Berk et al., 1979; Ferrari et al., 2014, 2008; 
Horwitz et al., 2008).  Consequently, E1A is able to modulate the production of other 
HAdV gene products, as well as suppress the cell’s immune response, force the cell into 
S phase, and block differentiation. 
As a relatively small protein, E1A’s ability to bind promiscuously to host targets and 
affect several cellular processes stems from the many features contained within its 
sequence.  Consistent with the constraints of viruses’ limited coding potential, E1A 
serves as a prime example of efficiency; as typifies many hub proteins (both viral and 
cellular) E1A is largely unstructured (with only a few globular regions) and is packed 
with short linear interaction motifs (SLiMs) (Davey et al., 2011; Ferreon et al., 2009; 
Pelka et al., 2008) (Figure 1.7).  SLiMs allow E1A to exist in a dynamic and flexible 
state, enabling it to sample various conformations to carry out its plethora of overlapping 
protein-protein interactions (Dunker et al., 2005; Kim et al., 2008).  While CR1 and CR2 
of E1A bear some similarity to parts of human papillomavirus (HPV) E7 and 
polyomavirus (HPyV) large T antigen, E1A has no known cellular ortholog (Figge et al., 
1988; Phelps et al., 1988; Vousden and Jat, 1989).  Instead, its protein interaction motifs 
have likely evolved independently as functional mimics of cellular counterparts, 
presumably providing selective advantages for HAdV. 
1.3.3 E1A can act as either an oncoprotein or tumour suppressor 
Radical alterations to cellular protein interaction networks are seen not only during 
infections by DNA tumour viruses, but also in many types of cancer.  Given that the 
functions of viral oncoproteins like E1A and the cis-acting genome variations found in 
tumours often converge on the same pathways, E1A is a valuable tool for identifying host 
proteins affected by the processes of transformation and tumourigenesis (Rozenblatt-
Rosen et al., 2012).  In fact, trans-acting viral products have been demonstrated to be 
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Figure 1.6.  The HAdV-5 E1A interactome. 
Diagrammatic representation of the E1A protein interaction network.  The network was 
constructed using Gephi 0.9.1 with data from BioGRID build 3.4.144.  E1A is placed in 
the centre of the network with its primary interacting partners depicted as the large circles 
emanating outward.  Each primary interactor is supported by at least two peer-reviewed 
publications and is sized proportional to the number of its own binding partners.  These 
secondary interactors are depicted as the smaller circles and are coloured and positioned 
near the primary E1A interactor to which they bind. 
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capable of successfully predicting cancer-relevant targets at rates on par with functional 
genomics and large-scale cataloguing of tumour mutations. 
As mentioned previously, HAdV does not cause cancer in humans as the lytic infection is 
typically rapid and self-limiting and the viral genome does not normally integrate into the 
host genome (Lion, 2014; Mackey et al., 1976; Mende et al., 2004).  However, E1A alone 
is capable of immortalizing cells in culture when introduced by stable transfection 
(Graham et al., 1977; Houweling et al., 1980; Whittaker et al., 1984).  In combination 
with a cooperating oncogene, such as HAdV E1B or activated Ras, it can fully transform 
these cells (Gallimore and Turnell, 2001; Subramanian et al., 1991; Van den Elsen et al., 
1983).  For instance, these properties led to the creation of the widely-used HEK293 cell 
line which stably express the E1 region of HAdV-5, inserted into chromosome 19 of a 
cell derived from a primary human embryonic kidney culture (Graham et al., 1977; Louis 
et al., 1997).  E1A is also required for the ability of HAdV to cause tumours in 
immunocompromised rodents (Trentin et al., 1962).  Consequently, E1A can help 
identify critical regulators of cell growth and gene expression that are likely relevant to 
cancer. 
Paradoxically, exogenous expression of E1A in previously-transformed cell lines can 
suppress oncogenic phenotypes (Deng et al., 2002, 1998; Frisch and Mymryk, 2002; 
Mymryk, 1996).  This ability to act as a tumour suppressor reduces metastasis, 
angiogenesis, and tumourigenicity in vivo.  E1A can also induce apoptosis and convert 
cells from a mesenchymal-like to an epithelial-like cell type in this context.  While the 
complete mechanisms driving E1A’s oncogenic and tumour suppressive abilities are not 
yet completely understood, E1A can be used as a tool to enhance knowledge of these 
fundamental processes and shed insight on how both viruses and cancers disrupt them. 
1.3.4 E1A as a tool for identifying eukaryotic regulatory proteins 
The E1A protein is extremely modular and multifunctional, as each of its conserved 
regions (Figure 1.5) can function differently and independently from each other (Bayley 
and Mymryk, 1994).  This highly modular nature has made E1A ideal for mutagenesis 
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studies, as insertions, deletions, and point mutations typically only affect a subset of 
functions while leaving others intact.  Even small fragments of E1A protein can retain 
functionality when expressed in isolation.  Thus, E1A has a remarkable history for being 
used to discover and study novel host regulatory proteins (Pelka et al., 2008).   
Many of E1A’s binding partners are intimately linked with transcription and cell cycle 
control (Granberg et al., 2005; White, 2001; Zhao et al., 2003) (Figure 1.6).  Therefore, 
the study of these virus-host interactions has revealed deep molecular knowledge of vital 
cellular processes.  One well-known example is the interaction between E1A and 
retinoblastoma protein (pRb), which was the first example of a viral oncoprotein 
interacting with a tumour suppressor (Whyte et al., 1988).  Here E1A used two distinct 
binding interfaces to supplant the E2F family of proteins from pRb, benefitting the virus 
in multiple ways (Fattaey et al., 1993).  First, released E2Fs induce activation of HAdV 
genes, particularly the E2 transcription unit (indeed, E2Fs derive their proper name from 
this initial observation) (Reichel et al., 1987).  Second, E2Fs also activate E2F-responsive 
cellular genes, which control entry into S-phase of the cell cycle (Ghosh and Harter, 
2003; Pagano et al., 1992).  In addition, the molecular characterization of the E1A-pRb 
interaction led to the identification of the LxCxE SLiM (Figure 1.7), which was also 
subsequently found to be required for pRb-binding by a number of cellular proteins 
(Avvakumov et al., 2004; Corbeil and Branton, 1994; Dahiya et al., 2000; Ikeda and 
Nevins, 1993). 
Another well-characterized transcriptional repressor, C-terminal binding protein (CtBP1 
and 2), was also discovered through its interaction with HAdV E1A (Boyd et al., 1993).  
As its name suggests, CtBP binds to E1A via a PxDLS SLiM in E1A’s C-terminus 
(Avvakumov et al., 2004; Quinlan et al., 2006; Schaeper et al., 1995).  E1A appears to 
compete with endogenous proteins to bind CtBP1/2 and relieve its repression of host 
genes involved in cell growth and apoptosis (Bergman and Blaydes, 2006; Chinnadurai, 
2009, 2002).  E1A may also use CtBP1/2 to bring itself to, and activate, promoters that 
are normally repressed (effectively converting these cellular repressors into coactivators) 
(Bruton et al., 2008).  These interactions between E1A and various eukaryotic regulatory 
proteins have been widely exploited in defining the molecular biology of the cell.  
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Figure 1.7.  Diagrammatic representation of E1A’s protein interaction motifs. 
Experimentally-validated protein interaction motifs are displayed.  These include both 
SLiMs and globular domains.  Generic α-helix and zinc finger structures were adapted 
from the Protein Data Bank (PDB): 2GLH and 1GDC (Andreotti et al., 2006; Baumann et 
al., 1993).  Notable interactions with cellular proteins conferred by these motifs are also 
listed.  
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Therefore, by continuing to use genetic and biochemical approaches to discover novel 
interacting partners of E1A we may identify yet unknown proteins important in various 
cellular processes. 
1.3.5 E1A modulates viral transcription 
Many viruses require host enzymes to produce nucleic acid polymers in the form of either 
viral genomes and/or transcripts.  HAdV is no exception and requires both host RNA 
polymerases and DNA-binding transcription factors in order to transcribe its own genes 
(Berk, 2013).  The HAdV genome has evolved to contain many cis-acting elements 
capable of engaging with RNAPII and various TFs, but the coordination of these virus-
host interactions is multifactorial and complex (Fernandes and Rooney, 1997; Hurst and 
Jones, 1987; Kovesdi et al., 1986; Parks et al., 1988; Reichel et al., 1987; SivaRaman and 
Thimmappaya, 1987; Watanabe et al., 1988; Williams et al., 1990; Wu and Berk, 1988).  
E1A’s ability to act as a molecular hub is crucial in this context.  It can associate with 
various eukaryotic transcriptional components and modify their activities to initiate viral 
gene expression (Figure 1.6).  As such, E1A has served as a paradigm for studying viral 
transcription via the retasking of cellular TFs. 
A productive HAdV infection requires E1A-mediated activation of the other viral early 
genes, as they encode crucial components that perform various tasks during infection 
including: inhibiting apoptosis, replicating the viral genome, suppressing the immune 
response, and transporting viral mRNA (discussed in more detail above) (Berk, 2013).  
Transactivation (a portmanteau of ‘transcriptional activation’) ability of E1A has been 
largely mapped to its N-terminus and CR3 regions (both of these can drive reporter gene 
expression when fused to a heterologous DNA-binding domain), though E1A makes 
protein-protein interactions along its entire sequence that contribute to modulating 
transcription, consistent with its modular nature (Bondesson et al., 1994; Lillie and 
Green, 1989; Martin et al., 1990; Yousef et al., 2009).   
Transactivation by E1A has been best-characterized within its CR3 region, one of the few 
portions of E1A containing a structure (a zinc finger) (Culp et al., 1988; Fahnestock and 
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Lewis, 1989; Jelsma et al., 1988).  Via this region, E1A binds and recruits several 
components of TFIID complex to nucleate formation of the RNAPII preinitiation 
complex (PIC) (Geisberg et al., 1994; Webster et al., 1991; Webster and Ricciardi, 1991).  
These include TATA-binding protein (TBP) and various TBP-associated factors 
(Geisberg et al., 1995; Mazzarelli et al., 1995). Unsurprisingly, these interactions alone 
are necessary but not sufficient for wild-type (WT)-levels of E1A transactivation.  E1A 
also binds MED23, a component of the multi-protein Mediator adaptor complex, and its 
recruitment to promoters serves as a potent activation step (Ablack et al., 2010; Boyer et 
al., 1999; Cantin et al., 2003; Stevens et al., 2002).  While E1A lacks direct DNA-binding 
ability itself, it does bind to several promoter-targeting transcription factors, including 
members of the cAMP (cyclic adenosine monophosphate) response element/activating 
transcription factor (ATF) family, activator protein-1 (AP-1), upstream stimulatory factor 
(USF), and Sp1 (Liu and Green, 1994, 1990; Ström et al., 1998).  Additionally, E1A CR3 
binds coactivators (such as pCAF) as well as repressors of transactivation, including 
GCN5 and BS69 (Ablack et al., 2012; Hateboer et al., 1995; Shuen et al., 2002).  
Therefore, this portion of E1A appears to coordinate the presence of sequence-specific 
transcription factors with both activating and repressive complexes, allowing for tight 
control of viral transcription kinetics. 
The N-terminus of E1A also can enhance transcription and it is densely-packed with 
many protein-protein interaction sites (Figure 1.8).  These include motifs that confer 
interactions with transcription factors/cofactors like p300/CBP, myogenein, AP-2, p400, 
protein kinase A (PKA), Bre1, TRRAP, thyroid hormone receptor (TR), components of 
the proteasome, among others (Arany et al., 1995; Deleu et al., 2001; Eckner et al., 1994; 
Fax et al., 2001; Fonseca et al., 2012; Fuchs et al., 2001; Grand et al., 1999; King et al., 
2016a; Meng et al., 2003; Somasundaram et al., 1996; Taylor et al., 1993; Turnell et al., 
2000; Wahlström et al., 1999).  Many of these interactions remain quite uncharacterized.  
It is clear, however, that different regions of E1A cooperate to maximize control over 
specific interaction partners or establish novel connections servicing viral gene 
expression.  Instead of encoding its own RNA polymerase and proteins to act as DNA-
binding TFs, HAdV can use a single viral hub (E1A) to coordinate a massive reshuffling 
of host transcriptional machinery.  Excitingly, the roles of many binding partners and 
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Figure 1.8.  Binding partners of the N-terminus of E1A. 
Protein sequence of HAdV-5 E1A N-terminus (residues 1-82) is shown.  Key features are 
denoted by blue text and include the N-terminal transactivation domain (TAD), nuclear 
export signal (NES), and a non-canonical nuclear localization signal (NLS).  The mapped 
binding sites of cellular target proteins are depicted by dashed lines.  Less-characterized 
interactors or those that were experimentally-demonstrated only in yeast are italicized.  
Note that several interactors have multiple binding sites on full-length E1A, including 
TBP, p300/CBP, and Rb and family members.  
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their place within the E1A proteome still require vigorous investigation to delineate their 
potential roles in transcription in both infected and uninfected conditions. 
Research on E1A-mediated viral gene expression has largely focused on the initiation 
step of transcription.  However, transcription is a complex, multi-stage process involving 
regulation of initiation as well as elongation and termination (Weake and Workman, 
2010).  More recent studies on E1A have revealed that it also plays a role in enhancing 
the elongation step of HAdV transcripts produced by RNAPII.  The potential for E1A to 
enhance elongation was originally established from observations that cellular factors 
recruited to promoters in an E1A-dependent manner were also found associated on 
downstream areas being actively transcribed (Rasti et al., 2006).  These initial findings 
were expanded upon in studies examining E1A’s direct interaction with MED23.  
MED23 bridged associations between E1A and multiple other components of the 
Mediator complex, including MED26 and MED26-associated super elongation complex 
(SEC) (Vijayalingam and Chinnadurai, 2013).  These interactions all contributed to E1A-
mediated activation of HAdV early gene expression.  However, the SEC also contains 
factors known to regulate the elongation of mRNA transcripts produced by RNAPII.  
Specifically, the SEC can relieve pausing of RNAPII on nascent transcripts, which serves 
as a form of checkpoint control (Luo et al., 2012).  While a specific role for the SEC on 
elongation of HAdV transcripts wasn’t elucidated, the authors’ findings demonstrated 
that E1A-mediated transactivation was likely more complex than merely triggering the 
efficient formation of pre-initiation complexes.  Subsequent investigation into elongation 
effects conferred by E1A resulted in discovery of a bona fide mechanism driving 
elongation of HAdV transcripts (Fonseca et al., 2014).  E1A associated indirectly with 
the human Paf1 complex, composed of several proteins that accompany RNAPII from 
promoter to 3’ end of mRNA.  In this capacity, Paf1 participates in multiple aspects of 
transcription including recruitment of histone modifying enzymes, assembly of 
elongation factors that prevent dissociation of RNAPII from template, and association 
with factors required for proper termination of newly-synthesized mRNA (Fonseca et al., 
2013; Tomson and Arndt, 2013).  Loss of an E1A-Paf1 interaction during HAdV 
infection did not noticeably affect the initiation of HAdV early gene expression; 
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however, there was a drastic decrease in both E1A and RNAPII occupancy at the 3’ ends 
of early transcription units, implying a severe defect in elongation efficiency of these 
viral transcripts.  This was confirmed by demonstrating a decreased frequency both of 
full-length transcripts and H3K36 trimethylation (an elongation-specific chromatin mark) 
in these conditions (Butler and Dent, 2012; Fonseca et al., 2014).   
The aforementioned studies have established an enhanced model of E1A-mediated viral 
transcription that includes both initiation- and elongation-specific functions; however, the 
understanding of E1A’s effects on elongation is in its infancy.  If and how E1A interacts 
with components in other complexes that comprise elongation machinery remains 
unknown, as does a role for E1A in modulating elongation of host transcripts.  Also, 
while other human pathogens such as influenza A virus (IAV), human 
immunodefficiency virus (HIV), and herpes simplex virus (HSV) have been previously 
shown to manipulate elongation in various ways, it remains to be determined whether 
E1A from all HAdV species behave similarly (Fox et al., 2017; Lu et al., 2013; Pflug et 
al., 2017). 
1.3.6 E1A modulates cellular transcription 
The dawn of next-generation sequencing (NGS) technology aided in expanding the scope 
of E1A-mediated gene expression to include a global view of host cell transcription.  
During HAdV-5 infection of primary cells, it was discovered that E1A associated with 
the regulatory regions of more than 17,000 host genes (Ferrari et al., 2008; Horwitz et al., 
2008).  It was also demonstrated that E1A could either activate or repress many of these 
genes via the recruitment of cellular transcriptional machinery in a manner similar to how 
it controls viral gene expression (discussed above).  Despite large sets of published data, 
the means by which E1A individually regulates the overwhelming number of host target 
genes is still being dissected (Ferrari et al., 2014, 2009; Radko et al., 2015).  E1A can 
recruit transcriptional activators (such as p300/CBP) to activate transcription at 
previously-repressed sites.  Alternatively, it can use these same interactions to recruit 
itself, along with transcriptional repressors (like pRb and family members p130 and 
p107), to suppress transcription (Horwitz et al., 2008).  E1A-mediated modulation of host 
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transcription is therefore multifaceted, allowing a mere single viral protein to assert 
diverse effects on the global kinetics of cellular gene expression.   
Additionally, these large-scale studies have revealed how E1A can drastically alter the 
regulation of cellular chromatin at the epigenetic level (Ferrari et al., 2012, 2008).  
Histone post-translational modifications (hPTMs) offer an additional level of host genetic 
regulation by loosening or restricting access of transcriptional machinery to nucleosomes 
(Chi et al., 2010).  Highlighting E1A’s ability to invade every aspect of an infected cell’s 
protein network, E1A causes extensive reorganization of these PTMs during HAdV 
infection.  E1A can sterically inhibit histone-modifying enzymes or act as a bridge 
between enzyme and substrate to enhance and establish novel connections.  For instance, 
E1A can restructure chromatin at cellular Cdc6 and cyclin A genes to stimulate entry into 
S-phase (Ghosh and Harter, 2003).  E1A displaces the repressive E2F4 and p130 proteins 
associated with histone deacetylase (HDAC1/2) and Suv39H1 histone methylase, which 
would normally induce repressive heterochromatin.  This allows acetylation of H3K9 by 
the E1A-bound TRRAP-PCAF-p400 acetyltransferase complex, activating transcription 
from these loci (Fuchs et al., 2001; Sha et al., 2010).  Similarly, E1A’s concomitant 
associations with lysine acetyl transferases (KAT), p300 and CBP, and thousands of host 
gene promoters results in widespread acetylation of H3K18 across the human genome 
(Ferrari et al., 2008; Horwitz et al., 2008).  Consequently, many cellular genes become 
transcriptionally active from these sites including those involved in cell cycling and 
macromolecular synthesis.  A more recent study from our lab demonstrated E1A’s 
interaction with Bre1 (an E3 ubiquitin ligase involved in modifying histone H2B) could 
block Bre1’s ability to monoubiqutinate H2B during HAdV infection (Fonseca et al., 
2012).  This resulted in repression of type I interferon-stimulated genes (ISGs) which 
normally require this hPTM for their full transcription. 
The ultimate purpose for E1A’s transcriptional reprogramming of host genes is to block 
innate immunity, induce cell cycle, and reverse the differentiated phenotype in quiescent 
cells (Berk, 2013, 2005; Pelka et al., 2008).  This provides the virus with abundant 
precursor pools of dNTPs and NTPs for viral DNA and RNA synthesis, and activates 
pathways required for protein synthesis.  It also represses antiviral response genes that 
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would otherwise inhibit the virus’ replication and spread to neighbouring cells.  The sum 
of these effects is the creation of a host environment that is more optimal for a productive 
HAdV life cycle.  Consequently, how E1A repurposes endogenous host factors to alter 
these downstream pathways remains an intense area of molecular research. 
1.4 Protein Kinase A (PKA) 
1.4.1 Discovery and structure of PKA 
Phosphorylation was first demonstrated to be a means of regulating protein activity in 
1958 with the observation that an enzyme, phosphorylase kinase (PHK), was activated by 
the addition of a phosphate moiety (Krebs et al., 1959; Krebs and Fischer, 1956).  Over 
the past sixty years, the widespread importance of phosphorylation in cell biology has 
been conclusively demonstrated and extensively studied (Vlastaridis et al., 2017).  Entire 
protein networks in cells can be regulated by the additions or subtractions of phosphate 
molecules, which can act as reversible switches for protein binding and localization, or 
modulate the assembly of complex tertiary and quaternary structures (Taylor et al., 2013, 
2012; Welch et al., 2010; Westheimer, 1987).  Remarkably, approximately 2 percent of 
the entire human genome encodes for protein kinases (Manning et al., 2002).   
Protein kinase A (PKA) was the second kinase ever discovered (Walsh et al., 1968), was 
the first to have its sequence analyzed (Shoji et al., 1981), and the first to have its 
structure crystallized (Knighton et al., 1991).  Consequently, much of what is known 
about phosphorylation, intracellular signaling, and kinase structure stems from using 
PKA as a model protein.  PKA genes are conserved down to fungi or even single-celled 
organisms such as Plasmodium falciparum and Trypanosomes (Haste et al., 2012; 
Kannan et al., 2007).  PKA can therefore be considered an ancient evolutionary 
mechanism contributing to the conversion of extracellular signals into biological 
responses. 
PKA primarily exists as an inactive, tetrameric holoenzyme (Taylor et al., 2013, 2012) 
(Figure 1.9).  Two catalytic subunits (C) are bound by two regulatory subunits (R) that 
exist as a constitutive homodimer.  In mammalian cells, there are three isoforms of the C-
subunit (Cα, Cβ, and Cγ) (Skalhegg and Tasken, 2000; Søberg et al., 2013; Turnham and 
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Figure 1.9.  Organization and function of PKA. 
(A)  R-subunits contain a docking/dimerization (D/D) domain in their N-terminus and 
two cyclic nucleotide binding (CNB) domains in their C-terminus.  These structural 
regions are separated by a flexible linker sequence containing an inhibitory site (IS) that 
binds the catalytic subunit to maintain its inactive state.  C-subunits are comprised of two 
structural lobes that when folded, surround the active site cleft.  The N-terminal lobe 
binds ATP while the C-terminal lobe forms the framework for catalytic machinery and 
binding of substrates.  (B)  Illustration of PKA R- and C-subunit interactions.  Adapted 
from PDB: 2QVS (Wu et al., 2007).  (C) General PKA mechanism and downstream 
function.   R-subunit homodimers bind two C-subunits, completing an inactive tetrameric 
holoenzyme.  When local levels of cAMP rise, the binding of this 2nd messenger to the R-
subunit CNB domains causes conformational changes that free the C-subunits.  Nearby 
protein substrates with the consensus sequence: R-R-x-S/T-Φ can be phosphorylated on 
Ser or Thr residues in an ATP-dependent manner.  PKA functions in both the cytoplasm 
and nucleus in a variety of biological pathways. 
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Scott, 2016).  These share about 93% amino acid identity and are functionally-similar.  
However, Cγ is expressed only in the testis and Cβ is most highly expressed in neural 
tissue.  Cα is ubiquitously-expressed in all tissues, is a binding partner of HAdV E1A and 
is therefore a focus of this thesis.  Additional specificity for PKA is provided by the four 
unique, non-redundant isoforms of R-subunits (RIα, RIIα, RIβ, and RIIβ) (Canaves and 
Taylor, 2002; Skalhegg and Tasken, 2000).  These share only 40% amino acid identity (at 
most), and based on their cell type-specific expression and additional protein binding 
partners, add layers of regulation to PKA catalytic activity.  RIα and RIIα are both direct 
binding targets of E1A and like Cα will be the main focus of this thesis. 
As the earliest solved kinase structure, the study of PKA subunits provided crucial 
insights into the structural nature of all eukaryotic kinases (Hanks et al., 1988; Knighton 
et al., 1991; Kornev et al., 2006).  The catalytic core of the Cα subunit is composed of 
two ‘lobes,’ an N-terminal β-sheet and an α-helical C-terminus (a general organization 
that is common across the human kinome).  Highly conserved residues cluster around the 
active site cleft that lies between the two lobes (Taylor et al., 2013, 2012).  Binding of 
adenosine triphosphate (ATP) commits Cα for catalysis, where it adds a phosphate 
moiety to serine (Ser) or threonine (Thr) residues on substrates containing the minimal 
consensus sequence Arg-Arg-x-Ser/Thr-Φ (Kennelly and Krebs, 1991; Masterson et al., 
2010; Shabb, 2001). 
Both RIα and RIIα subunits form homodimers mediated by an N-terminal 4-helix bundle 
termed a ‘docking/dimerization (D/D) domain’ (Taylor et al., 2013, 2012).  The spatial 
organization of the R-subunit isoforms are generally similar (Banky et al., 1998; Kim et 
al., 2005; Wu et al., 2007).  At the C-terminus are two cyclic nucleotide binding (CNB) 
domains.  The D/D and CNB domains are separated by a flexible linker sequence 
containing an inhibitory sequence (IS).  The IS resembles a PKA substrate and binds to 
the Cα active site cleft, keeping it inactive.  The intrinsically disordered nature of the 
linker dictates the disparate quaternary structures of PKA holoenzymes between the 
different R-isoforms. 
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PKA auto-phosphorylates itself during initial folding which is essential for full 
maturation (Keshwani et al., 2012; Steichen et al., 2012).  Additional phosphorylation by 
either another PKA or 3-phosphoinositide-dependent protein kinase 1 (PDK1) after 
leaving the ribosome is required for full functionality (Cauthron et al., 1998; Cheng et al., 
1998).  However, turnover activity is not regulated by auto-phosphorylation, but rather by 
cyclic adenosine monophosphate (cAMP).  Around the same time that protein 
phosphorylation was being initially characterized, cAMP (produced by adenylyl cyclase) 
was discovered as a 2nd messenger molecule (Northup et al., 1980; Rall and Sutherland, 
1958).  Binding by cAMP to each of the CNB domains on PKA R-subunits causes them 
to undergo major conformational changes that release the C-subunits. Free Cα is then 
able to phosphorylate its cognate substrates. 
1.4.2 Cellular functions of PKA 
PKA is ubiquitous in every mammalian cell and carries out functions in both the 
cytoplasm and nucleus to regulate a wide array of biological events (Taylor et al., 2012).  
Specificity of function is conferred not only by the numerous PKA subunit isoforms and 
additional splice variants, but also cell-type specific expression and localization of related 
signaling components (Skalhegg and Tasken, 2000; Taskén and Aandahl, 2004; Welch et 
al., 2010; Wong and Scott, 2004).  These can include dozens of different G protein-
coupled receptors (GPCR), adenylyl cyclase that produces cAMP, phosphodiesterases 
(PDE) that break cAMP down, phosphatases, A-kinase anchoring proteins (discussed 
later), and the dedicated PKA substrates.  In this sense, cells carefully organize 
machinery to create discrete foci of cAMP signaling. 
The list of cellular gene products predicted or validated as phosphorylated by PKA has 
long been known to number in the hundreds (Diella et al., 2004; Gao et al., 2008; Shabb, 
2001).  Unsurprisingly, this kinase exerts functional consequences within a plethora of 
biological pathways, including memory formation, cell differentiation, proliferation, 
transcription, metabolism, apoptosis, and trafficking, among others (Johnson et al., 2001; 
Taylor et al., 2012).  Additionally, new substrates for PKA are continually being 
described, aided by the advent of molecular tools such as catalytic inhibitors (H89 or 
PKI), cAMP stimulants like forskolin (fsk), and anchoring disruptors (RIAD and 
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sAKAPis) (Alasbahi and Melzig, 2012; Carlson et al., 2006; Chijiwa et al., 1990; Gold et 
al., 2006). 
In the broadest sense, PKA is a master regulator of intracellular molecular signaling, even 
participating in feedback within its own signaling pathway.  When intracellular cAMP 
levels are high, PKA phosphorylates the β2-adrenergic receptor which causes the 
downstream inhibitory Gi protein to inhibit adenylyl cyclase, lowering cAMP production 
(Daaka et al., 1997; Hausdorff et al., 1990).  Similarly, PKA also activates multiple PDEs 
which hydrolyze cAMP to reduce overall levels of this 2nd messenger (Conti, 2000).  In 
addition to cAMP signaling, PKA cross-talks in other discrete pathways by targeting 
proteins in the cGMP, calcium, Rho, mitogen-activated protein kinase (MAPK), and 
protein phosphatase 1 (PP1) signaling networks (Shabb, 2001). 
At a more focused level, one of PKA’s major functions involves modulating cellular 
transcription.  Many PKA substrates include TFs or cofactors localized within the 
nucleus that function through the cis-acting cAMP response element (CRE) commonly 
found in promoters.  Well-characterized TFs, whose CRE-binding ability is modulated 
via phosphorylation by PKA, include CRE-binding protein (CREB), CRE modulator 
(CREM), and members of the activating transcription factor (ATF) family (De Cesare 
and Sassone-Corsi, 2000; Gonzalez and Montminy, 1989; Rehfuss et al., 1991).  Through 
CREB alone, PKA is putatively capable of affecting transcription of thousands of cellular 
genes (Daniel et al., 1998; Mayr and Montminy, 2001; Zhang et al., 2005).  Additional 
TF targets of PKA include NF-κB and nuclear factor of activated T cells (NFAT), though 
their roles in cAMP-mediated transcriptional signaling are less clear (Serfling et al., 
2000; Ye, 2000).  Given the roles for both PKA and HAdV E1A in regulating gene 
expression, PKA is a well-connected and attractive target for molecular reprogramming 
by E1A during a HAdV infection. 
Additional miscellaneous functions of PKA phosphorylation are numerous.  They include 
epigenetic modifications of histones - in fact, histone H1 was the first PKA substrate to 
have its phosphorylation site established in vivo (DeManno et al., 1999; Langan, 1969).  
PKA also signals within cascades controlling cell death, phosphorylating proapoptotic 
34 
 
 
factors such as BAD or glycogen synthase kinase-3 (GSK-3) (Li et al., 2000; Lizcano et 
al., 2000).  Over a third of PKA’s known targets are involved in controlling ion channels 
and water homeostasis, allowing PKA to affect molecular interactions mediating muscle 
contractions and cell-to-cell signaling in cardiovascular and neuronal tissues (Dagda and 
Das Banerjee, 2015; Gold et al., 2013; Shabb, 2001).  Metabolic targets of PKA include 
enzymes in the glycolysis and gluconeogenesis pathways, allowing PKA to integrate into 
the control of blood glucose levels (Okar and Lange, 1999).  Lastly, PKA has been well-
studied for its capacity to affect cytoskeletal arrangements.  PKA activity regulates actin 
bundling and downstream cell motility and adhesion (Chen et al., 2013; McKenzie et al., 
2011).  It also participates in the dynein-mediated transport of cargo along microtubule 
networks, a process actually usurped by HAdV virions during the entry phase of infection 
(Bremner et al., 2009; Scherer et al., 2014; Suomalainen et al., 2001).  To summarize, the 
diversity of its substrates, along with its flexible recognition properties make PKA a 
crucial component for molecular control of a cell. 
In general, kinases are highly conserved across widely distinct phyla, underlining their 
biological importance (Kannan et al., 2007).  Kinase mutations are often associated with 
disease, making them ideal targets for drug discovery and PKA is no exception (Taylor et 
al., 2012).  Given the range of functions PKA’s reach extends into, it has been studied as 
a molecular component in several human disease contexts, including cataracts, diabetes, 
cardiovascular disease, and multiple types of cancer (Gold et al., 2013; McKenzie et al., 
2011; Palorini et al., 2016; Pattabiraman et al., 2016).  In addition, dysregulation of the 
cAMP signaling pathway is exploited by a diverse range of viral pathogens such as HSV, 
HIV, varicella-zoster virus (VZV), HPV, hepatitis C virus (HCV), and hepatitis B virus 
(HBV)  (Barnitz et al., 2010; Benetti and Roizman, 2004; Boon et al., 2015; Cartier et al., 
2003; Delury et al., 2013; Desloges et al., 2008; Giroud et al., 2013; Majeau et al., 2007; 
Okabe et al., 2006).  How this occurs in the context of HAdV infection via E1A is the 
focus of this thesis. 
1.4.3 A-kinase anchoring proteins (AKAPs) 
Localization of the PKA holoenzyme is a major contributing factor for achieving its 
functional specificity.  This spatiotemporal control of PKA activity is conferred by
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Figure 1.10.  Organization and function of AKAPs. 
(A)  Structural representation of an AKAP amphipathic α-helix motif binding across the 
D/D domain of PKA R-subunit homodimer.  Adapted from PDB: 3IM4 (Sarma et al., 
2010).  (B)  The general organization of functional domains within AKAPs is depicted.  
AKAPs are variably-sized, polyvalent, and differentially-localized within the cytoplasm 
of cells.  AKAP-PKA interactions can be RI-, RII, or dual-specific. Along with their 
PKA-binding helix, AKAPs typically contain interaction motifs for other components of 
cAMP signaling, such as PDEs, phosphatases, and PKA substrates.  They also tend to 
possess a targeting domain that directs AKAPs along with their compartmentalized 
binding partners to distinct subcellular compartments. 
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cellular A-kinase anchoring proteins (AKAPs), a set of polyvalent and highly dynamic 
scaffold proteins (Taylor et al., 2012; Welch et al., 2010; Wong and Scott, 2004).  First 
discovered in the 1980s, there are now over 30 distinct AKAPs in humans, each 
providing similar but distinct abilities to regulate PKA (Theurkauf and Vallee, 1982).  
AKAPs all contain a hallmark PKA-binding motif comprised of an amphipathic α-helix 
(Carr et al., 1991).  This directly binds with high-affinity to the hydrophobic groove in 
the D/D domain of PKA R-subunit dimers (Figure 1.10).  AKAP-PKA interactions occur 
in the cytoplasm and are usually specific for either RIα or RIIα subunits, but dual-
specificity AKAPs exist as well (Carlson et al., 2006; Gold et al., 2006). 
In addition to binding PKA, AKAPs can contain motifs directing their subcellular 
localization to specific compartments such as the cytoskeleton, centrosome, golgi, ER, 
mitochondria, or NPC (Taylor et al., 2012; Welch et al., 2010; Wong and Scott, 2004).  
Here AKAPs will simultaneously tether interactions between PKA, substrates, and up- or 
down-stream regulators of the cAMP pathway.  By carefully controlling the proximity of 
this broad-specificity kinase, AKAPs enable tight and efficient control of cAMP 
signaling mediated through PKA.  The interface between AKAPs and PKA therefore 
offers a target for manipulation, a feature exploited by HAdV E1A. 
1.5 Viral Mimicry 
How individual viral proteins can radically alter the robust interaction networks found in 
eukaryotes remains a fascinating topic of study.  The highly organized nature of cells 
requires orchestration of countless protein-protein interactions mediated via structural 
domains or interaction motifs such as SLiMs (Davey et al., 2015; Dunker et al., 2005; 
Kim et al., 2008).  This feature is also shared by some viral proteins, whose enhanced 
evolutionary flexibility allows them to quickly adapt to cellular environments, enabling 
integration into and rewiring of their protein networks (Davey et al., 2011).  This includes 
ex nihilo evolution of SLiMs – the ability to rapidly develop a functional domain within a 
previously non-functional protein sequence.  Consequently, viruses always have an 
advantage in the unceasing arms race between pathogen and host.  Viral hubs like HAdV 
E1A can manipulate target proteins (and secondary interactors) using only small stretches 
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of amino acid sequence, including motifs that mimic cellular counterparts (King et al., 
2016a; Pelka et al., 2008).  Instead of encoding entire orthologs of large cellular 
components or evolving complicated globular structures, this strategy is an efficient 
means of increasing the functionality of the size-constrained HAdV genome (Avgousti et 
al., 2016; Chahal et al., 2012; King et al., 2016b).  The success of viral mimicry is 
overwhelmingly demonstrated by how often it has evolved convergently in genetically-
distinct viruses (Brito and Pinney, 2017; Chemes et al., 2015; Via et al., 2015).  It is also 
telling that the full complement of cellular processes have been shown as susceptible to 
viral “corruption” in this manner (Davey et al., 2011).  Understanding the mechanisms 
driving viral hijacking of host components via mimicry will reveal new molecular aspects 
of cell regulation, viral pathogenesis, and human disease. 
1.6 Thesis Overview 
The work within this thesis involves the biochemical and functional analysis of the 
protein-protein interaction between HAdV E1A and cellular PKA.  Originally identified 
in 2001, the E1A-PKA association remained largely uncharacterized and its biological 
importance unknown (Fax et al., 2001).  Here, extensive mutagenesis was utilized to 
determine the precise molecular mechanism of this virus-host interaction, ultimately 
revealing a novel example of viral mimicry.  Subsequent findings validated the functional 
importance of this role for E1A in enhancing the HAdV replication cycle.  The 
conservation of this function across the seven HAdV species was also determined, 
demonstrating its evolutionary importance.  Finally, a detailed model was established 
explaining E1A’s ability to engage in mimicry for the purpose of rewiring cellular cAMP 
signaling to benefit HAdV infection. 
1.6.1 Chapter 2: Functional and structural mimicry of cellular protein 
kinase A anchoring proteins by a viral oncoprotein 
In this study, we performed extensive mutational analysis on both HAdV-5 E1A and 
cellular PKA subunits to characterize the molecular determinants of their protein-protein 
interaction.  We demonstrated that the N-terminus of E1A has evolved to structurally 
mimic the PKA-binding domain of cellular AKAPs.  We also showed this mimicry to be 
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functional, as E1A could emulate AKAP activity in vivo.  E1A relocalizes PKA to the 
nucleus of infected cells via an interaction with the D/D domain in PKA’s regulatory 
subunits.  This required an AKAP-like amphipathic α-helix motif in E1A’s N-terminus.  
Importantly, we showed that during HAdV infection, E1A competes with endogenous 
AKAPs for PKA binding.  We also showed that incorporation of E1A’s AKAP-like motif 
into a cellular AKAP mutant unable to bind PKA restored the interaction.  Functionally, 
E1A’s ability to act like a ‘viral AKAP’ (vAKAP) contributed to efficient viral 
transcription, protein synthesis, and progeny production. 
1.6.2 Chapter 3: Mimicry of cellular A kinase anchoring proteins is a 
conserved and critical function of E1A across various human 
adenovirus species 
Following the previous chapter, we examined the ability of E1A proteins from all seven 
species of HAdV to act as ‘viral AKAPs.’  We showed that E1A from representative 
viruses from five of seven HAdV species make protein-protein interactions with PKA 
subunits.  The conserved mechanism of this binding included each of these distinct E1As 
using small, AKAP-like motifs in their N-terminal regions to bind the D/D domain of 
PKA R-subunits.  Like with HAdV-5, this caused relocalization of PKA into the nucleus.  
Interestingly, different HAdV species had a preference for one particular PKA isoform 
(RIα or RIIα) over another.  Notably, we showed these newly characterized vAKAPs 
could integrate into cAMP signaling to activate transcription from a cAMP-responsive 
promoter.  Additionally, we demonstrated the vAKAP function of E1A contributes to 
viral genome replication and infectious progeny production for several, unique HAdV 
species.  These data established that mimicry and subversion of this important cellular 
regulatory pathway is a conserved feature for multiple viral pathogens and enhanced the 
knowledge of how vAKAPs function. 
1.6.3 Chapter 4: General Discussion 
To conclude the thesis, I examine the overall significance of my work and address 
lingering questions related to the projects presented.  Additionally, I present potential 
follow-up experiments including some preliminary analysis of genome-wide changes to 
cellular transcription possibly linked to the E1A’s role as a vAKAP. 
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Chapter 2  
2 Functional and structural mimicry of cellular protein 
kinase A anchoring proteins by a viral oncoprotein 
“Research is what I'm doing when I don't know what I'm doing.”  
– Wernher von Braun 
2.1 Introduction 
As obligate intracellular parasites, all viruses are critically dependent upon the host cell.  
Intensive selective pressure, rapid replicative cycle times and severe restrictions on viral 
genome size combine to drive virus evolution.  As a consequence, viral regulatory 
proteins have been relentlessly forged into exquisitely sophisticated instruments that 
functionally reprogram the infected cell (Rozenblatt-Rosen et al., 2012).  Studies of 
human adenovirus (HAdV), a small DNA tumour virus, illustrate the profound impact of 
viral proteins on multiple host functions to maximize viral propagation (Ferrari et al., 
2014, 2008; Fonseca et al., 2012; Miyake-Stoner and O’Shea, 2014; Shah and O’Shea, 
2015; Soria et al., 2010). 
The multifunctional E1A proteins of HAdV are particularly adept at targeting key cellular 
regulators. Through these interactions, E1A creates a cellular milieu more conducive for 
replication by altering or inhibiting the normal function of host targets and establishing 
new connections in the host protein interaction network.  Indeed, E1A enhances cell 
cycle entry, subverts innate immunity and intensively reprograms the cellular gene 
expression program (Ferrari et al., 2014, 2008; Pelka et al., 2008).  The modular E1A 
proteins are dense with short linear sequence motifs that bind to and alter the activity of 
dozens of critical cellular proteins (Ferrari et al., 2009; Ferreon et al., 2013).  Many of the 
interaction motifs in E1A are functional mimics of highly similar sequences present in 
cellular regulatory proteins.  Thus, viral evolution has converged to generate specific high 
affinity protein interaction surfaces that perturb cell regulation by competing with 
endogenous targets.   
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Cellular compartmentalization of proteins is a widespread cellular mechanism that 
ensures the interaction of signalling molecules with a localized subset of appropriate 
effector proteins.  As one well studied example, the activation of protein kinase A (PKA) 
signalling by the second messenger cyclic AMP (cAMP) is precisely restricted to discrete 
subcellular regions (Taylor et al., 2012).  This is primarily achieved by a diverse set of 
cytoplasmic scaffolds collectively known as A-kinase anchoring proteins (AKAPs).   
AKAPs bind to PKA regulatory subunits via a well characterized amphipathic α-helix, 
localizing them to distinct cellular loci near PKA’s substrates (Wong and Scott, 2004).  
Compartmentalization of PKA allows its enzymatic activity to be directed in a spatially 
defined and temporally specified manner and dysregulation of this compartmentalization 
has pathophysiological consequences (Gold et al., 2013). 
Although the E1A proteins from multiple HAdVs can synergize with cAMP to alter viral 
and cellular gene expression (Engel et al., 1991, 1988; Hardy and Shenk, 1988; B H Lee 
and Mathews, 1997; Müller et al., 1989) the exact mechanism remains unclear.  
Interestingly, HAdV-12 E1A binds directly to the regulatory subunits of PKA, resulting 
in the relocalization of one isoform from the cytoplasm to the nucleus (Brockmann and 
Esche, 2003; Fax et al., 2001).  These results suggest that E1A may function as a ‘viral 
AKAP’ by redirecting the subcellular localization of PKA to alter transcription. 
Here we show that HAdV E1A mimics cellular AKAPs in both structure and function.  
We found that the PKA RIα and RIIα subunits are conserved targets of most HAdV E1A 
species.  Structural modeling and a docking analysis predict a remarkable similarity 
between the binding of E1A and cellular AKAPs to PKA, which was confirmed 
experimentally.  In addition, we observed E1A-mediated relocalization of PKA subunits 
and competition between E1A and cellular AKAPs during infection that contribute to 
HAdV gene expression and overall viral replication.  Together, our studies identify E1A 
as the first known viral AKAP, and reveal a unique example of viral subversion of the 
PKA pathway via structural mimicry. 
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2.2 Materials and Methods 
2.2.1 Cell lines and transfections 
Human A549 (provided by Russ Wheeler, Molecular Pathology/Genetics London Health 
Sciences Centre), HT1080 (purchased from the American Type Culture Collection), and 
HEK293 cells (Graham et al., 1977) were grown at 37ᵒC with 5% CO2 in DMEM 
(Multicell) supplemented with 10% fetal bovine serum (FBS) (Gibco).  Plasmids were 
transfected into A549 and HT1080 cells using XtremegeneHP (Roche) following the 
manufacturer’s recommendation.  After 24 hours of incubation, transfected cells were 
used for downstream experiments. 
2.2.2 Virus infection of cells 
All viruses were derived from the HAdV-5 dl309 background and express the 289R and 
243R E1A proteins (Egan et al., 1988; Jones and Shenk, 1979).  A549 cells were infected 
with WT (dl309) or HAdV containing the indicated E1A mutant:  ΔE1A (dl312), Δ4-25 
(dl1101).  Cells were infected at a multiplicity of infection (MOI) of 5 pfu (plaque-
forming units)/cell.  Cell cultures were infected at 50% confluence and subconfluent cells 
were collected at indicated time points for downstream experiments. 
2.2.3 RNAi knockdown 
Downregulation of PKA subunits RIα, RIIα, and Cα was performed using Silencer Select 
siRNA (Thermo).  The following PKA oligos were utilized: s286 (PRKAR1A), s11086 
(PRKAR2A), and s11065 (PRKACA).  Four hours after seeding, siRNA was delivered to 
A549 cells via transfection with Silentfect (BioRad) according to the manufacturer’s 
instructions.  A scrambled siRNA was used as a negative control.  Treated cells were 
used for experiments 48 hours post-transfection.  Downregulation of E1A in HEK293 
cells was performed using a cocktail of E1A-specific siRNAs generated by Thermo 
Fisher’s design platform: (GAUUUUUCCCGAGUCUGUAtt, 
CGGAGGUGUUAUUACCGAAtt, and CUGUAUGAUUUAGACGUGAtt). 
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Table 2.1.  List of plasmids used in this chapter 
Clone Backbone(s) Notes 
13S Ad3 E1A pEGFP-C2 Species B 
13S Ad4 E1A pEGFP-C2 Species E 
13S Ad5 E1A pEGFP-C2, pcDNA3 Species C 
13S Ad9 E1A pEGFP-C2 Species D 
13S Ad12 E1A pEGFP-C2 Species A 
13S Ad40 E1A pEGFP-C2 Species F 
Ad5 E1A 1-82 pEGFP-C2 N-terminus and CR1 
Ad5 E1A 93-139 pEGFP-C2 CR2 
Ad5 E1A 139-204 pEGFP-C2 CR3 
Ad5 E1A 187-289 pEGFP-C2 Exon 2 including CR4 
*Ad5 E1A Δ1-82 pcDNA3  
*Ad5 E1A Δ1-29 pcDNA3  
*Ad5 E1A Δ1-14 pcDNA3  
Ad5 E1A Δ4-25 pcDNA3 dl1101 
*Ad5 E1A Δ16-28 pcDNA3  
Ad5 E1A Δ26-35 pcDNA3  
Ad5 E1A Δ30-49 pcDNA3  
Ad5 E1A Δ48-60 pcDNA3  
Ad5 E1A Δ61-69 pcDNA3  
Ad5 E1A Δ70-81 pcDNA3  
*Ad5 E1A 1-29 pEGFP-C2  
*Ad5 E1A 1-14 pEGFP-C2  
*Ad5 E1A 14-28 pEGFP-C2  
*Ad5 E1A 16-28 pEGFP-C2  
*Ad5 E1A 29-49 pEGFP-C2  
*Ad5 E1A D21K pcDNA3  
*Ad5 E1A E26K pcDNA3  
*Ad5 E1A V27K pcDNA3  
*Ad5 E1A E26A V27A pcDNA3  
*Ad5 E1A E25K pcDNA3  
*PKA RIα pcDNA-HA, pcDNA-MYC From Addgene 23741 
*PKA RIIα pcDNA-HA, pcDNA-MYC From Addgene 23789 
*PKA Cα pcDNA-HA From Addgene 23495 
*PKA RIα Q28E pcDNA-HA  
*PKA RIα L31A K32A pcDNA-HA  
*PKA RIα I35A V36A pcDNA-HA  
*PKA RIα Δ1-63 pcDNA-MYC ΔD/D 
*PKA RIIα Δ1-45 pcDNA-MYC ΔD/D 
*PKA RIα 1-63 pEGFP-N1 D/D only 
*PKA RIIα 1-45 pEGFP-N1 D/D only 
RIAD pEGFP-C2 LEQYANQLADQIIKEAT, from 
Alan Howe 
sAKAPis pEGFP-C2 QIEYLAKQIVDNAIQQAK, 
from Alan Howe 
D-AKAP1 pEGFP-C2 From Thomas Kuntzinger 
*D-AKAP1 Δ344-357 pEGFP-C2  
*AKAP-E1A pEGFP-C2 AKAP-E1A chimera 
*Novel clone generated for this study 
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2.2.4 Plasmids 
All constructs were expressed in vectors under control of the CMV promoter.  WT RIα, 
RIIα, and Cα were PCR amplified (from Addgene 23741, 23789 and 23495) and cloned 
into pcDNA4-HA and pCANmyc.  RIα Δ1-63 and RIIα Δ1-45 were similarly derived and 
expressed in pCANmyc.  D/D fragments of RIα and RIIα were both expressed as EGFP 
fusions from pEGFP-N1.   E1A fragments were expressed as fusions to EGFP and either 
described previously (1-82, 93-139, 139-204, 187-289) (Pelka et al., 2011) or derived via 
PCR and cloned into pEGFP-C2 (1-29, 1-14, 14-28, 16-28, 29-49).  WT HAdV-5 E1A 
and its associated deletion mutants were all expressed in pcDNA3.   These constructs 
were previously described (Δ4-25, Δ26-35, Δ30-49, Δ48-60, Δ61-69, Δ70-81) (Pelka et 
al., 2011) or generated via PCR (Δ1-82, Δ1-14, Δ1-29, Δ16-28).  Point of mutants of E1A 
(D21K, E26K, V27K, E26A V27A, E25K) and RIα (Q28E, L31A K32A, I35A V36A) 
were generated by PCR and expressed in pcDNA3 and pcDNA-HA respectively.   The 
largest E1A isoform from six HAdV species were cloned as EGFP fusions.  D-AKAP1 
mutants were generated via PCR of a construct kindly provided by Thomas Kuntziger 
(Oslo) and expressed in pEGFP-C2.  RIAD-EGFP and sAKAPis-EGFP were provided by 
Alan Howe (Vermont).  A list of plasmids used in this chapter can be found in table 2.1. 
2.2.5 Western blotting and co-immunoprecipitation 
Cells were lysed in NP-40 lysis buffer (150mM NaCl, 50mM Tris-HCL pH 7.5, 0.1% 
NP-40) with protease inhibitor cocktail.  Protein concentrations were determined using 
BioRad protein assay reagent using BSA as a standard.  Immunoprecipitations were 
carried out at 4ᵒC for 4 hours, or overnight for endogenous interactions.  2% of sample 
was kept as input control.  After washing with NP-40 buffer, complexes were boiled in 
25 µL of LDS sample buffer for 5 minutes.  Samples were separated on NuPage 4-12% 
Bis-Tris gradient gels (Life Technologies) and transferred onto a PVDF membrane 
(Amersham).  Membranes were blocked in 5% skim milk constituted in TBS with 0.1% 
Tween-20.  Horseradish peroxidise-conjugated secondary antibody was detected using 
Luminata Forte or Crescendo substrate (Millipore).  For biochemical fractionation of
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Table 2.2.  List of primary antibodies used in this chapter 
Reactivity Purpose Description Company 
RIα Western Mouse monoclonal BD 
RIα IF, ChIP Rabbit polyclonal Thermo 
RIIα Western Mouse monoclonal BD 
RIIα IF, ChIP Rabbit polyclonal Santa Cruz 
Cα Western Mouse monoclonal BD 
Cα IF, ChIP Rabbit polyclonal Santa Cruz 
M73 (E1A) Western, IP, IF Mouse monoclonal In-house 
M58 (E1A) Western Mouse monoclonal In-house 
Actin Western Rabbit polyclonal Sigma 
EGFP Western, IP Rabbit polyclonal Clontech 
9E10 (MYC) Western Mouse monoclonal In-house 
3F10 (HA) Western Rat monoclonal Roche 
AKAP7 Western, IP Rabbit polyclonal Santa Cruz 
2A6 (E1B-55K) Western Mouse monoclonal In-house 
B68 (DBP) Western, IF Mouse monoclonal In-house 
E3-19K Western Rabbit serum In-house 
1807-4 (E4orf6) Western Rabbit polyclonal In-house 
Ad5 capsid Western Rabbit polyclonal Abcam 
Histone H3 Western Rabbit polyclonal Abcam 
76 
 
 
infected A549 cells, nuclear and cytoplasmic extracts were acquired using an NE-PER kit 
from Thermo-Fisher.  Primary antibodies used in this chapter can be found in table 2.2. 
2.2.6 Immunofluorescence microscopy and image analysis 
Cells were fixed in 3.7% paraformaldehyde, permeabilized on ice using 0.2% Triton X-
100, and blocked using 3% BSA in phosphate-buffered saline (PBS).   Samples were 
incubated in the indicated primary antibody for 1 hour at room temperature or 4ᵒC 
overnight and another hour at room temperature with secondary antibodies (Alexa Fluor 
594 α-rabbit, Alexa Fluor 488 α-mouse) (Life Technologies).  Samples were mounted 
with Prolong Gold reagent containing DAPI (Life Technologies).  Confocal images were 
acquired using a Fluoview 1000 laser scanning confocal microscope (Olympus Corp).  
Non-confocal images were acquired using an Eclipse Ti-U inverted laser microscope 
(Nikon).  Quantification of total cellular signal and nuclear signal was conducted using 
ImageJ.  Cells were normalized for both cytoplasmic and nuclear size and %nuclear 
signal was determined as previously described (Magico and Bell, 2011). 
2.2.7 Quantitative RT-PCR 
Total RNA was prepared with Trizol extraction (Life Technologies).  A total of 1 µg of 
RNA was reverse transcribed into cDNA by random priming using the qScript cDNA 
supermix (Quanta Biosciences) following the manufacturer’s instructions.   
Quantification of cDNA was done using Power SYBR-Green mastermix (Applied 
Biosystems) with oligonucleotide sequences that specifically recognize the indicated 
target.  Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control for 
total cDNA along with a no-RT negative control.  Results were normalized to the 
GAPDH and uninfected samples and calculated using the ΔΔCt method (Schmittgen and 
Livak, 2008).  A list of all primers used in this chapter can be found in tables 2.3 and 2.4. 
2.2.8 Chromatin immunoprecipitation 
Approximately 107 cells per sample were cross-linked in 2mM ethylene glycol 
bis(succinimidyl succinate) (EGS) for 1 hour followed by 1% formaldehyde for 15 
minutes at room temperature.  Reactions were quenched with 0.125M glycine and
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Table 2.3.  List of qPCR primers used in this chapter 
Target Region Location Forward Reverse Size 
GAPDH Transcript 566-644 ACTGCTTAGCACCCCTGG
CCAA 
ATGGCATGGACTGTGGT
CATGAGTC 
79 
E1A Transcript 715-834 ACACCTCCTGAGATACA
CCC 
TTATTGCCCAGGCTCGTT
AAGC 
120 
E1B Transcript 578-697 GACAATTACAGAGGATG
GGC 
CACTCAGGACGGTGTCT
GG 
120 
E2 Transcript 17-155 GGGGGTGGTTTCGCGCT
GCTCC 
GCGGATGAGGCGGCGTA
TCGAG 
138 
E3 Transcript 13-162 GAGGCAGAGCAACTGCG
CC 
GCTCTCCCTGGGCGGTA
AGCCGG 
150 
E4 Transcript 3-129 GCCCCCATAGGAGGTAT
AAC 
GGCTGCCGCTGTGGAAG
CGC 
127 
GAPDH Promoter 231 bp 
upstream 
of TSS 
TTCGCCCCAGGCTGGAT
GG 
AGGCGGAGGACAGGATG
GC 
126 
E1B Promoter 1546-1708 GGTGTAAACCTGTGATT
GCG 
CAGATGTAACCAAGATT
AGCCC 
162 
E3 Promoter 27501-
27633 
GGCGGCTTTCGTCACAG
GG 
TCTGAAATGTCCCGTCCG
G 
132 
E4 Promoter 35585-
35694 
CAGCTCAATCAGTCACA
GTGTAAAAAAGGGCC 
TGCGGTTTTCTGGGTGTT
TT 
110 
78 
 
 
Table 2.4.  List of cloning primers used in this chapter 
Clone Forward Reverse Notes 
Ad5 E1A 
Δ1-82 
ATCCGAATTCATGTTTCCGCCGGCG
CCCGG 
CGGCTCGAGCTCCACACACGCAA
TCACAGG 
 
Ad5 E1A 
Δ1-29 
CCACGAATTCGATAATCTTCCACCT
CCTAGC 
CGGCTCGAGCTCCACACACGCAA
TCACAGG 
 
Ad5 E1A 
Δ1-14 
TTCGAATTCATGGCCGCCAGTCTTT
TG 
ACTGTCGACTTATGGCCTGGGAC
GTTTACAGCTC 
 
Ad5 E1A 
Δ16-28 
ATTACCGAAGAAATGGCTGATAAT
CTTCCACC 
GGTGGAAGATTATCAGCCATTTC
TTCGGTAAT 
Internal 
CGACGAATTCATGAGACATATTATC
TGC 
CGGCTCGAGCTCCACACACGCAA
TCACAGG 
Flanking 
Ad5 E1A 
1-29 
CGACGAATTCATGAGACATATTATC
TGC 
GTTGTCGACTTAAGCCAGTACCT
CTTCG 
 
Ad5 E1A 
1-14 
CGACGAATTCATGAGACATATTATC
TGC 
CATCCTCGAGCTATTCTTCGGTA
ATAAC 
 
Ad5 E1A 
14-28 
GATGGAATTCGAAATGGCCGCCAG
TC 
CATCCTCGAGCTACAGTACCTCT
TCGATC 
 
Ad5 E1A 
16-28 
GATGGAATTCGCCGCCAGTCTTTTG CATCCTCGAGCTACAGTACCTCT
TCGATC 
 
Ad5 E1A 
29-49 
GATGGAATTCGCTGATAATCTTCCA
C 
CATCCTCGAGCTATAAATCATAC
AGTTCG 
 
Ad5 E1A 
D21K 
CCGCCAGTCTTTTGAAACAGCTGAT
CGAAG 
CTTCGATCAGCTGTTTCAAAAGA
CTGGCGG 
Internal 
CGACGAATTCATGAGACATATTATC
TGC 
CGGCTCGAGCTCCACACACGCAA
TCACAGG 
Flanking 
Ad5 E1A 
E26K 
GACCAGCTGATCGAAAAAGTACTG
GCTGATAATC 
GATTATCAGCCAGTACTTTTTCG
ATCAGCTGGTC 
Internal 
CGACGAATTCATGAGACATATTATC
TGC 
CGGCTCGAGCTCCACACACGCAA
TCACAGG 
Flanking 
Ad5 E1A 
V27K 
CAGCTGATCGAAGAGAAACTGGCT
GATAATCTTC 
GAAGATTATCAGCCAGTTTCTCT
TCGATCAGCTG 
Internal 
CGACGAATTCATGAGACATATTATC
TGC 
CGGCTCGAGCTCCACACACGCAA
TCACAGG 
Flanking 
Ad5 E1A 
E26A 
V27A 
GACCAGCTGATCGAAGCCGCCCTG
GCTGATAATC 
GATTATCAGCCAGGGCGGCTTCG
ATCAGCTGGTC 
Internal 
CGACGAATTCATGAGACATATTATC
TGC 
CGGCTCGAGCTCCACACACGCAA
TCACAGG 
Flanking 
Ad5 E1A 
E25K 
TTGGACCAGCTGATCAAAGAGGTA
CTGGCTGAT 
ATCAGCCAGTACCTCTTTGATCA
GCTGGTCCAA 
Internal 
CGACGAATTCATGAGACATATTATC
TGC 
CGGCTCGAGCTCCACACACGCAA
TCACAGG 
Flanking 
PKA RIα ATCCGGATCCATGGAGTCTGGCAGT
ACC 
GATGCTCGAGTCAGACAGACAGT
GACACAAAAC 
 
PKA RIIα AGTCGGATCCATGAGCCACATCCA
GATC 
TATTCTCGAGCTACTGCCCGAGG
TTGCCCAG 
 
PKA Cα ATACGGATCCATGGGCAACGCCGC
CGCC 
GCCGGTCGACCTAAAACTCAGAA
AACTCCTT 
 
PKA RIα 
Q28E 
CAGAAGCATAACATTGAAGCGCTG
CTCAAAGAT 
ATCTTTGAGCAGCGCTTCAATGT
TATGCTTCTG 
Internal 
ATCCGGATCCATGGAGTCTGGCAGT
ACC 
GATGCTCGAGTCAGACAGACAGT
GACACAAAAC 
Flanking 
PKA RIα 
L31A 
K32A 
AACATTCAAGCGCTGGCCGCCGAT
TCTATTGTGC 
GCACAATAGAATCGGCGGCCAG
CGCTTGAATGTT 
Internal 
ATCCGGATCCATGGAGTCTGGCAGT
ACC 
GATGCTCGAGTCAGACAGACAGT
GACACAAAAC 
Flanking 
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PKA RIα 
I35A 
V36A 
CTGCTCAAAGATTCTGCCGCCCAGT
TGTGCACTGC 
GCAGTGCACAACTGGGCGGCAG
AATCTTTGAGCAG 
Internal 
ATCCGGATCCATGGAGTCTGGCAGT
ACC 
GATGCTCGAGTCAGACAGACAGT
GACACAAAAC 
Flanking 
PKA RIα 
Δ1-63 
ATCCGGATCCCAGATTCAGAATCTG
CAG 
GATGCTCGAGTCAGACAGACAGT  
PKA RIIα 
Δ1-45 
AGCCGGATCCATGCCAGCCTCAGT
CCTGCCCGC 
TATTCTCGAGCTACTGCCCGAGG
TTGCCCAG 
 
PKA RIα 
1-63 
ATCCCTCGAGATGGAGTCTGGCAGT
ACC 
CATCGGATCCTTTGCCTCCTCCTT
CTC 
 
PKA RIIα 
1-45 
AGCCCTCGAGATGAGCCACATCCA
GATC 
CATAGGATCCGCGCGGGCCTCGC
GCAG 
 
D-AKAP1 
Δ344-357 
GATAGAAATGAGGAGGAAGCAACC
GAACAGG 
CCTGTTCGGTTGCTTCCTCCTCAT
TTCTATC 
Internal 
GATGGAATTCATGGCAATCCAGTTC
CG 
CATCGCGGCCGCTCAAAGGCTTG
TGTAGTAG 
Flanking 
AKAP1-
E1A 
GAGGTACTGGAAGCAACCGAACAG
GTG 
CGGCCATTTCCTCCTCATTTCTAT
CCAAG 
Internal 
(AKAP 
template) 
GAAATGAGGAGGAAATGGCCGCCA
GTC 
CGGTTGCTTCCAGTACCTCTTCG
ATCAG 
Internal 
(E1A 
template) 
GATGGAATTCATGGCAATCCAGTTC
CG 
CATCGCGGCCGCTCAAAGGCTTG
TGTAGTAG 
Flanking  
(AKAP-
E1A) 
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washed twice with cold PBS.  Cell pellets were processed in ChIP buffer 1 (10mM 
HEPES [pH 6.5], 10mM EDTA, 0.5mM EGTA, 0.25% Triton X-100), ChIP buffer 2 
(10mM HEPES [pH 6.5], 1mM EDTA, 0.5 mM EGTA, 200mM NaCl), and ChIP buffer 
3 (50mM Tris-HCl [pH 8], 10mM EDTA, 0.5% Triton X-100, 1% SDS, and protease 
inhibitors).  Lysates were sonicated in an ultrasonic bioruptor bath (Diogenode) to yield 
DNA fragments between 200-500 basepairs.  Eighty µg of chromatin supernatant was 
used for ChIP, 1% of this was kept for input controls.  Samples were diluted 10-fold in 
ChIP dilution buffer (50mM Tric-HCl [pH 8], 10mM EDTA, 150mM NaCl, 0.1% Triton 
X-100, protease inhibitors) and precleared with 30µL of Protein G Dynabeads 
(Invitrogen) for 1 hour at 4ᵒC.  Immunoprecipitations were performed overnight at 4ᵒC 
using 5µg of the indicated antibody.  The next morning, 30µL of Dynabeads were 
incubated with each sample for 2 hours.  Beads were then washed with twice each with 
wash buffer 1 (20mM Tris-HCl [pH 8], 2mM EDTA, 150mM NaCl, 1% Triton X-100, 
0.1% SDS), wash buffer 2 (20mM Tris-HCl [pH 8], 2mM EDTA, 500mM NaCl, 1% 
Triton X-100, 0.1% SDS), and wash buffer 3 (10mM Tris-HCl [pH 8], 1mM EDTA).  
Immunocomplexes were extracted twice with 150µL of elution buffer (0.1M NaHCO3, 
1% SDS).  Twenty five µL of 2.5M NaCl was added to the 300µL pooled elutions and 
incubated overnight at 65ᵒC to de-crosslink the complexes.  DNA was purified using a 
PCR purification kit (Thermo).  qPCR using SYBR-Green was performed as described 
previously using 80nM oligos and 0.5µL of ChIP DNA per 15µL reaction. 
2.2.9 Statistical analysis 
All experiments were carried out with three biological replicates performed in duplicate.  
Graphs represent mean and standard error of the mean (S.E.M.) of all biological 
replicates.  For western blots a representative image was selected.  Statistical significance 
of numerical differences was calculated using one-way ANOVA and Holm-Sidak post-
hoc comparison between experimental conditions. 
2.2.10 Docking methods 
To model the interaction between PKA and E1A, we first performed a structural 
prediction of the amino terminus of E1A by submitting the primary sequence to Phyre 2 
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(Kelley et al., 2015).  The predicted structure of E1A was subsequently docked onto PKA 
(PDB ID: 3IM4) using the standard settings profile of ClusPro2.0 (Kozakov et al., 2013).  
Residues forming an E1A-PKA binding interface within 4 Angstroms were selected for 
further experimental analysis. All images were generated in the PyMOL Molecular 
Graphics System, Version 1.8 Schrödinger, LLC.  Additional in silico comparisons of 
HAdV-5 and HAdV-4 E1A were conducted using Clustal Omega (Goujon et al., 2010) 
and the UCL Department of Computer Science’s PSI-PRED protein sequence analysis 
workbench (Buchan et al., 2013). 
2.3 Results 
2.3.1 Multiple PKA subunits are conserved targets of HAdV E1A 
The E1A proteins from multiple HAdVs synergize with cAMP to alter viral and cellular 
gene expression.  A direct interaction between HAdV-12 E1A and the type I and type II 
regulatory subunits of PKA (RIα and RIIα) was previously reported, but has not been 
investigated further (Fax et al., 2001).  It was also not known if this interaction was 
specific to HAdV-12 E1A.  To further explore the E1A-PKA interaction, A549 lung 
adenocarcinoma cells were infected with wildtype (WT) HAdV-5 or a ΔE1A virus and 
co-immunoprecipitations were performed (Figure 2.1A).  Similarly to HAdV-12 E1A, 
HAdV-5 E1A interacted with endogenous PKA regulatory subunits RIα and RIIα.  
Interestingly, we also found a previously unknown interaction between HAdV-5 E1A and 
the endogenous PKA catalytic subunit Cα.  siRNA-mediated downregulation of specific 
PKA subunits demonstrated that E1A’s association with Cα required expression of RIα 
and RIIα (Figure 2.1B).  This suggests that the interaction with the Cα subunit may be 
indirect and that E1A binds the entire PKA holoenzyme.   
To determine if the interactions between E1A and the PKA subunits are evolutionarily 
conserved across the different HAdV species, HT1080 fibrosarcoma cells were 
transfected with vectors expressing the PKA subunits and the largest E1A isoform from 
six different HAdV species. Co-immunoprecipitation analysis revealed that RIα, RIIα, 
and Cα all interacted with each of the E1A proteins tested, with the exception of HAdV-4
82 
 
 
Figure 2.1.  Multiple subunits of PKA are conserved targets of HAdV-5 E1A during 
infection. 
(A, B) A549 cells were infected with either WT (dl309) or ΔE1A HAdV-5 (dl312) at an 
MOI of 5 pfu/cell and cell lysates were harvested for co-immunoprecipitation.  (A) 
Associations between E1A and endogenous PKA subunits RIα, RIIα, and Cα are shown.  
(B)  Cells were treated with the indicated siRNAs (shown in the inset panel) prior to 
infection.  Associations between E1A and endogenous PKA subunits RIα, RIIα, and Cα 
are shown.  The interaction between E1A and the PKA catalytic subunit Cα required the 
presence of PKA regulatory subunits, indicating an indirect association.  E1A’s 
interaction with the regulatory subunits was unaffected by the Cα knockdown.  (C, D) 
HT1080 cells were co-transfected with PKA subunits and various E1A constructs 
expressed as fusions to EGFP and cell lysates were harvested for co-
immunoprecipitation.  (C)  Full-length E1A proteins from 6 different HAdV species all 
interacted with PKA subunits RIα, RIIα, and Cα to varying degrees, with the exception of 
HAdV-4.  (D)  Of the E1A fragments tested (shown in the inset panel) only the N-
terminus was sufficient for interaction with PKA.  This region of E1A has several regions 
of high amino acid sequence conservation between various HAdV species (E). 
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(Figure 2.1C).  The conservation of the E1A-PKA interaction across most HAdV species 
suggests that targeting of PKA is an important evolutionarily conserved function of E1A.  
E1A is comprised of a series of protein interaction modules that often can function 
independently (Pelka et al., 2008).  To grossly define which portion of E1A is required 
for PKA interaction, lysates from HT1080 cells expressing the PKA subunits and the 
indicated large fragments of HAdV-5 E1A expressed as EGFP-fusions, were subjected to 
Co-IP.  The N-terminal 82 residues of HAdV-5 E1A were sufficient for association with 
PKA (Figure 2.1D).  Interestingly, this region of E1A has been previously shown to be 
involved in alterations in cAMP signaling (Gedrich et al., 1992).  In addition, the 
interaction of HAdV-12 E1A with PKA similarly mapped to residues 1-79 in a yeast 
interaction assay (Fax et al., 2001).  As can be seen from the amino acid sequence 
alignment, there are several areas of high sequence similarity in this region in the E1A 
proteins from various HAdV species (Figure 2.1E). 
2.3.2 The sequence of E1A that binds PKA resembles a cellular 
AKAP 
To determine the minimal region of HAdV-5 E1A necessary and sufficient for PKA 
interaction, we carried out a detailed mutational analysis of the N-terminus of E1A.  Cells 
were co-transfected with vectors expressing PKA subunits and the indicated E1A 
mutants, each expressed in the context of full-length HAdV-5 E1A and containing a 
small in-frame deletion in the N-terminus.  As expected, deletion of residues 1-82 
abrogated interaction with PKA, confirming that the E1A N-terminus as necessary and 
sufficient for binding PKA (Figure 2.2A).  Several smaller, overlapping deletions also 
had similar defects for PKA-binding, specifically Δ1-29, Δ4-25, Δ16-28, and Δ26-35.  
However, adjacent deletion mutants Δ1-14 and Δ30-49, or more distant deletions retained 
interaction.  This suggests that a region spanning residues 14-29 of HAdV-5 E1A is 
necessary for PKA binding.    
We next co-transfected cells with PKA and small E1A fragments expressed as EGFP 
fusions.  Co-immunoprecipitation on lysates of these cells demonstrates that the 14-28 
region of E1A was sufficient to confer an interaction with PKA (Figure 2.2B).  This 
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Figure 2.2.  E1A contains an AKAP-like domain that is necessary and sufficient for 
binding PKA. 
HT1080 cells were co-transfected with PKA subunits and various E1A constructs and 
cell lysates were harvested for co-immunoprecipitation.  (A)  Mutational analysis using 
N-terminal deletion mutants of full-length E1A (shown in the inset panel) revealed that 
amino acids 14-28 are necessary for binding PKA subunits.  (B)  The N-terminal region 
of E1A, when expressed as a fragment fused to EGFP (shown in the inset panel), was 
also sufficient for binding PKA subunits.  This region of E1A bears amino acid similarity 
to a variety of known AKAPs and is predicted to contain an amphipathic α-helix (C).
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region is similar in the E1A proteins from most HAdV species (Figure 2.1E) and also has 
noticeable sequence similarity to the PKA-binding regions of a number of cellular 
AKAPs (Figure 2.2C).  Interestingly, AKAPs bind PKA regulatory subunits via an 
amphipathic α-helix secondary structure motif (Newlon et al., 1999; Sarma et al., 2010), 
and modeling of the N-terminus of HAdV-5 E1A predicts it also forms an amphipathic α-
helix (Figure 2.3).  Furthermore, the E1A proteins from all HAdV species are strongly 
predicted to form an α-helix in this region (Gedrich et al., 1992; Pelka et al., 2008), with 
the exception of HAdV-4 E1A, which is predicted to form a lower-confidence helix 
(Figure 2.4A) and does not bind PKA efficiently (Figure 2.1C).  Taken together, this 
suggests that E1A binds PKA by structurally mimicking the AKAPs’ amphipathic α-helix 
motif. 
2.3.3 E1A binds the same surface of PKA targeted by cellular AKAPs 
We performed in silico molecular modeling to predict the docking of the N-terminus of 
E1A with PKA. Docking simulations performed using the crystal structure of a dual-
specificity cellular AKAP in complex with the RIα homodimer of PKA suggest that the 
interaction of E1A with RIα is virtually equivalent to that of the cellular AKAP (Figure 
2.3A-D, F).  This model predicts a number of distinct interactions between E1A and RIα 
(Figure 2.3E, G), which were experimentally tested (Figure 2.3H, I).  E1A mutants 
D21K, E26K, V27K and E26A/V27A, reduced the interaction with RIα as predicted, 
whereas substitution of E25 with K, which is not predicted to alter binding, had no effect 
(Figure 2.3H).  Similarly, RIα mutants Q28E, L31A K32A and I35A/V36A displayed a 
reduced ability to bind E1A as predicted by the model (Figure 2.3I).  These results 
indicate that the docking model can correctly predict key residues necessary for binding, 
which further suggests that E1A structurally mimics a cellular AKAP in order to bind 
PKA. 
Cellular AKAPs bind to the docking/dimerization (D/D) domain located at the N-
terminus of the PKA regulatory subunits RIα and RIIα (Banky et al., 1998; Newlon et al., 
1999).  Given the sequence and predicted structural similarity between E1A and cellular 
AKAPs, we tested if the D/D domain was necessary for the interaction with E1A. 
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Figure 2.3.  E1A is predicted and confirmed to dock to PKA equivalently to a 
cellular AKAP. 
(A,B,C) Cartoon and stick representations of the predicted E1A helix docking to Protein 
Kinase A regulatory subunit R1α (dimer;red). Residues represented in sticks are within 
4A of each other, suggesting potential interactions. Key predicted interactions are circled.  
(D) Electrostatic surface representation of PKA R1α and alpha carbon tracing of E1A 
demonstrates limited potential electrostatic interactions, and multiple hydrophobic 
interactions.  (E) Sequence analysis reveals the residues of PKA R1α important for 
AKAP binding are similar to the residues implicated in the predicted interaction with 
E1A.  (F) Crystal structure of AKAP interacting with PKA regulatory subunit RIα (PDB 
ID 3IM4). AKAP structure is shown in blue, Surface electrostatics of PKA are depicted, 
with blue and red representing positive and negative charges respectively.  (G) Sequence 
of the predicted E1A helix and the residues implicated in PKA interaction according to 
ClusPro2.0 docking.  (H) E1A mutants D21K, E26K, V27K and E26A/V27A reduced 
interaction with RIα, whereas substitution of E25 with K, which is not predicted to alter 
binding, had no effect.  (I) RIα mutants Q28E, L31A K32A and I35A/V36A displayed a 
reduced ability to bind E1A. 
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Figure 2.4. HAdV-4 E1A is not predicted to form a helix that is capable of binding 
PKA in an equivalent manner as the HAdV-5 E1A AKAP-like sequence. 
(A) The PSI-PRED protein sequence analysis workbench was used to predict the helical 
propensity of the N-terminal regions of HAdV-5 and HAdV-4 E1A.  Although both 
sequences are predicted to form helices, HAdV-4 has a lower confidence in forming this 
secondary structure.  (B)  When attempting to dock the HAdV-4 E1A sequence to RIα 
using Clus-Pro, electrostatic interactions at both the amino and carboxy ends of this lower 
confidence structure are absent that are predicted to contribute to the AKAP like 
interaction with PKA observed with HAdV-5 E1A.  As expected, in the absence of these 
interactions, even in the most energy minimized states calculated for HAdV-4, HAdV-5 
E1A demonstrated a more stable energy minimization.  (C)  Using Clustal, the sequences 
of HAdV-5 and HAdV-4 E1A are compared, with the residues demonstrated as crucial 
for PKA-binding (Figure 2.3) highlighted by boxes here.  The corresponding residues in 
HAdV-4 E1A are quite different and lack the requisite chemical properties to form bonds 
with PKA.  Additionally, several bulky alphatic residues present in HAdV-5 E1A, which 
appear to stabilize the interaction with PKA via hydrophobic interactions, are also absent 
in HAdV-4 E1A. 
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Transfected HAdV-5 E1A was unable to co-immunoprecipitate RIα or RIIα lacking their 
D/D domain (Δ1-63 and Δ1-45, respectively, Figures 2.5A, B).  In addition, when the 
D/D domains of RIα and RIIα were expressed as fusions to EGFP, they alone were 
sufficient to co-immunoprecipitate E1A (Figure 2.5C).  Thus, the N-terminus of E1A not 
only resembles an AKAP based on sequence, but also binds to the same site on the PKA 
regulatory subunits targeted by cellular AKAPs. 
2.3.4 E1A functions as a viral AKAP 
We next determined if the structural similarity between E1A and cellular AKAPs 
extended to functional similarity.  We tested whether E1A could compete with 
endogenous AKAPs for PKA-binding during infection.  A549 cells were infected with 
WT HAdV-5, a ΔE1A virus, or a virus expressing an E1A mutant unable to bind PKA 
(Δ4-25).  Cell lysates were prepared 18 hours post-infection, subjected to 
immunoprecipitation with an anti-AKAP7 antibody and any co-precipitating PKA 
subunits were detected via western blot with specific antibodies for each target.  AKAP7 
is a dual-specificity AKAP (Gold et al., 2006), which binds both RIα and RIIα directly, 
and indirectly binds Cα.  Infection with HAdV-5 did not alter the expression of AKAP7 
or the various PKA subunits.  However, infection disrupted the endogenous interactions 
between AKAP7 and PKA.  Disruption of the AKAP7-PKA interaction during infection 
required E1A and was dependent on the AKAP-like domain in E1A (Figure 2.6A).  
These data establish that the AKAP-like region in E1A competes with endogenous 
AKAPs for PKA interaction during infection.  These results also suggests that E1A can 
out-compete at least some cellular AKAPs for binding to PKA, which likely contributes 
to previously observed perturbation of cellular cAMP signalling by HAdV infection 
(Engel et al., 1991, 1988; Gedrich et al., 1992). 
We next tested whether in silico-designed peptide inhibitors, which block AKAP-PKA 
interactions by binding PKA regulatory subunits with sub-nanomolar affinities, could 
affect E1A’s interaction with PKA.  These well characterized inhibitors are short peptides 
expressed as EGFP-fusions which specifically block binding to RIα (RIAD) or RIIα 
(sAKAPis) (Carlson et al., 2006; Gold et al., 2006).  HT1080 cells were co-transfected 
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Figure 2.5.  The D/D domains of PKA regulatory subunits are necessary and 
sufficient for binding E1A. 
HT1080 cells were co-transfected with E1A and a variety of PKA regulatory subunit 
constructs and cell lysates were harvested for co-immunoprecipitation.  Deletion of the 
D/D domain (shown in the inset panels) in either RIα (A) or RIIα (B) reduced the 
interaction with WT E1A.  (C)  When expressed as EGFP fusions (shown in the inset 
panel) these D/D domains were sufficient for binding E1A.  Images are cropped to 
exclude the IgG heavy chain signal. 
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Figure 2.6.  E1A can compete with and function like an AKAP. 
(A)  A549 cells were infected with either WT HAdV-5, ΔE1A virus, or a virus that lacks 
PKA-binding (Δ4-25[dl1101]) and cell lysates were harvested for co-
immunoprecipitation.  Interactions between the endogenous dual-specificity AKAP7 and 
PKA subunits was disrupted in the presence of WT E1A, but remained intact in presence 
of an E1A mutant unable to bind PKA.  (B)  HT1080 cells were co-transfected with E1A, 
PKA, and the indicated high affinity AKAP-PKA binding inhibitors (shown in the inset 
panel).  The binding inhibitors disrupted the E1A-PKA interactions in an isoform-specific 
manner.  (C)  HT1080 cells were co-transfected with PKA and the indicated D-AKAP1 
construct.  An AKAP1 mutant lacking its binding for PKA was rescued by cloning in the 
AKAP-like sequence of HAdV-5 E1A. 
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with vectors expressing the PKA subunits, WT E1A, and each of the inhibitors.  Lysates 
were subjected to immunoprecipitation with an anti-E1A antibody and interacting PKA 
subunits were detected by western blot.  As expected based on their high affinity, both 
RIAD and sAKAPis competitively reduced E1A’s interaction with PKA in a subunit-
specific manner, reinforcing E1A’s role as a dual-specificity viral AKAP (Figure 2.6B). 
Using an expression construct for a known cellular dual-specificity AKAP (AKAP1) 
(Gold et al., 2006), we next tested E1A’s ability to rescue the PKA-binding function of 
this AKAP when its PKA-binding domain was deleted.  HT1080 cells were co-
transfected with PKA subunits and EGFP-fusions of WT AKAP1, an AKAP1 mutant 
lacking its PKA-binding domain (AKAP1Δ), or an AKAP1 construct with E1A residues 
14-28 cloned in lieu of the deletion (AKAP1-E1A).  Lysates were subjected to 
immunoprecipitation with an anti-EGFP antibody and co-precipitating PKA was detected 
via western blot.  As expected, the AKAP1Δ mutant lost the ability to bind PKA.  
However, incorporation of the E1A AKAP-like sequence into this mutant rescued PKA-
binding to WT levels (Figure 2.6C).  Together, these results strongly suggest that the 
AKAP-like motif in E1A is functionally indistinguishable from that found in an authentic 
cellular AKAP. 
2.3.5 E1A alters PKA subcellular localization 
Transfection of cells with HAdV-12 E1A induces a relocalization of the RIIα subunit of 
PKA from the cytoplasm to the nucleus (Fax et al., 2001).  We tested E1A’s ability to 
alter PKA’s subcellular localization in vivo during a HAdV-5 infection (Figures 2.7, 
2.8A).  A549 cells were infected with WT virus (dl309), a ΔE1A virus (dl312), or the Δ4-
25 E1A deletion mutant virus (dl1101) that does not bind PKA.  At 18 hours post-
infection, cells were subjected to immunofluorescence staining and biochemical 
fractionation to determine the subcellular localization of PKA.  In WT-infected cells, 
endogenous RIα was rerouted from the cytoplasm into the nucleus.  Additionally, in 
infected cells, RIα appeared to overlap with the HAdV-5 encoded DNA-binding protein 
(DBP), suggesting possible co-localization with viral replication centres during infection 
(Figure 2.9).  In contrast, the distribution of PKA subunits in cells infected with either the 
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Figure 2.7.  E1A alters PKA R1α subcellular localization during infection. 
A549 cells were infected with either WT HAdV-5, ΔE1A virus or a virus mutant unable 
to bind PKA (Δ4-25).  Cells were fixed, permeabilized and stained for confocal 
immunofluorescence.  In the presence of WT E1A, RIα exhibited a drastic shift from 
exclusively cytoplasmic localization into the cell nucleus (A).  This redistribution did not 
occur during ΔE1A or Δ4-25 infections.  RIIα and Cα were not re-localized in the same 
manner as RIα (Figure 2.8A) Scale bars represent 200µm.  (B) Quantification of nuclear 
signal relative to total cellular signal.  Statistically significant differences are denoted 
(*p<0.001) n=50.  (C) Nuclear and cytoplasmic extracts from infected cells were 
prepared by biochemical fractionation and the presence of E1A and PKA subunits in each 
fraction were detected by western blot.  The presence of nuclear RIα in WT-infected cells 
confirms the results observed by immunofluorescence. 
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Figure 2.8.  Subcellular localization of RIIα and Cα during HAdV-5 infection and 
localization of all PKA subunits in HEK293 cells. 
(A) A549 cells were infected with either WT HAdV-5 (dl309), ΔE1A virus (dl312) or a 
virus lacking PKA-binding (dl1101; Δ4-25).  Cells were fixed, permeabilized and stained 
for confocal immunofluorescence.  RIIα appears cytoplasmic in all experimental 
conditions.  Cα appears nuclear-cytoplasmic in all experimental conditions, although it 
may be enriched for nuclear localization in the presence of WT E1A.  (B) HEK293 cells 
(which are stably transformed due to expression of HAdV-5 E1A and E1B) were stained 
and individual PKA subunits and were demonstrated to have a similar localization 
phenotypes as in HAdV-infected cells.  The nuclear relocalization of RIα appears more 
diffuse and less punctate in these cells, possibly due to lack of recruitment to viral 
replication centres as there is no infection occurring in these virally transformed cells.  In 
a separate experiment, endogenous E1A was successfully knocked down to undetectable 
levels via siRNA-transfection (the knockdown efficiency of various E1A-specific 
siRNAs generated for this experiment is shown in the inset panel).  The amount of RIα 
detected in the nucleus is greatly reduced when E1A expression is knocked down.  Scale 
bars represent 200µm. 
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Figure 2.9.  Co-staining of PKA and viral replication centres during HAdV-5 
infection. 
A549 cells were infected with the indicated virus (MOI 5) and were subsequently fixed, 
permeabilized and stained with antibodies specific for the indicated PKA subunits or 
HAdV-5 DNA-binding protein (DBP) and DAPI as indicated.  Images were acquired on a 
Nikon Eclipse inverted laser microscope.  During WT infection, a portion of nuclear RIα 
appears to co-stain with the HAdV-5 DBP, suggesting overlap with viral replication 
centres.  This is not observed during infection with mutant virus encoding E1A incapable 
of binding PKA (dl1101).  Under both conditions, RIIα appears to remain cytoplasmic, 
whereas Cα maintains a diffuse nuclear/cytoplasmic localization.  Scale bars represent 
200µm. 
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ΔE1A or Δ4-25 virus resembled uninfected cells.  Thus, the relocalization of RIα is E1A- 
dependent and requires the AKAP motif.  Subcellular localization of RIIα appeared to be 
unaffected by the presence of E1A and Cα retained its nuclear/cytoplasmic phenotype in 
both uninfected and infected cells, thereby rendering any conclusions regarding its 
relocalization difficult (Figure 2.8A). 
RIα, but not RIIα, is similarly trafficked into the nucleus of HEK293 cells, which stably 
express HAdV-5 E1A. Knockdown of E1A in HEK293 cells reduces the amount of RIα 
in the nucleus, further suggesting that E1A is functioning as an AKAP in these cells to 
redistribute PKA (Figure 2.8B).  Interestingly, HAdV-5 E1A appears to primarily affect 
type-I PKA, whereas the previously reported effect of HAdV-12 E1A was restricted to 
type-II PKA. 
2.3.6 E1A uses PKA to enhance HAdV gene expression 
Previous studies indicated that E1A and cAMP synergize to activate viral gene 
expression (Engel et al., 1991, 1988; Gedrich et al., 1992; Hardy and Shenk, 1988; B. H. 
Lee and Mathews, 1997; Müller et al., 1989).  To determine if the E1A-PKA interaction 
contributes to HAdV early gene transcription, A549 cells were first treated with control 
siRNA or siRNA specific for each PKA subunit and then infected with WT (dl309), 
ΔE1A (dl312), or Δ4-25 (dl1101) HAdV-5.  Cells were harvested 20 hours post-
infection, cDNA was prepared and the expression of a panel of HAdV early genes known 
to be activated by E1A was determined by quantitative real-time PCR.  Knockdown of 
RIα, RIIα, or Cα did not affect expression of the E1A (Figure 2.10A) or E1B (Figure 
2.10B) transcription units for any of the tested viruses.  However, mRNA levels were 
significantly reduced for both the E3 (Figure 2.10D) and E4 (Figure 2.10E) transcription 
units in WT virus infected cells treated with siRNA for each of the PKA subunits, 
demonstrating that PKA plays a role in the regulation of these transcription units.  
Importantly, cells infected with the Δ4-25 virus also showed decreased expression of E3 
and E4 as compared to WT infection, and this was not further reduced by knockdown of 
any PKA subunit (Figure 2.10D, 2.10E). This is fully consistent with the inability of this 
mutant E1A protein to bind PKA and relocalize it to the nucleus.  Mechanistically,
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Figure 2.10.  The interaction between E1A and PKA subunits is required for full 
expression of HAdV-5 E3 and E4 transcripts. 
A549 cells were treated with control siRNA or siRNA specific for PKA subunits (shown 
in the inset panel) and infected with either WT HAdV-5 or the indicated mutants.  RT-
qPCR was performed with a panel of HAdV-5 early genes, normalized to GAPDH and 
fold change to control treated cells was plotted.  Results for the HAdV-5 E1A (A), E1B 
(B), E2 (C), E3 (D) and E4 (E) transcription units are shown.  A statistically significant 
decrease from control-treated cells is indicated (*p<0.05) n=3. 
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Figure 2.11.  PKA is recruited to HAdV early gene promoters in an E1A-dependent 
manner. 
A549 cells were infected with the indicated viruses at an MOI of 5 and harvested 20 
hours post-infection.  Chromatin immunoprecipitation (ChIP) was performed with 
antibodies specific for the indicated proteins.  DNA was probed via qPCR for the 
presence of multiple HAdV early gene promoters (E1B, E3, and E4) and a cellular 
GAPDH promoter previously shown to be unaffected by E1A in similar conditions 
(Fonseca et al. 2013).  Data was normalized to input samples and compared to a non-
specific control antibody and ΔE1A-infected cells.  A statistically significant increase 
from ΔE1A-infected cells for each specific ChIP reaction is indicated (* p<0.05, n=3).  In 
WT-infected cells (dl309), the catalytic subunit (Cα) is specifically recruited to the 
HAdV E3 and E4 promoters whose transcription was shown to be affected by the E1A-
PKA interaction.  This recruitment is E1A-dependent as neither ΔE1A HAdV (dl312) nor 
virus incapable of binding PKA (dl1101; Δ4-25) could recruit Cα.  In contrast, Cα is not 
recruited to the GAPDH promoter and while it was present on the E1B promoter, this was 
independent of E1A and does not appear to affect transcription (Figure 2.10).  
Interestingly, neither regulatory subunit of PKA was directly recruited to the HAdV 
genome.  Instead, it appears E1A uses the interaction with the PKA regulatory subunits to 
retask the catalytic component of the holoenzyme to sites of action in the nucleus.
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chromatin immunoprecipitation (ChIP) experiments showed that PKA’s catalytic subunit 
(Cα) was recruited to the HAdV E3 and E4 promoter regions in an E1A-dependent 
manner (Figure 2.11).  In contrast, E1A did not specifically recruit Cα to the E1B or 
GAPDH promoters, whose transcription was unaffected by the E1A-PKA interaction 
(Figure 2.10).  These results strongly support a mechanism of early gene activation that 
relies on the AKAP function of E1A. 
Although knockdown of PKA regulatory subunits had no statistically significant effect on 
E2 transcripts, knockdown of the catalytic subunit reduced E2 expression for both WT 
and Δ4-25 virus (Figure 2.10C).  This suggests an independent effect for PKA on this 
transcription unit that does not rely on the AKAP motif. 
To extend the observations that PKA plays a role in HAdV gene expression, we further 
examined PKA’s role in HAdV-5 protein production (Figure 2.12).  A549 cells were 
treated with control siRNA or siRNA specific for each PKA subunits and infected with 
WT HAdV-5.  Cell lysates were collected at 12, 24, and 36 hours post-infection.  Viral 
protein production was assayed by western blot using antibodies against an array of 
HAdV-5 proteins representing both early and late transcription units.  Compared to 
control-treated cells, knockdown of PKA subunits had no effect on the production of 
HAdV-5 E1A proteins.  In contrast, knockdown of the individual PKA subunits caused a 
notable reduction in several early proteins.  These included a reduction in E3-19K at each 
time point examined, a reduced level of E4orf6 expression at 24 hours post-infection and 
a delay in expression of the E2-encoded DBP.   E1B-55K was also reduced, most notably 
in the RIα knockdown.  Interestingly, many of the late proteins also exhibited lower 
expressions levels in PKA-knockdown cells, including hexon, penton, protein V, and 
protein VII.  This confirms a role for PKA in regulating HAdV-5 gene expression. 
2.3.7 E1A uses PKA to enhance viral replication 
To establish the biological significance of E1A’s role as a viral AKAP, we also assessed 
the effect of the E1A-PKA interaction on viral replication (Figure 2.13).  A549 cells were 
treated with either control siRNA or siRNA specific for each PKA subunit and infected 
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Figure 2.12.  PKA is required for WT levels of HAdV-5 protein production. 
A549 cells were treated with control siRNA or siRNA specific for PKA subunits and 
infected with WT HAdV-5 (dl309; MOI of 5).  Cells were harvested at 12, 24, and 36 hr 
post-infection and viral protein production was assayed by western blot using antibodies 
against representative proteins from an array of HAdV-5 transcription units. 
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with either WT or Δ4-25 HAdV-5.  Production of infectious virus progeny was assayed at 
various time points over 72 hours by plaque assay.  The production of WT virus was 
reduced by knockdown of each PKA subunit when compared to control-treated cells.  
Although the production of the Δ4-25 virus was reduced as compared with WT infection, 
it was not further reduced by knockdown of either RIα or RIIα.  This again suggests that 
the lack of PKA-binding by this E1A mutant is functionally equivalent to PKA 
knockdown.  These results indicate that HAdV replication requires PKA activity and that 
E1A’s interaction with PKA’s regulatory subunits is required for WT-levels of 
replication.  Interestingly, we observed a reduction in progeny production for both WT 
and Δ4-25 virus in cells treated with Cα-specific siRNA.  However, the observed 
reduction compared to control-siRNA treated cells was more severe in the WT infection, 
suggesting an additional role for PKA in HAdV-5 infection that is E1A-independent and 
specific for PKA’s catalytic subunit.  Altogether, these results confirm that the targeting 
of PKA by the AKAP motif in E1A is a critical aspect in the HAdV-5 replicative cycle. 
2.4 Discussion 
Cellular AKAPs function as scaffolds that target PKA and other signaling enzymes to 
specified subcellular locations.  These multivalent anchoring proteins serve as important 
focal points for the processing and integration of intracellular signaling (Colledge and 
Scott, 1999; Taskén and Aandahl, 2004).  We report here that the adenovirus E1A 
oncoproteins function as the first known viral AKAPs.  Intriguingly, E1A interacts with 
both the RIα and RIIα subunits of PKA in a way that precisely mimics that of cellular 
dual-specificity AKAPs.  Specifically, we found that E1A bound to the N-terminal D/D 
domain of the regulatory subunit dimer of PKA, which is the same exact domain targeted 
by cellular AKAPs (Taylor et al., 2012; Wong and Scott, 2004).  We identified a short 
conserved sequence in HAdV-5 E1A spanning residues 14-28 that was necessary and 
sufficient for interaction with either RIα or RIIα.  Like the PKA interaction domains of 
cellular AKAPs, this region of E1A is predicted to form an amphipathic α-helix.  This 
apparent structural mimicry allows E1A to bind PKA with an affinity comparable to 
cellular AKAPs, such that E1A can successfully compete with endogenous cellular 
AKAPs for PKA interaction during infection (Figure 2.14). 
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Figure 2.13.  Interactions between E1A and PKA are required for full HAdV-5 
progeny production. 
A549 cells were treated with control siRNA or siRNA specific for PKA subunits and 
infected with either WT HAdV-5 or a virus encoding E1A unable to bind PKA (Δ4-25).  
Cells were collected at various time points up to 72 hr post-infection.  Production of 
infectious progeny virus was quantitatively assayed by plaque formation on HEK293 
cells (A).  Data are shown over 36-72 hr.  Growth of WT virus was decreased by 
knockdown of each PKA subunit.  Growth of HAdV E1A Δ4-25 was not affected by 
knockdown of PKA regulatory subunits, but was affected by knockdown of PKA Cα 
(though to a lesser extent than WT HAdV-5).  (B) Total viral progeny production at 60 
hours post-infection when virus replication appeared to peak in most conditions.  All 
values are represented as mean ± SEM.  The statistically significant reductions in viral 
titres compared to control-treated cells are denoted (*p<0.01). 
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In support of our in vivo and in vitro results, molecular modeling based on a known 
structure of the AKAP/PKA interaction predicts that E1A binds the exact same surface of 
the PKA regulatory subunit in a fashion virtually identical to that determined for cellular 
AKAPs (Figure 2.3).  Substitution of specific residues predicted by this model to make 
contacts reduced the interaction in vivo, supporting the validity of this structural model of 
molecular mimicry. 
Functionally, as observed for cellular AKAPs, E1A relocalizes PKA to target sites of 
action.  In the case of E1A, the interaction with PKA induces a specific relocalization to 
the nucleus, which contributes to viral gene expression and efficient virus propagation 
during infection.  Competition by E1A with cellular AKAPs for PKA interaction may 
also influence cellular gene expression, which may provide some insight into the 
previous observations that E1A influences cAMP signaling (Engel et al., 1991, 1988; 
Gedrich et al., 1992; B. H. Lee and Mathews, 1997; Miller et al., 1995; Müller et al., 
1989).  The E1A region mapped as necessary and sufficient for PKA-binding also 
overlaps with regions previously implicated in E1A’s ability to function as a transforming 
oncoprotein (Chinnadurai, 2011).  Whether PKA contributes to the immortalizing activity 
of E1A remains unknown, though PKA itself has been investigated in a variety of cancer-
related functions (Gold et al., 2013; Palorini et al., 2016; Pattabiraman et al., 2016) 
Our results also demonstrate that PKA is a conserved target of the E1A proteins from 
multiple HAdV species, suggesting that this interaction is functionally important for the 
virus.  The E1A proteins from all HAdV types tested bound PKA strongly, with the 
exception of HAdV-4 E1A; modeling of an interaction between HAdV-4 E1A and PKA 
predicts that key electrostatic and hydrophobic contacts are absent, which are necessary 
for the HAdV-5 E1A PKA interaction (Figures 2.3H, 2.4).  Interestingly, HAdV-4 is 
unique as it is the sole member of species E HAdV and arose from an interspecies 
recombination event between chimpanzee and human adenovirus (Dehghan et al., 2013). 
As mentioned above, during HAdV-5 infection, E1A was able to out-compete 
endogenous cellular AKAP7 for PKA interaction; however, there exist a plethora of 
other, diverse AKAPs with varying affinities for PKA.  For example, the in silico-
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designed ‘super AKAPs’ RIAD and sAKAPis (Carlson et al., 2006; Gold et al., 2006) 
blocked the binding of E1A to the PKA RIα and RIIα subunits, respectively.  Thus, the 
affinity of the E1A/PKA interaction is not high enough to compete with synthetic AKAPs 
with sub-nanomolar affinities for PKA.  Consequently, these inhibitors are potential tools 
for further study of E1A function in the context of its role as a viral AKAP.    
During HAdV-5 infection, a substantial fraction of the RIα subunit was trafficked from 
the cytoplasm into the nucleus in an E1A-dependent manner.  We also observed signal 
overlap between RIα and HAdV DBP (Figure 2.9), suggesting co-localization with viral 
replication centres.  Interestingly, the HAdV-5 E1A-mediated shift in RIα localization is 
the opposite finding reported for E1A from HAdV-12, which relocalized RIIα only (Fax 
et al., 2001).  While both E1As bound to both type-I and –II PKA in Co-IP assays, our 
studies suggest that in biologically-relevant conditions they each may exhibit higher 
affinity or preference for one PKA flavour over another, a property shared by many 
cellular AKAPs (Gold et al., 2006; Taylor et al., 2012; Wong and Scott, 2004).  The 
binding affinities and potential preferences of E1A proteins from the other HAdV species 
during infection remains to be fully explored.  It also remains to be determined if type-I 
and type-II PKA are completely interchangeable, or if there are functional consequences 
driving the preference of each virus for each regulatory subunit type.  
Interestingly, nuclear localization of the PKA holoenzyme is considered relatively 
unusual, but has been studied in detail in HEK-293 cells (Sample et al., 2012).  We 
confirmed nuclear localization of RIα in these cells, which constitutively express HAdV-
5 E1A (Graham et al., 1977).  Our results suggest that nuclear localization of PKA in 
HEK-293 cells is a likely consequence of the AKAP function of E1A.  Furthermore, our 
data suggests that the results of studies of PKA function in these cells may be confounded 
by the impact of viral manipulation of this pathway.    
The targeting of PKA by E1A is required for maximal expression of the HAdV-5 E3 and 
E4 transcription units.  It appears that E1A is using the regulatory subunits of PKA as a 
bridge to bind Cα, redistributing it to associate with other E1A binding partners at 
preferred sites within the nucleus, such as the HAdV early gene promoters (Figure 2.11).
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Figure 2.14.  E1A functions as a viral AKAP. 
During infection, the viral E1A protein interacts with the PKA holoenzyme.  This occurs 
via structural mimicry of the PKA interaction domain of cellular AKAPs.  As a 
consequence, competition occurs between the viral AKAP and cellular AKAPs for 
interaction with PKA.  The interaction of E1A with PKA leads to a relocalization of a 
subset of PKA to the nucleus, likely to HAdV early gene promoters within virus 
replication centres.  This interaction and relocalization is required for efficient viral 
transcription, protein expression and progeny production. 
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This could establish new localized connections with cAMP-regulated transcriptional 
machinery, such as CREB or ATF, at viral or cellular loci.  This may help explain the 
previously-observed ability of E1A to cooperate with cAMP in transcriptional activation 
(Engel et al., 1991, 1988; Müller et al., 1989). 
The importance of PKA during a productive infection is further underscored by our 
observation that siRNA-mediated downregulation of PKA subunits reduces progeny 
production by WT HAdV-5.  It is likely that the observed defect in the virus’ ability to 
express numerous crucial transcripts and proteins in the absence of PKA (or the AKAP 
function of E1A) contributes greatly to this.  It is also possible that the E1A-PKA 
interaction affects cellular tasks that influence HAdV replication, given that PKA and 
cAMP have been previously shown to extensively modulate cellular transcription, protein 
expression, and cell signaling (Guo et al., 2012; Sands and Palmer, 2008; Zambon et al., 
2005; Zhang et al., 2005).   As expected, growth of a virus expressing an E1A mutant 
unable to bind PKA (Δ4-25) was reduced relative to WT.  Importantly, knockdown of 
regulatory subunits RIα and RIIα did not further reduce the overall replication of this 
mutant, confirming that the lack of the E1A-PKA interaction contributes to its growth 
defect.  Interestingly, loss of Cα expression negatively affected overall viral replication 
for both WT and Δ4-25 viruses, suggesting an E1A-independent effect of Cα on the 
HAdV life cycle.  This may be related to reports that PKA activity is involved in dynein-
mediated transport of species C HAdV virions to the nucleus during the establishment of 
infection (Scherer et al., 2014; Suomalainen et al., 2001).   
Although E1A is presently unique in its ability to function as a viral AKAP, the important 
role of PKA in cellular homeostasis makes it an attractive target for modulation during 
infection by other viruses.  For example, the Herpes simplex virus-1 US3 kinase interacts 
with and activates PKA to block apoptosis (Benetti and Roizman, 2004).  Varicella-zoster 
virus also upregulates PKA expression and modulates phosphorylation of PKA substrates 
to improve replication (Desloges et al., 2008).  More typically, PKA is recruited to 
phosphorylate viral proteins, altering their stability, folding or ability to interact with 
other targets (Barnitz et al., 2010; Cartier et al., 2003; Majeau et al., 2007; Okabe et al., 
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2006).  As one well characterized example, the E6 oncoprotein from human 
papillomavirus (HPV) is phosphorylated by PKA during infection, allowing it to interact 
with numerous cellular proteins (Boon et al., 2015; Delury et al., 2013).  While E1A does 
not appear to be a substrate for PKA, its unique mechanism of commandeering this 
enzyme via mimicry highlights the diverse ways in which viruses can repurpose the same 
cellular factors.  It is also interesting that rather than encoding an entire PKA ortholog or 
an entire viral protein to subvert PKA function, HAdV uses a short 15 amino acid 
fragment of the versatile E1A protein to retask PKA for the benefit of the virus.  The fact 
that the AKAP mimic motif in E1A also overlaps regions required for targeting other 
cellular regulatory proteins (Fonseca et al., 2012; Meng et al., 2005; Rasti et al., 2005) 
further demonstrates the incredible effect of selective pressure on maximizing the impact 
of the relatively limited coding capacity of HAdV.  
In summary, we conclusively identify E1A as the first known viral AKAP.  We 
demonstrate that the N-terminus of E1A has evolved to mimic the appearance, structure 
and function of the PKA interaction domain of cellular AKAPs.  Furthermore, we have 
established that the AKAP function of E1A plays a biologically significant role in 
redirecting PKA to the nucleus during infection, where it is repurposed to enhance HAdV 
early gene expression and viral progeny production. 
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Chapter 3  
3 Mimicry of cellular A-kinase anchoring proteins is a 
conserved and critical function of E1A across various 
human adenovirus species 
“When you run the marathon, you run against the distance, not against the other runners 
and not against the time.”  
– Haile Gebrselassie 
3.1 Introduction 
The E1A oncoprotein of human adenovirus (HAdV) is the first viral protein produced 
upon infection and performs numerous crucial tasks required for viral command of the 
host cell (Frisch and Mymryk, 2002; Pelka et al., 2008).  By binding to and modulating 
the activities of important cellular regulatory proteins, E1A alters the transcriptional 
landscape of infected cells to favour viral replication (Ferrari et al., 2014, 2008; Hearing 
and Shenk, 1986).  The targets of E1A are diverse in both form and function, highlighting 
its modular and multifunctional nature.  As a relatively small protein, E1A is densely 
packed with protein interaction motifs ranging in size from a mere few to dozens of 
amino acids (Ferreon et al., 2013; Pelka et al., 2008).  Additionally, many of these motifs 
are functional mimics of cellular counterparts suggesting E1A has coevolved with its host 
to be an effective competitor for its targeted binding partners.   
The N-terminus of HAdV-5 E1A (~aa1-40) alone is capable of interacting with roughly a 
dozen cellular proteins and contains strong transcriptional activation ability (Bondesson 
et al., 1994; Pelka et al., 2008; Yousef et al., 2009).  Indeed, viral genes as well as 
cellular genes involved in cell cycle, signalling, differentiation, and immunity are 
modulated by the protein-protein interactions from this small portion of a single viral 
protein.  Recently, protein kinase A (PKA) was shown to be a target of HAdV-5 E1A via 
viral mimicry (King et al., 2016a).  PKA primarily exists as a tetrameric holoenzyme 
consisting of two catalytic subunits (C) bound by a regulatory subunit (R) homodimer 
(Taylor et al., 2013).  Multiple isoforms of both C- and R-subunits exist, providing 
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additional levels of functional specificity based on cell-type specific expression, 
additional binding partners, and substrate recognition.  Cα specifically was manipulated 
by HAdV-5 E1A via E1A’s ability to bind both the RIα- and RIIα-type regulatory 
subunits.  This was mediated through the N-terminus of HAdV-5 E1A which contains a 
binding motif similar to that found in PKA’s canonical cellular interacting partner(s), A-
kinase anchoring proteins (AKAPs).  AKAPs are polyvalent and highly dynamic scaffold 
proteins that provide spatiotemporal control of PKA by localizing it within the cell 
(Banky et al., 1998; Gold et al., 2006; Newlon et al., 1999). Their hallmark PKA-binding 
motif is an amphipathic α-helix that directly binds with high-affinity to the hydrophobic 
groove in the D/D domain of PKA R-subunit dimers.  Most AKAP-PKA interactions are 
specific for either RIα or RIIα subunits but dual-specificity AKAPs exist as well. In 
addition to binding PKA, AKAPs typically contain motifs directing their subcellular 
localization to specific intracellular compartments or organelles.  AKAPs enable tight and 
efficient control of cAMP signaling by simultaneously tethering interactions between 
PKA, substrates, and up- or down-stream regulators of the pathway.  PKA serves several 
signalling roles in cell biology, including transcriptional regulation, making it an 
attractive target for manipulation by a viral hub like E1A (Guo et al., 2012; Sands and 
Palmer, 2008; Zambon et al., 2005; Zhang et al., 2005).  E1A’s own amphipathic α-helix 
motif allowed it to outcompete endogenous AKAPs to bind with PKA and relocalize it to 
the nucleus.  The alteration of PKA compartmentalization by this ‘viral AKAP’ (vAKAP) 
was biologically significant as it enhanced viral transcription, protein synthesis, and 
progeny production. 
The mechanism behind E1A-mediated manipulation of PKA was well-characterized in 
the context of HAdV-5 infection.  However, while protein-protein binding was shown to 
be largely conserved between PKA and E1A proteins of different HAdV species, very 
little is known regarding how E1A from other HAdVs may affect this important cellular 
kinase.  The N-terminal sequence of E1A, containing the PKA-binding α-helix, is not as 
conserved as other portions of this protein (Avvakumov et al., 2004) and it has been 
shown that altering a single or few amino acids can disrupt the interaction between E1A 
and PKA (King et al., 2016a).  Whether all species of HAdV utilize E1A as a vAKAP has 
yet to be determined.  There may also exist varying preferences for PKA subunit binding 
123 
 
 
or relocalization, and this may confer differential effects on replication for distinct 
HAdVs. 
Here we analyze representative E1A proteins from seven HAdV species for their abilities 
to act as vAKAPs.  We found that while not all species of E1A could engage in this form 
of mimicry, the mechanism described for HAdV-5 E1A is largely conserved between 
several distinct HAdVs.  Building upon previous observations, different E1As exhibit a 
preference for one type of PKA regulatory subunit (RIα or RIIα) over the other.  While 
exploring this finding, we identified individual residuesin the PKA-binding motifs of 
vAKAPs that when altered by site-directed mutagenesis can convert the preferred 
interaction to the alternative regulatory subunit.  Additionally, we provide new 
mechanistic insights into how HAdV alters cellular cAMP signalling and show viruses 
capable of manipulating PKA have an enhanced ability to drive cAMP-regulated 
transcription.  An E1A-PKA interaction is also a conserved requirement for wild-type 
(WT) levels of viral genome replication and infectious progeny production.  Together, 
our results characterize a shared mechanism for viral manipulation of a cellular kinase 
which enhances the life cycle of numerous human adenoviruses. 
3.2 Materials and Methods 
3.2.1 Cell lines and transfections 
Human A549 (provided by Russ Wheeler, Molecular Pathology/Genetics London Health 
Sciences Centre), HEK293, HT1080, and HeLa (purchased from the American Type 
Culture Collection) were grown at 37ᵒC with 5% CO2 in DMEM (Multicell) 
supplemented with 10% fetal bovine serum (Gibco).  Plasmids were transfected into 
HT1080 and HeLa cells using XtremegeneHP (Roche) following the manufacturer’s 
recommendation.  After 24 hours of incubation, transfected cells were used for 
downstream experiments. 
3.2.2 Viruses and infection of cells 
Wild-type (WT) HAdV-5 (dl309) was previously described (Jones and Shenk, 1979) and 
mutants dl312 and dl1101 are derived from the same background to express no E1A and 
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E1AΔ4-25 respectively.  HAdV-5 dl520 and dl1131/520 express only the “12S” product 
of E1A with the latter containing an additional C-terminal deletion (219-289) (Mymryk 
and Bayley, 1993).  WT serotypes of HAdV-3 (strain GB Lot 11W), -4 (strain RI-67 Lot 
3W), -9 (Strain Hicks Lot 1W), and -12 (Strain Huie Lot 8W) were purchased from the 
ATCC via Cedarlane.  A549 cells were infected at a multiplicity of infection (MOI) of 5 
plaque-forming units/mL (for HAdV-5) or 25 for all other virus species to attain similar 
levels of infection.  Cell cultures were infected at ~50% confluence and subconfluent 
cells were collected at indicated time points for downstream experiments.  For plaque 
assays, HEK293 cells were infected with serially-diluted samples for 1 hour at 37ᵒC 
before being overlayed with DMEM containing 1% SeaPlaque Agarose (Lonza). 
3.2.3 RNAi knockdown 
Downregulation of PKA subunits RIα, RIIα, and Cα was performed using Silencer Select 
siRNA (Thermo), specifically s286 (PRKAR1A), s11086 (PRKAR2A), and s11065 
(PRKACA).  Four hours after seeding, siRNA was delivered to A549 and HT1080 cells 
via transfection with Silentfect (BioRad) according to the manufacturer’s instructions.  A 
scrambled siRNA was used as a negative control.  Treated cells were used for 
experiments 48 hours post-transfection.   
3.2.4 Plasmids 
All constructs were expressed in vectors under control of the CMV promoter, with the 
exception of the luciferase reporter which was driven by the cAMP-responsive rat 
PEPCK promoter (Klemm et al., 1996).  WT RIα, RIIα, and Cα along with ΔD/D mutants 
were previously described (King et al., 2016a).  WT full-length HAdV-52 E1A was 
synthesized using IDT’s gene synthesis platform from a published genome sequence 
(Jones et al., 2007).  E1A fragments, truncations, and deletion mutants for all species 
were expressed as fusions to EGFP and either previously described (King et al., 2016a) or 
derived via PCR and cloned into pEGFP-C2.  Chimeras (HAdV-4 chimera and HAdV-5 
chimera) and point mutants (HAdV-5 D21E, E26T, V27L and HAdV-3 E22D, T27E, 
L28V) were cloned similarly.  A list of all plasmids used in this chapter can be found in 
table 3.1. 
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Table 3.1.  List of plasmids used in this chapter 
Clone Backbone(s) Notes 
13S Ad3 E1A pEGFP-C2 Species B 
13S Ad4 E1A pEGFP-C2 Species E 
13S Ad5 E1A pEGFP-C2, pcDNA3 Species C 
13S Ad9 E1A pEGFP-C2 Species D 
13S Ad12 E1A pEGFP-C2 Species A 
13S Ad40 E1A pEGFP-C2 Species F 
*13S Ad52 E1A pEGFP-C2 Species G, Jones et al., 2007 
Ad5 E1A 1-82 pEGFP-C2 N-terminus and CR1 
*Ad3 E1A Δ1-82 pEGFP-C2  
Ad3 E1A 1-82 pEGFP-C2 N-terminus and CR1 
*Ad9 E1A Δ1-81 pEGFP-C2  
Ad9 E1A 1-81 pEGFP-C2 N-terminus and CR1 
*Ad12 E1A Δ1-79 pEGFP-C2  
Ad12 E1A 1-79 pEGFP-C2 N-terminus and CR1 
*Ad40 E1A Δ1-77 pEGFP-C2  
Ad40 E1A 1-77 pEGFP-C2 N-terminus and CR1 
*Ad52 E1A Δ1-75 pEGFP-C2  
*Ad52 E1A 1-75 pEGFP-C2 N-terminus and CR1 
*Ad3 E1A 1-13 pEGFP-C2  
*Ad3 E1A 11-28 pEGFP-C2  
*Ad3 E1A 28-82 pEGFP-C2  
*Ad3 E1A Δ11-28 pEGFP-C2  
*Ad9 E1A 1-14 pEGFP-C2  
*Ad9 E1A 12-29 pEGFP-C2  
*Ad9 E1A 30-81 pEGFP-C2  
*Ad9 E1A Δ12-29 pEGFP-C2  
*Ad12 E1A 1-13 pEGFP-C2  
*Ad12 E1A 12-27 pEGFP-C2  
*Ad12 E1A 28-79 pEGFP-C2  
*Ad12 E1A Δ12-27 pEGFP-C2  
*Ad12 E1A Δ37-49 pEGFP-C2  
*Ad12 E1A Δ12-27,37-49 pEGFP-C2  
*Ad40 E1A 1-12 pEGFP-C2  
*Ad40 E1A 12-26 pEGFP-C2  
*Ad40 E1A 25-77 pEGFP-C2  
*Ad40 E1A Δ12-26 pEGFP-C2  
PKA RIα pcDNA-HA, pcDNA-MYC  
PKA RIIα pcDNA-HA, pcDNA-MYC  
PKA Cα pcDNA-HA  
PKA RIα Δ1-63 pcDNA-HA ΔD/D 
PKA RIIα Δ1-45 pcDNA-HA, pcDNA-MYC ΔD/D 
Ad5 E1A Δ16-28 pEGFP-C2  
*Ad5 chimera E1A pEGFP-C2 Ad5 backbone with Ad4 N-terminus 
*Ad4 chimera E1A pEGFP-C2 Ad4 backbone with Ad5 N-terminus 
*Ad5 E1A D21E E26T V27L pEGFP-C2  
*Ad3 E1A E22D T27E L28V pEGFP-C2  
PEPCK-luc pGL3-Basic From Joshua Hamilton 
*Novel clone generated for this study 
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Table 3.2.  List of primary antibodies used in this chapter 
Reactivity Purpose Description Company 
RIα Western Mouse monoclonal BD 
RIα IF Rabbit polyclonal Thermo 
RIIα Western Mouse monoclonal BD 
RIIα IF Rabbit polyclonal Santa Cruz 
Cα Western Mouse monoclonal BD 
Cα IF Rabbit polyclonal Santa Cruz 
Actin Western Rabbit polyclonal Sigma 
EGFP Western, IP Rabbit polyclonal Clontech 
9E10 (MYC) Western, IP Mouse monoclonal In-house 
3F10 (HA) Western Rat monoclonal Roche 
CREB1 Western Rabbit polyclonal Santa Cruz 
CREB1-pSer133 Western, IF Rabbit polyclonal Santa Cruz 
M73 (E1A) Western, IF Mouse monoclonal In-house 
M37 (E1A) IF Mouse monoclonal In-house 
cAMP IF Rabbit monoclonal Abcam 
B68 (DBP) IF Mouse monoclonal In-house 
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3.2.5 Western blotting and co-immunoprecipitation 
Cells were lysed in NP40 lysis buffer (150mM NaCl, 50mM Tris-HCL pH 7.5, 0.1% NP-
40) with protease inhibitor cocktail.  Protein concentrations were determined using 
BioRad protein assay reagent using BSA as a standard.  Co-immunoprecipitations were 
carried out at 4ᵒC for 4 hours.  2% of sample was kept as input control.  After washing 
with NP40 buffer, complexes were boiled in 25 µL of LDS sample buffer for 5 minutes.  
Samples were separated on NuPage Bis-Tris gels (Life Technologies) and transferred 
onto a PVDF membrane (Amersham).  Membranes were blocked in 5% skim milk or 3% 
bovine serum albumin (BSA) constituted in TBS with 0.1% Tween-20.  Horseradish 
peroxidise-conjugated secondary antibody was detected using Luminata Forte or 
Crescendo substrate (Millipore).  Primary antibodies used in this chapter can be found in 
table 2.2. 
3.2.6 Immunofluorescence microscopy 
Cells were fixed in 3.7% paraformaldehyde, permeabilized on ice using 0.2% Triton X-
100, and blocked using 3% BSA in phospho-buffered saline (PBS).  Samples were 
incubated in the primary antibody for 1 hour at room temperature or 4ᵒC overnight and 
another hour at room temperature with secondary antibody (Alexa Fluor 594 or 488 α-
rabbit; Life technologies).  Samples were mounted with Prolong Gold reagent containing 
DAPI (Life technologies).  Confocal images were acquired using a Fluoview 1000 laser 
scanning confocal microscope (Olympus Corp).  Quantification of total cellular signal 
and nuclear signal was conducted using ImageJ.  Cells were normalized for both 
cytoplasmic and nuclear size and %nuclear signal was determined as previously 
described (Cohen et al., 2014). 
3.2.7 Virus replication assay 
A549 cells were treated with siRNAs followed by HAdV infection for 1 hour at 37ᵒC at 
the indicated MOI.  Total cell DNA was purified at 6 and 48 hours post-infection using a 
DNeasy Blood and Tissue Kit (QIAGEN).  Viral DNA levels were quantified by qPCR 
with Power SYBR Green (Thermo) using a forward primer that recognizes a conserved 
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Table 3.3.  List of qPCR primers used in this chapter 
Target Region Location Sequence Size 
GAPDH-F Cellular cDNA 566-587 ACTGCTTAGCACCCCTGGCCAA 79 
GAPDH-R Cellular cDNA 620-644 ATGGCATGGACTGTGGTCATGAGTC 
E1A-All-F Promoter Variable AGAGGCCACTCTTGAGTGC Variable 
Ad3E1A-R Exon1 702-721 TACAGATCGTGCAGCGTAGG 271 
Ad4E1A-R Exon1 690-709 AGCGAAGGTGTCTCAAATGG 206 
Ad5E1A-R Exon1 697-715 CGTCACGTCTAAATCATAC 224 
Ad9E1A-R Exon1 711-730 GGGCATCTACCTCCAGATCA 226 
Ad12E1A-R Exon1 641-659 CGGCAGACTCCACATCAAG 221 
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Table 3.4.  List of cloning primers used in this chapter 
Clone Forward Reverse Notes 
13S Ad52 
E1A 
ATTGGAATTCATGAGGCTGGTCC
CC 
CATCGTCGACTTAGGTCAGCTT
A 
Jones et 
al., 2007 
Ad3 E1A 
Δ1-82 
ATCCGAATTCATGAACCCTCCTCC
TGAGACA 
GGATGTCGACTCATTGCCTTGG
CAGTTT 
 
Ad9 E1A 
Δ1-81 
ATCCGAATTCATGACTCCACTTCA
TACAC 
AGTGTCGACGTCTAGTTCCTGG
GGCG 
 
Ad12 E1A 
Δ1-79 
ATTCGAATTCATGCCGGAGCCTC
CTGTA 
CAGGTCGACTTAATTACATCTA
GGGCGTTTC 
 
Ad40 E1A 
Δ1-77 
ATTGGAATTCATGAGCGGTTCGG
GTGAT 
GTGGTCGACTCAGGAGCACTTG
GGGCGC 
 
Ad52 E1A 
Δ1-75 
ATTGGAATTCATGTCTCACAGCA
GTGA 
CATCGTCGACTTAGGTCAGCTT
A 
 
Ad52 E1A 
1-75 
ATTGGAATTCATGAGGCTGGTCC
CC 
CATCGTCGACCTAACCCTCCTC
AGCCG 
 
Ad3 E1A 1-
13 
TACGAATTCATGAGACACCTGCG
CTTC 
GGATGTCGACTTAGGAGATAAC
CT 
 
Ad3 E1A 
11-28 
ATCCGAATTCATGGTTATCTCCAG
TGAGAC 
CATCGTCGACTTAGGTATTTAC
CACAAA 
 
Ad3 E1A 
28-82 
ATCCGAATTCATGCTAATGGGAG
ACGAC 
AGTGTCGACTTATATGTCCAAT
CCTTCATCGG 
 
Ad3 E1A 
Δ11-28 
TTCCTGCCACAGGAGCTAATGGG
AGACGAC 
GTCGTCTCCCATTAGCTCCTGTG
GCAGGAA 
Internal 
TACGAATTCATGAGACACCTGCG
CTTC 
GGATGTCGACTCATTGCCTTGG
CAGTTT 
Flanking 
Ad9 E1A 1-
14 
CTGGAATTCATGAGACACCTGCG
CC 
CATCGTCGACTTACTCACCGGG
CACAGT 
 
Ad9 E1A 
12-29 
ATTCGAATTCATGCCCGGTGAGC
TGGCT 
CATCGTCGACTTACTCCAATAC
TGTAT 
 
Ad9 E1A 
30-81 
ATTCGAATTCATGGACGAACTGC
ATCCA 
ATAGTCGACTTAAGATTCGTTG
GCTATGTCAG 
 
Ad9 E1A 
Δ12-29 
CTGCCTTCAACTGTGGACGAACT
GCATCCA 
TGGATGCAGTTCGTCCACAGTT
GAAGGCAG 
Internal 
CTGGAATTCATGAGACACCTGCG
CC 
AGTGTCGACGTCTAGTTCCTGG
GGCG 
Flanking 
Ad12 E1A 
1-13 
CTACGAATTCATGAGAACTGAAA
TGACTCCC 
CAGCGTCGACTTACTGATACGA
CAG 
 
Ad12 E1A 
12-27 
ATCCGAATTCATGTATCAGGAAG
CTGAC 
CATCGTCGACCTAAAAAAAGTT
GTCCA 
 
Ad12 E1A 
28-79 
ATCCGAATTCATGAACGAGGTAC
CCAGT 
TGAGTCGACTAAAAACAACCCC
TCACTGGC 
 
Ad12 E1A 
Δ12-27 
CCCTTGGTCCTGTCGAACGAGGT
ACCCAGT 
ACTGGGTACCTCGTTCGACAGG
ACCAAGGG 
Internal 
CTACGAATTCATGAGAACTGAAA
TGACTCCC 
CAGGTCGACTTAATTACATCTA
GGGCGTTTC 
Flanking 
Ad12 E1A 
Δ37-49 
AGTGATGATGATCTTGAGTCTGC
CGGTGAA 
TTCACCGGCAGACTCAAGATCA
TCATCACT 
Internal 
CTACGAATTCATGAGAACTGAAA
TGACTCCC 
CAGGTCGACTTAATTACATCTA
GGGCGTTTC 
Flanking 
Ad12 E1A 
Δ12-27,37-
49 (same as 
Δ37-49 with 
Δ12-27 as 
template) 
AGTGATGATGATCTTGAGTCTGC
CGGTGAA 
TTCACCGGCAGACTCAAGATCA
TCATCACT 
Internal 
CTACGAATTCATGAGAACTGAAA
TGACTCCC 
CAGGTCGACTTAATTACATCTA
GGGCGTTTC 
Flanking 
Ad40 E1A 
1-12 
TCAGAATTCATGAGAATGCTGCC
GG 
CATCGTCGACCTACCAGTTCCC
G 
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Ad40 E1A 
12-26 
ATTGGAATTCATGTGGGATGACA
TGT 
CATCGTCGACCTAAAACACATA
TTCA 
 
Ad40 E1A 
25-77 
ATTGGAATTCATGGTGTTTGATTT
C 
TCAGTCGACTTACTCTGCAGCG
CTCTCAG 
 
Ad40 E1A 
Δ12-26 
TTTACCGGGAACGATTTCCCTGA
ACCT 
AGGTTCAGGGAAATCGTTCCCG
GTAAA 
Internal 
TCAGAATTCATGAGAATGCTGCC
GG 
GTGGTCGACTCAGGAGCACTTG
GGGCGC 
Flanking 
Ad5 
chimera 
E1A 
CGAGGAGGCTTCATTTCCGCCGG
CGC 
GCGCCGGCGGAAATGAAGCCTC
CTCG 
Internal 
TCCGAATTCATGAGGCACCTAAG
AGAC 
ACTGTCGACTTATGGCCTGGGA
CGTTTACAGCTC 
Flanking 
Ad4 
chimera 
E1A 
ATTGACTTACTCACTAGCCCTAGC
TCAGA 
TCTGAGCTAGGGCTAGTGAGTA
AGTCAAT 
Internal 
CGACGAATTCATGAGACATATTA
TCTGC 
GTGGTCGACTTAATGCCTGGGG
CGTTTCC 
Flanking 
Ad5 E1A 
D21E E26T 
V27L 
TTTGGAGCAGCTGATCGAAACCC
TACTGG 
CCAGTAGGGTTTCGATCAGCTG
CTCCAAA 
Internal 
CGACGAATTCATGAGACATATTA
TCTGC 
ACTGTCGACTTATGGCCTGGGA
CGTTTACAGCTC 
Flanking 
Ad3 E1A 
E22D T27E 
L28V 
TACTGGACTTTGTGGTAAATGAG
GTAATGGGA 
TCCCATTACCTCATTTACCACA
AAGTCCAGTA 
Internal 
TACGAATTCATGAGACACCTGCG
CTTC 
GGATGTCGACTCATTGCCTTGG
CAGTTT 
Flanking 
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sequence in E1A in combination with a serotype-specific reverse primer.  Values are 
normalized to GAPDH and the fold-increase of viral copy number at 48 hours was 
calculated by normalizing to ‘input’ viral DNA at 6 hours post-infection.  Viral 
replication efficiency in the presence of PKA knockdowns was presented as the relative 
value compared to scrambled control siRNA-treated cells, which were normalized to 1.  
A list of all primers used in this chapter can be found in tables 3.3 and 3.4. 
3.2.8 Luciferase reporter assay 
HT1080 cells were co-transfected with a constitutive β-galactosidase reporter plasmid for 
normalization, a plasmid containing the luciferase gene driven by the rat PEPCK 
promoter, and the indicated EGFP-E1A fusion constructs.  The reporter was validated by 
6 hours of 0.5µM forskolin (fsk) treatment and siRNA-mediated knockdown of PKA 
protein.  24 hours post-transfection, cells were lysed in 200 µL of the supplied lysis 
buffer (Promega).  For detection of luciferase production, 50 µL of lysate was mixed with 
50µL of the provided Luciferase Substrate (Promega) immediately before detection of 
light was measured using a Berthold Lumat LB 9507.  Relative light values were set to an 
empty plasmid control, were normalized to protein levels via Bradford Assay, and further 
normalized via β-galactosidase activity as detected by ONPG (Ortho-Nitrophenyl-β-D-
Galactopyranoside). 
3.2.9 PKA activity assay 
PKA activity in cell lysates was measured using the Protein Kinase A Colorimetric 
Activity Kit (Thermo).  1x106 A549 cells were seeded overnight then either treated with 
fsk for 6 hours or infected with the indicated virus.  After harvesting at the indicated 
timepoints, PKA activity of the cell lysates was assayed using the protocol outlined by 
the manufacturer.  Activity in uninfected cells were normalized to 1 and compared to all 
other conditions. 
3.2.10 Statistical analysis 
All experiments were carried out with three biological replicates performed in duplicate.  
Graphs represent mean and standard error of the mean (S.E.M.) of all biological 
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replicates.  For western blots, a representative image was selected.  Statistical 
significance of numerical differences was calculated using t-tests (Figure 3.11) or one-
way ANOVA and Holm-Sidak post-hoc comparisons (Figures 3.4, 3.12, 3.13) between 
experimental conditions. 
3.3 Results 
3.3.1 Protein kinase A subunits are conserved binding targets of the 
N-terminal region of E1A across numerous HAdV species 
The full-length isoforms (“13S”) of E1A proteins from representative viruses of six 
HAdV species (A-F) were previously tested for protein-protein interactions with PKA 
subunits.  E1A from HAdV-12 (species A), HAdV-3 (species B), HAdV-5 (species C), 
HAdV-9 (species D), and HAdV-40 (species F) could associate with PKA via co-
immunoprecipitation (Co-IP) while HAdV-4 (species E) could not (King et al., 2016a).  
However, the detailed mechanisms behind these individual interactions have only been 
further explored for HAdV-5 and HAdV-12 (Fax et al., 2001; King et al., 2016a).  
Additionally, a seventh species of HAdV (G) has been recently classified, containing a 
lone member, HAdV-52 (Jones et al., 2007).  To further investigate these E1A-PKA 
interactions, HT1080 fibrosarcoma cells were transfected with vectors expressing PKA 
subunits along with either WT E1A from the seven HAdV species or the indicated 
fragments/portions of E1A (Figure 3.1). 
Co-immunoprecipitation analysis revealed that RIα, RIIα, and Cα all associated with the 
majority of the E1A proteins tested. E1A from HAdV-5 was used as a positive control 
while the non-binding E1A from HAdV-4 was used as a negative control.  E1A from 
HAdV-4 and the less-characterized HAdV-52 were the only non-binding types observed.  
For the E1As which bound (HAdV-3, -5, -9, -12, -40), the N-terminal portion of these 
proteins was both necessary and sufficient for conferring these interactions, though this 
was notably weakest for HAdV-40 E1A.  These data show for the first time where PKA 
binds on each of these unique E1As, and the observations align with those previous for 
both HAdV-5 and -12 (Fax et al., 2001; King et al., 2016a).  Additionally, this region of 
E1A has been previously shown to be associated with alterations in cAMP signalling 
133 
 
 
 
Figure 3.1.  Protein Kinase A subunits are conserved binding targets of HAdV 
E1A’s N-terminus. 
HT1080 cells were co-transfected with PKA subunits and various WT or mutant E1A 
constructs from 7 HAdV types (shown in the inset panel).  Whole cell lysates were 
harvested for co-immunoprecipitation.  WT E1A from HAdV-3, -5, -9, -12, and -40 
associates with RIα, RIIα, and Cα, whereas E1A from HAdV-4 and -52 do not.  Deletion 
of the entire E1A N-terminus ablated the interactions, whereas the N-terminus alone was 
sufficient for binding. 
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(Engel et al., 1991, 1988; Hardy and Shenk, 1988; Lee and Mathews, 1997; Müller et al., 
1989) and has been characterized as being a conserved transactivation domain 
(Bondesson et al., 1994; Yousef et al., 2009). 
3.3.2 E1A proteins that bind PKA use an AKAP-like sequence motif 
The minimal region of E1A required to bind PKA was previously delineated for HAdV-5 
(King et al., 2016a).  To determine the regions within E1A for the other HAdVs whose 
E1As have putative viral AKAP activity, we carried out more detailed mutational 
analyses for each distinct E1A (Figure 3.2A-D).  Cells were co-transfected with vectors 
expressing PKA subunits and either WT or the indicated portions of E1A for several 
HAdV species.  For HAdV-3 (Figure 3.2A), -9 (Figure 3.2B), -12 (Figure 3.2C), and -40 
(Figure 3.2D), overlapping deletions or truncations within the N-terminus were tested.  
HAdV-3, -9, and -40 each contained a small region that was both necessary and sufficient 
for associating with PKA subunits (amino acids 11-28, 12-29, 12-26 respectively).  Each 
of these regions bears strong similarity to the PKA-binding motif within HAdV-5 E1A, 
as well as those of cellular AKAPs (9).  Also like HAdV-5 E1A and cellular AKAPs, 
these motifs are predicted to contain α-helical secondary structure (Pelka et al., 2008).  
HAdV-12 E1A appeared to have two regions contributing to its binding with PKA 
(amino acids 12-27 and 37-49) and deletion of both was required to fully abrogate this 
interaction.  While unexpected, this observation does align with that of a previous report 
on this E1A’s interaction with PKA (Fax et al., 2001) and may suggest additional, 
unconventional means of manipulating PKA by this E1A type.  Taken together, these 
results demonstrate that the utilization of AKAP mimicry is a conserved function of the 
E1As which bind to PKA. 
3.3.3 E1A binds to PKA via the PKA docking-dimerization domain 
Cellular AKAPs bind PKA via the docking-dimerization (D/D) domain of PKA 
regulatory subunits (RIα and RIIα) (Banky et al., 1998; Newlon et al., 1999).  Given the 
predicted sequence and structural similarities between cellular AKAPs and the E1As that 
bind PKA, we tested if the D/D domain was necessary for the observed E1A-PKA 
interactions (Figure 3.3).  Cells were co-transfected with WT E1A from seven HAdV
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Figure 3.2.  E1A proteins that bind PKA use an AKAP-like sequence motif. 
HT1080 cells were co-transfected with PKA subunits and E1A constructs from either 
HAdV-3, -9, -12, or -40 (A-D).  Mutation schemes are shown in the inset panels.  Cell 
lysates were harvested and co-immunoprecipitation analysis of each E1A protein 
revealed that amino acids 11-28 for HAdV-3 (A), aa12-29 for HAdV-9 (B), aa12-27, 37-
49 for HAdV-12 (C), and aa12-26 for HAdV-40 (D) were necessary and sufficient for 
binding PKA subunits. 
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Figure 3.3.  HAdV species whose E1A proteins bind PKA do so via PKA’s docking-
dimerization domain. 
HT1080 cells were co-transfected with WT E1A from 7 species of HAdV along with 
either both WT PKA regulatory subunits (“R”) or both subunits lacking their D/D 
domains (“ΔR”).  Whole cell lysates were harvested for co-immunoprecipitation.  
Deletion of the D/D domains in either HA-tagged RIα or MYC-tagged RIIα abrogated 
the interactions with E1A. 
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species along with either WT PKA regulatory subunits or mutants lacking their respective 
D/D domains (RIαΔ1-63 and RIIαΔ1-45).  As expected, neither HAdV-4 nor -52 E1A 
interacted with any PKA construct tested.  E1A from HAdV-3, -5, -9, -12, and -40 co-
immunoprecipitated with WT PKA regulatory subunits but failed to associate with those 
lacking the D/D domains.  Thus, multiple E1As not only resemble AKAPs themselves, 
but also require the same site on the PKA regulatory subunits that is targeted by cellular 
AKAPs and the previously characterized HAdV-5 E1A for interaction. 
3.3.4 Distinct E1A proteins relocalize PKA regulatory subunits in a 
type-specific manner 
The subcellular redistribution of PKA subunits was previously explored with E1A from 
HAdV-5 and HAdV-12.  Those two proteins were found to have contrasting preferences 
for the type-I and type-II regulatory subunits, respectively (Fax et al., 2001; King et al., 
2016a).  Here we sought to extend our investigation into how E1A from different HAdVs 
affect PKA by utilizing both infection and transfection-based approaches.  HeLa cells 
were transiently transfected with EGFP-tagged WT E1A proteins from all seven HAdV 
species and proteins were subsequently detected via autofluorescence (EGFP) or 
immunofluorescence staining (PKA) (Figure 3.4A-C).  While PKA Cα appeared nuclear-
cytoplasmic and broadly similar in all immunofluorescence experiments (data not 
shown), notable differences emerged between RIα and RIIα.  As expected, neither 
HAdV-4 nor HAdV-52 E1A, which did not bind PKA, showed any ability to alter the 
subcellular localization of PKA subunits RIα or RIIα (Figure 3.4A).  The relocalization 
phenotypes for both HAdV-5 (RIα specific) and HAdV-12 E1A (RIIα specific) were 
reproduced as positive controls.  This confirmed that different E1As exhibit a type 
‘preference’ for functionally altering the PKA subunits they bind (Figure 3.4B, C).  
Similar to HAdV-5, E1A from HAdV-9 caused the RIα subunit to be redirected from the 
cytoplasm into the nucleus (Figure 3.4B).  In contrast, E1A from HAdV-3 caused the 
RIIα subunit to be relocalized, similarly to E1A from HAdV-12 (Figure 3.4C).  HAdV-40 
E1A did not appear to relocalize either PKA regulatory subunit (Figure 3.4A). 
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Figure 3.4.  Distinct E1A proteins relocalize PKA regulatory subunits in a type-
specific manner. 
HeLa cells were transfected with EGFP-tagged WT or mutant E1A constructs from 7 
species of HAdV.  Cells were fixed, permeabilized, and proteins were detected via 
autofluorescence (E1A) or by immunofluorescence (PKA).  Scale bars represent 100µm 
and the targeted PKA subunit is indicated above each group of panels.  A) EGFP alone or 
E1A from HAdV-4, -52, and -40 showed no relocalization of either PKA regulatory 
subunit.  E1A from HAdV-3 and -12 showed no relocalization of RIα, whereas HAdV-5 
and -9 E1A showed no relocalization of RIIα.  B) HAdV-5 and -9 E1A caused a shift of 
RIα from the cytoplasm to the nucleus that was ablated when these E1A proteins had 
their AKAP-like motifs deleted.  Conversely, (C) HAdV-3 and -12 E1A caused a shift of 
RIIα from the cytoplasm to the nucleus that was ablated when their PKA-binding regions 
were removed.  Quantification of nuclear signal relative to total cellular signal is also 
shown next to representative images for the indicated E1A species (values are displayed 
as mean ± SD *p<0.001, n=50). 
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Figure 3.5.  The C-terminus of E1A, which contains the nuclear localization signal, 
is required for efficient retasking of PKA. 
A549 cells were infected with either HAdV-5 dl520 or dl1131/520 (the E1A proteins 
expressed by these viruses are shown in the adjacent panel).  After 24 hours, cells were 
fixed, permeabilized, and stained for confocal immunofluorescence.  E1A lacking the C-
terminal bipartite NLS was deficient for both its nuclear localization and 
recompartmentalization of RIα.  Scale bars represent 100µm. 
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Figure 3.6.  Localization of PKA regulatory subunits in cells infected with various 
HAdV species. 
A549 cells were infected with either WT HAdV-3, -4, -5 (dl309), -9, or -12 at an MOI of 
5 (for HAdV-5) or 25 (for all other viruses).  After 24 hours cells were fixed, 
permeabilized, and stained for confocal immunofluorescence.  RIα appears to be more 
nuclear in HAdV-5 or -9 infected cells compared to uninfected cells.  In contrast, RIIα 
appears more nuclear in HAdV-3 or -12 infected cells.  Scale bars represent 100µm.
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Mutant E1As containing deletions which abrogate PKA-binding for each species were 
tested side-by-side with the cognate WT E1A control (Figure 3.4A-C).  As expected, the 
removal of the previously-established binding motifs within each E1A protein abrogated 
the protein’s ability to relocalize PKA in transfected conditions.  The relocalization of 
PKA regulatory subunits was therefore E1A-dependent and required the AKAP-like 
motif necessary for PKA interaction, as previously demonstrated with HAdV-5 E1A.  
Using HAdV-5 as a model, we also demonstrated that the nuclear localization signal 
(NLS) of E1A is needed to contribute to PKA relocalization, but not CR3 (Figure 3.5).  
While WT “12S” virus (dl520) relocalized RIα despite the absence of CR3, a mutant 
lacking both CR3 and the C-terminal bipartite NLS (dl1131/520) was deficient for 
relocalization of RIα.  This suggests that binding of the regulatory subunit by E1A is not 
sufficient for efficient recompartmentalization of PKA and that relocalization requires 
cooperation with other functions located in the C-terminus of E1A.  PKA localization 
was also examined in A549 cells infected with WT strains of HAdV-3, -4, -9, and -12 
(Figure 3.6).  The observed staining phenotype matched that of the transfection-based 
experiments, suggesting that in vitro results faithfully reflect what occurs during an in 
vivo infection. 
The curious observation that E1A proteins are able to associate with both RIα and RIIα in 
Co-IP experiments, yet only relocalize one isoform in vivo led us to test whether 
differences in binding affinity for distinct subunits contributed to this selectivity.  First, 
we established a Co-IP-based squelching assay where untagged HAdV-5 E1A was 
titrated in as a competitor against EGFP-tagged HAdV-5 E1A (Figure 3.7A).  As 
expected, higher levels of competition eventually abrogated the ability of EGFP-E1A to 
Co-IP with PKA regulatory subunits.  We then applied these conditions to similarly test 
HAdV-5 E1A against EGFP-tagged E1A from HAdV-3, -9, -12, and -40 (Figure 3.7B).  
HAdV-3 and -12 E1As were more resistant to competition from HAdV-5 E1A when 
examining their associations with RIIα; conversely, their interactions with RIα were more 
susceptible to depletion in this competition assay.  Together these data suggest again that 
HAdV-3 and -12 have relatively higher affinity for RIIα while HAdV-5 prefers RIα.  
HAdV-9 E1A was susceptible to competition in a manner similar to how HAdV-5 was 
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Figure 3.7.  Different E1A species display an affinity preference for either RIα or 
RIIα. 
A) HT1080 cells were co-transfected with EGFP-tagged HAdV-5 E1A and PKA 
regulatory subunits.  Untagged HAdV-5 E1A was titrated in as a competitor against 
EGFP-E1A for binding PKA.  Whole cell lysates were harvested for Co-IP using an 
antibody against EGFP.  Increasing amounts of untagged E1A squelched EGFP-E1A’s 
interactions with RIα and RIIα.  B) Conditions optimized from (A) were used in a larger 
competition panel with EGFP-tagged E1A from HAdV-3, -9, -12, and -40.  HT1080 cells 
were similarly co-transfected with the indicated E1A species, PKA subunits, and 
increasing amounts of untagged HAdV-5 E1A.  Co-IP analysis revealed varying 
resistances and susceptibilities to competition from HAdV-5 E1A for binding either RIα 
or RIIα. 
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Figure 3.8.  Depriving HAdV-5 E1A of type-I PKA causes E1A to retask type-II 
PKA instead. 
A)  A549 cells were treated with the indicated control or RIα-specific siRNAs and 
subsequently infected with WT (dl309) HAdV-5.  Only in the absence of RIα protein 
does E1A relocalize some RIIα to the nucleus.  Scale bars represent 100µm.  B)  
Equilibrium models of how E1A may compete against cellular AKAPs (cAKAP) and 
determine which PKA isoform it relocalizes to the nucleus. 
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against itself (Figure 3.7A) reinforcing the similarity between these two E1A species.  
HAdV-40 E1A was the most susceptible to competition relative to other E1A proteins 
indicating that its association with PKA is the weakest. 
While E1As clearly have a preference to relocalize and bind one specific PKA isoform, 
the ability to functionally affect the other isoform remains a possibility.  Using HAdV-5 
as a model, we infected A549 cells pretreated with either a scrambled control siRNA or 
siRNA knocking-down RIα, HAdV-5 E1A’s preferred regulatory subunit, with WT 
(dl309) virus (Figure 3.8A).  In control cells, HAdV-5 E1A behaved as expected by 
relocalizing RIα into the nucleus while leaving RIIα in the cytoplasm.  However, when 
cells were deprived of RIα protein, some RIIα was localized within the nucleus along 
with E1A, a finding only observed previously for HAdV-3 and -12 E1A.  This suggests 
the siRNA-mediated removal of the RIα isoform of PKA shifted the binding equilibrium 
of E1A with RIIα in vivo, and that the increased interaction was sufficient to allow some 
of this isoform to be relocalized (Figure 3.8B).  While the observed 
recompartmentalization was not quite as dramatic as with RIα, this may be due to HAdV-
5 E1A’s apparent lower affinity for this particular subunit. 
3.3.5 E1A’s ability to act as a vAKAP is modular and malleable by 
mutagenesis 
To test if the ‘viral AKAP’ function of E1A was modular, we created a set of EGFP-
tagged constructs that combined various portions of E1A from HAdV-4 and HAdV-5 to 
form chimeric proteins.  Specifically, the N-terminal domains of each protein were 
swapped for the analogous region in the other.  When these constructs were tested 
alongside WT counterparts for binding PKA subunits via Co-IP, the chimera with the 
HAdV-5 N-terminus and HAdV-4 C-terminus gained the protein-protein interactions 
exhibited by WT HAdV-5 E1A, whereas the reciprocal chimera lost them (Figure 3.9A).  
Subsequently, these chimeras were transfected into HeLa cells and PKA subcellular 
localization was examined via immunofluorescence staining (Figure 3.9B).  As with the 
Co-IP assays, the HAdV-4 chimera gained the ability to relocalize the PKA RIα subunit 
when its N-terminus was replaced with that from HAdV-5.  In contrast, the HAdV-5
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Figure 3.9.  Viral AKAP mimicry is a modular function of E1A. 
A)  HT1080 cells were co-transfected with PKA subunits and either WT or chimeric E1A 
constructs and cell lysates were harvested for Co-IP.  The inset panel displays the 
construction of the HAdV-4 and -5 E1A chimeras (arrow indicates where N-terminal 
swap occurred).  The HAdV-4 chimera gained the ability to bind PKA subunits whereas 
this was lost for the HAdV-5 chimera.  B)  HeLa cells were transfected with the indicated 
EGFP-tagged E1A constructs.  Cells were fixed, permeabilized, and proteins were 
detected via autofluorescence (E1A) or by immunofluorescence (PKA).  Cells transfected 
with WT HAdV-5 or the HAdV-4 chimera exhibited a shift of RIα from the cytoplasm 
into the nucleus.  In contrast, WT HAdV-4 or the HAdV-5 chimera showed no noticeable 
relocalization of RIα.  Scale bars represent 100µm. 
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Figure 3.10.  Specific residues in the AKAP-like motif of E1As induce preference for 
specific PKA subunits. 
A)  HT1080 cells were co-transfected with PKA subunits and the indicated E1A 
constructs and cell lysates were harvested for Co-IP.  Both WT HAdV-3 and -5 along 
with mutants (HAdV-5 D21E, E26T, V27L and HAdV-3 E22D, T27E, L28V) retain 
similar levels of binding to PKA.  The mutation scheme in the inset panel shows residue 
positions previously-demonstrated as crucial in HAdV-5 along with the analogous 
positions in HAdV-3.  B)  HeLa cells were transfected with the indicated EGFP-tagged 
E1A constructs.  Cells were fixed, permeabilized, and proteins were detected via 
autofluorescence (E1A) or by immunofluorescence (PKA).  Cells transfected with WT 
HAdV-3 or the HAdV-5 D21E, E26T, V27L mutant exhibited a shift of RIIα from the 
cytoplasm into the nucleus.  In contrast, WT HAdV-5 or the HAdV-3 E22D, T27E, L28V 
mutant exhibited a relocalization of RIα.  Scale bars represent 100µm. 
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chimera with the HAdV-4 N-terminus behaved like the EGFP negative control and WT 
HAdV-4 E1A.   
To explore this concept of modularity further, we aimed to test if swapping individual 
residues within the AKAP-like motif of different E1As could alter their preference for 
relocalizing one type of PKA subunit over the other.  By comparing the sequences of the 
AKAP-like motifs between HAdV-3 and HAdV-5 E1A, triple point mutants for both 
E1As were designed (HAdV-5 D21E, E26T, V27L and HAdV-3 E22D, T27E, L28V) in 
an effort to exchange specificity.  These relatively conservative mutations are embedded 
within the predicted α-helix portions of both proteins and are at analogous positions that 
were previously demonstrated to be crucial for HAdV-5 E1A binding (King et al., 
2016a).  When tested alongside WT E1A counterparts for binding via Co-IP, both 
mutants retained the interaction with PKA subunits similar to that of WT E1A (Figure 
3.10A).  Next, the mutants were transfected into HeLa cells and examined for their ability 
to relocalize individual PKA subunits (Figure 3.10B).  Both triple mutants experienced a 
change in preference for which PKA subunit they relocalized to the nucleus.  When 
mutated in this way, HAdV-5 E1A, which previously preferred RIα, now altered RIIα 
distribution like WT E1A from HAdV-3 and -12.  When HAdV-3 E1A, which normally 
preferred RIIα, was mutated in this fashion, it relocalized RIα like WT E1A from HAdV-
5 or -9.  Thus, it appeared that the preference of E1As for specific PKA subunits can be 
altered using targeted mutagenesis of select residues. 
3.3.6 Interaction with PKA is required for full E1A-mediated 
transactivation of a PKA-driven promoter 
It was previously shown that the interaction between E1A and PKA could serve to 
enhance viral gene expression during HAdV-5 infection (King et al., 2016a).  
Additionally, co-transfected HAdV-12 E1A and PKA could activate the HAdV-12 E2 
promoter (Fax et al., 2001).  However, many cellular genes are also known to be 
regulated by PKA via signaling through cAMP (Guo et al., 2012; Sands and Palmer, 
2008; Zambon et al., 2005; Zhang et al., 2005).  Also, E1A has been demonstrated to 
affect cAMP-responsive cellular genes in certain contexts (Gedrich et al., 1992; Lee and
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Figure 3.11.  Interaction with PKA is required for full E1A-mediated 
transactivation of a PKA-driven promoter. 
HT1080 cells were transfected with a reporter consisting of the luciferase gene driven by 
the rat PEPCK promoter (sequence shown in inset panel) along with various WT or 
mutant E1A constructs from 7 HAdV species.  A 6-hour treatment of 0.5µM forskolin 
(fsk) and siRNA-mediated PKA knockdowns were performed to demonstrate this 
reporter’s cAMP-responsiveness and PKA-dependent regulation.  Protein levels of each 
E1A construct are also shown.  Luciferase activity was measured for each condition and 
light units were set relative to an empty plasmid control.  Each of the 7 WT E1As tested 
could transactivate this reporter, with those shown to bind PKA having the strongest 
effect.  For the 5 species that interacted with PKA, deletion of their PKA-binding motifs 
conferred a statistically-significant reduction on E1A’s ability to induce this reporter 
(with the exception of HAdV-40).  Values are displayed as displayed as mean ± S.E.M. 
*p<0.05, n=3. 
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Mathews, 1997; Miller et al., 1995).  We aimed to determine if the E1A proteins from 
different HAdVs could insert themselves into this signaling pathway and alter 
PKA/cAMP-regulated transactivation.  HT1080 cells were co-transfected with a 
luciferase reporter demonstrated to be cAMP- and PKA-regulated (driven by the rat 
phosphoenolpyruvate carboxykinase [PEPCK] promoter) along with various E1A 
constructs (Figure 3.11).  Initial experiments confirmed that this reporter is both cAMP-
inducible via forskolin treatment (an adenylyl cyclase activator that increases intracellular 
levels of cAMP), as well as dependent on PKA protein as shown by siRNA-mediated 
knockdown.  E1As shown to bind PKA were then compared to a species-specific deletion 
mutant lacking the PKA binding site for their effects on PEPCK-dependent transcription.  
Although all seven species of E1A were able to transactivate this reporter to levels higher 
than the EGFP (vector control) alone, those previously shown to both bind and relocalize 
PKA functioned as the strongest transactivators (HAdV-3, -5, -9, -12).  Deletion of the 
AKAP-like PKA-binding motifs in these E1As reduced their ability to drive expression 
of this reporter construct several-fold.  Transactivation by HAdV-40 E1A was weaker 
relative to the other E1As and deletion of its putative PKA-binding region did not affect 
this function.  Thus, similarly to the negative result in the relocalization assays (Figure 
3.4A), HAdV-40 appears to bind PKA in the Co-IP assays, but this interaction does not 
appear to functionally impact PKA-dependent transcription in vivo. 
3.3.7 HAdV infection stimulates the cAMP pathway 
Using HAdV-5 as a model, we further investigated how HAdV infection and E1A 
expression may cooperate with cellular cAMP signalling.  A549 cells infected with either 
WT (dl309), ΔE1A (dl312), or E1AΔ4-25 (dl1101) all showed increased levels of cellular 
cAMP over uninfected cells as visualized by immunofluorescence (WT virus is shown as 
representative) (Figure 3.12A).  This was accompanied by higher levels of 
phosphorylated CREB1 on Ser133 (a known PKA substrate) (Figures 12B, C) and higher 
levels of PKA kinase activity (Figure 12D).  Each of these findings was examined at 
timepoints before and after the onset of E1A protein production.  Notably, levels of PKA 
kinase activity and cAMP were similar across all timepoints post-infection for all viruses, 
indicating that they are independent of E1A and more likely a biological response to the 
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Figure 3.12.  HAdV-mediated stimulation of cAMP signalling allows WT E1A to 
retarget PKA activity. 
A549 cells were infected with either WT (dl309), ΔE1A (dl312), or E1AΔ4-25 (dl1101) 
HAdV-5 (MOI 5) and examined at the indicated timepoints post-infection using confocal 
immunofluorescence (A, B), western blot (C), or kinase assay (D).  A) Cellular cAMP 
levels were examined before and after the onset of viral replication (as indicated by 
staining for HAdV-5 ssDNA-binding protein [DBP]).  Production of cAMP is noticeably 
higher relative to uninfected cells both before and after E1A is expressed.  Results with 
WT virus are shown as representative of all infected conditions.  B)  Increased levels of 
phosphorylated CREB1 on Ser133 are present relative to uninfected cells and are shown 
for WT virus, localizing adjacent to and overlapping with virus replication centres.  Scale 
bars represent 100µm.  C)  Western blot analysis of phosphorylated CREB1 detected 
increased levels in all infected conditions, which was highest in WT-infected cells after 
production of E1A protein.  D)  Cell lysates were measured for PKA kinase activity, and 
displayed similarly higher levels of activity for all infected conditions.  Values are 
displayed as mean ± S.E.M. *p<0.05, n=3.  E)  HT1080 cells were co-transfected with 
PKA regulatory and catalytic subunits along with HAdV-5 E1A.  Co-IP analysis showed 
that E1A does not dissociate the PKA holoenzyme.  F)  HT1080 cells were co-transfected 
with RIα and/or RIIα in the presence or absence of the HAdV-5 E1A N-terminus and 
subjected to Co-IP.  No heterodimerization of PKA regulatory subunits was detectable 
even with a long exposure (LE) western blot. 
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infection itself.  We also showed that E1A itself is not causing aberrant interactions 
between PKA subunits (Figures 3.12E, F).  The coexpression of E1A did not inhibit the 
association between regulatory and catalytic PKA components (consistent with what we 
know of where E1A and PKA interact with each other) nor did its N-terminus induce any 
noticeable heterodimerization of type-I and -II regulatory subunits.  The most striking 
observation from these experiments was that only in WT-infected cells and after the onset 
of E1A protein expression did we observe the highest levels of phosphorylated CREB1 
on Ser133.  Given that the cAMP and kinase activity levels are similar between cells 
expressing either WT E1A or a mutant unable to bind PKA, it is likely the increased 
phosphorylation of this PKA-targeted transcription factor is due to WT E1A’s vAKAP 
function.  In these conditions, high levels of phosphorylated CREB1 were localized 
immediately adjacent to and overlapping with virus replication centres (Figure 3.12B). 
3.3.8 Requirement of PKA for viral replication is conserved across 
numerous HAdV species 
To firmly establish the biological significance of these distinct E1As as vAKAPs, we 
assessed PKA’s role in multiple steps of the viral replicative cycle.  A549 cells were 
treated with either control siRNA or siRNA specific for the indicated PKA subunits and 
infected with WT HAdV-3, -4, -9, -12 (MOI 25) or HAdV-5 (MOI 5) (Figure 3.13A, B).  
The efficiency of viral genome replication was assessed by qPCR of genomic viral DNA 
at 48 hours post-infection compared to an “input” sample at 6 hours post-infection and 
normalized to cellular GAPDH (Figure 3.13A).  For HAdV-3, -5, -9, and -12, knockdown 
of the PKA regulatory subunits resulted in an inhibition of viral DNA replication.  This 
was not observed for HAdV-4, whose E1A does not bind PKA.  This suggests that 
viruses that bind and relocalize PKA benefit from the interaction and require it for full, 
WT-levels of DNA replication.  Knockdown of the catalytic subunit of PKA resulted in 
an inhibition for all viruses, including HAdV-4.  This may be due to an additional role for 
this protein in the HAdV replicative cycle that is Cα-specific and E1A-independent.   
Production of infectious progeny virus was assayed at 72 hours post-infection by plaque 
assay (Figure 3.13B).  The production of WT progeny for each HAdV serotype tested 
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Figure 3.13.  Requirement of PKA for viral replication is conserved across 
numerous HAdV species. 
A549 cells were treated with control siRNA or siRNA specific for PKA subunits and 
infected with either HAdV-5 (MOI 5) or HAdV-3, -4, -9, or -12 (MOI 25).  Values for 
each virus were normalized to 1.0 in control-treated cells and displayed as mean ± 
S.E.M., n = 3.  A)  DNA was isolated at 6 hours post-infection as a gauge of viral input 
and at 48 hours post-infection to measure viral genome replication.  Relative viral DNA 
levels were quantified by qPCR reactions using a forward primer that recognizes a 
conserved sequence in E1A in combination with a species-specific reverse primer.  B)  
Cells were collected at 72 hours post-infection and production of infectious progeny virus 
was quantitatively assayed by plaque formation on HEK293 cells.  For both genome 
replication and progeny production, knockdown of PKA regulatory subunits caused 
impairment for HAdV-3, -5, -9, and -12.  The non-PKA binding HAdV-4 was unaffected.  
Knockdown of either the catalytic subunit or all 3 PKA components together impaired all 
viruses.  *p<0.05, n=3. 
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mirrored the observed phenotypes for genome replication.  Only HAdV-4 was unaffected 
by the knockdown of PKA regulatory subunits, confirming that viruses that target PKA 
via E1A do so as part of an important aspect of their replicative cycles.  As observed for 
viral genome replication, knocking down both the regulatory and catalytic subunits in 
combination did affect all HAdVs tested.  This finding matches previous observations for 
HAdV-5 (Scherer et al., 2014; Suomalainen et al., 2001) and again suggests the influence 
of an alternative, E1A-independent role for the Cα protein in HAdV biology. 
3.4 Discussion 
Mimicry is an often-exploited strategy utilized by numerous protein products of HAdV to 
facilitate virus-host interactions (Avgousti et al., 2016; Chahal et al., 2012; King et al., 
2016a, 2016b).  HAdV E1A in particular is a remarkably well-connected viral hub 
protein capable of altering the protein interaction network in an infected cell to create an 
environment conducive for viral replication (Frisch and Mymryk, 2002; Pelka et al., 
2008).  By embedding itself deeply within numerous signalling pathways, E1A can exert 
tremendous influence upon cellular machinery in order to enhance various aspects of the 
HAdV life cycle.  We previously demonstrated that HAdV-5 E1A uses mimicry to act as 
a viral AKAP, facilitating an interaction with PKA that increased viral transcription, 
protein synthesis, and progeny production (King et al., 2016a).  In the present work, we 
have determined that despite some mechanistic flexibility, the manipulation of PKA via 
E1A is a conserved and important function for numerous, distinct species of HAdV. 
Even with having substantial differences in primary sequence, E1A proteins are often 
remarkably consistent in their functional similarities (Marshall et al., 2014).  Our findings 
establish that 5 representative members of the 7 species of HAdV express E1A proteins 
that make protein-protein interactions with PKA.  This apparent conservation suggests 
that the E1A-PKA interaction has played a potentially important role in the evolutionary 
history of the virus.  Indeed, the two HAdVs which don’t bind PKA via E1A (HAdV-4 
from species E and HAdV-52 from species G), along with HAdV-40 from species F 
(which bound with lower affinity relative to other species and didn’t functionally affect 
PKA) are considered more closely related to simian adenoviruses than the HAdVs that 
160 
 
 
have E1A which demonstrably function as viral AKAPs (HAdV-3, -5, -9, and -12) 
(Dehghan et al., 2013; Jones et al., 2007).  Along with lacking vAKAP functionality, 
these non-PKA-binding E1As also have more dramatic differences in both primary 
sequence and predicted secondary structure in the region responsible for the interaction 
compared to the other HAdV types (Pelka et al., 2008).  In particular, HAdV-52 E1A 
contains a single amino acid insertion in the core of this motif, which likely distorts the 
amphipathic nature of the predicted helix.  Among primate species, PKA is a well-
conserved kinase (Taylor et al., 2013) and it is unknown if closely-related simian 
adenovirus E1A proteins are capable of interacting with simian PKA.  However, we 
speculate that an interaction is unlikely given the lack of the requisite predicted 
amphipathic α-helical structure in the E1A N-terminus of these viruses.  Therefore, the 
capability of some HAdV E1As to function as vAKAPs likely arose from their extended 
coevolution with human as a result of providing a selective benefit for the virus within 
this particular host. 
For all viruses that did bind PKA, the N-terminus of E1A alone is both necessary and 
sufficient for this interaction, as previously observed within HAdV-5.  These E1As also 
target the D/D domains of PKA regulatory subunits as the binding interface in the same 
manner as cellular AKAPs (Banky et al., 1998; Newlon et al., 1999).  Furthermore, an 
AKAP-like motif in the E1A N-terminus containing a putative α-helical structure is 
responsible or at least contributory to this interaction.  E1A proteins from HAdV-3, -5, 
and -9 all contain this motif, which strongly resembles the PKA-binding region of 
cellular AKAPs.  This similarity indicates strong mechanistic conservation.  HAdV-12 
E1A also contains such a motif, but also utilizes a second, downstream region 
contributing to this E1A-PKA interaction.  This finding confirms the previously 
unexplored observation that HAdV-12 E1A bound PKA via two different N-terminal 
regions (Fax et al., 2001).  While recent studies of cellular AKAPs have revealed the 
ever-increasing diversity of PKA-binding motifs (Burgers et al., 2015), this secondary 
region bears no obvious similarity to the canonical α-helical domain utilized by cellular 
AKAPs.  It is possible that the largely unstructured nature of E1A allows for a second, 
novel binding site to form in solution, which strengthens PKA-binding, a feature 
observed with other targets of E1A (Ferreon et al., 2013).  This finding also reveals that 
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viral protein sequences outside canonical AKAP mimics may be capable of regulating 
PKA in both normal and infected conditions. 
During infection, multiple HAdV species induced a subset of PKA regulatory subunits to 
relocalize from the cytoplasm to the nucleus.  Transfection-based experiments using a 
range of E1A deletion mutants for each HAdV species confirmed that this phenotype was 
dependent on the PKA-binding motifs of E1A.  Different E1As had differing effects on 
specific PKA regulatory subunit types.  While E1A from HAdV-3, -5, -9, -12, and -40 
could all bind PKA in separate Co-IP experiments, HAdV-3 and -12 E1A specifically 
relocalized the RIIα subunit, whereas HAdV-5 and -9 E1A preferred the RIα subunit.  
HAdV-40 E1A does not display any ability to relocalize PKA, suggesting that the 
interaction may not be functionally relevant in vivo.  The relative differences in binding 
affinities between E1A species and PKA isoforms was confirmed in competition assays, 
reinforcing the idea of type-preference.  These data are consistent with previous reports 
on E1A-PKA interactions for HAdV-5 and -12 (Fax et al., 2001; King et al., 2016a) and a 
type-preference is also a feature of many cellular AKAPs (Gold et al., 2006).  This is also 
the first report of both HAdV-3 and -9 E1A acting as ‘viral AKAPs’ and explores the 
molecular determinants of this conserved E1A function in the greatest detail to-date. 
Our established viral AKAP model suggests that E1A uses the direct interaction with 
PKA regulatory subunits as a bridge to associate with the catalytic subunit, Cα (King et 
al., 2016a).  Cα was previously shown to be recruited to the promoters of E1A-regulated 
viral genes and was capable of enhancing transcription from these sites (King et al., 
2016a).  It is unclear if the preference for either RIα or RIIα confers the same, or different 
benefits and this could also be context dependent based on cell or tissue-specific 
expression levels.  The ability to target both regulatory types may also serve as an 
evolutionary redundancy ensuring the crucial interaction with PKA’s catalytic component 
regardless of the availability of individual PKA subunits.  To explore this, we deprived 
cells of RIα protein using siRNA then infected with HAdV-5.  In these conditions, where 
the preferred isoform for HAdV-5 is absent, some relocalization of RIIα occurred.  
Although the degree of relocalization was reduced, this may be related to HAdV-5’s 
relatively lower binding affinity for RIIα.  Nevertheless, this result suggests that the 
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potential to bind both type-I and -II PKA to at least some extent could be advantageous to 
HAdV as they may, to a degree, compensate for each other. 
While the hydrophobic component of the PKA-binding amphipathic α-helix is a 
necessary feature in both cellular and viral AKAPs (Gold et al., 2006; King et al., 2016a), 
adjacent residues confer critical electrostatic interactions and contribute to the preference 
for either RIα or RIIα (Burgers et al., 2015).  We explored this feature in the context of 
HAdV E1A by successfully creating mutants in HAdV-3 and -5 E1A that reversed each 
protein’s preference for the different PKA regulatory subunits.  Using previously-
validated residue positions in HAdV-5 E1A that are known to affect PKA-E1A 
interaction (King et al., 2016a), triple point mutants were created in both proteins that 
exchanged these residues in their analogous positions.  Both the novel HAdV-3 and -5 
mutants retained binding to both types of PKA subunits in Co-IP experiments, but their 
abilities to relocalize RIα and RIIα were reversed.  This demonstrates that like cellular 
AKAPs, individual amino acids in viral AKAPs specify their differential affinities for 
distinct PKA subunits, enhancing our knowledge of how type-I, type-II, and dual-
specificity AKAPs function. 
The targeting of PKA by E1A was previously shown to drive transcription of HAdV-5 
early genes via recruitment of Cα to viral promoters (King et al., 2016a).  E1A has also 
been shown to synergize with cAMP (Engel et al., 1991, 1988; Hardy and Shenk, 1988; 
Lee and Mathews, 1997; Müller et al., 1989).  Here we sought to expand upon this 
mechanism by exploring E1A-PKA interactions for various HAdV species in the context 
of the cAMP signaling pathway.  A luciferase reporter driven by the previously-
characterized rat PEPCK promoter (Klemm et al., 1996) was constructed and validated to 
be both cAMP-inducible and PKA-dependent.  E1A proteins from all 7 species of HAdV 
could activate expression from this reporter, which was expected given E1A has multiple 
transactivation domains and mechanisms for inducing transcription (Ablack et al., 2012; 
Bondesson et al., 1994; Duyndam et al., 1996; Pelka et al., 2008; Wong and Ziff, 1994; 
Yousef et al., 2009).  The E1A proteins from viruses that could bind and relocalize PKA 
subunits (HAdV-3, -5, -9, -12) induced this reporter to the greatest extent.  Deletion of 
the PKA-binding regions of these E1As severely handicapped their ability to 
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transactivate this construct.  Residual activation by these mutants was comparable to the 
levels observed for WT E1A species unable to bind PKA.  This confirms that the PKA 
interaction contributes to E1A-mediated transactivation of this PKA-responsive reporter. 
During HAdV-5 infection, notable alterations to the cellular cAMP signalling pathway 
occurred.  Indeed, increased levels of cAMP relative to uninfected cells were observed by 
immunofluorescence, as were higher levels of PKA kinase activity and phosphorylation 
of CREB1 on Ser133.  Most of these observations were consistent across timepoints 
before and after the production of E1A protein as well as between different HAdV-5 
mutants (WT, ΔE1A, and a mutant incapable of binding PKA).  This indicates that the 
stimulation of cAMP signalling is in response to the HAdV infection and independent of 
E1A.  The notable exception to this trend was that in the presence of WT E1A protein, a 
far higher level of phosphorylated CREB1 was observed both by western blot and 
immunofluoresence – where it localized adjacent to and overlapping with virus 
replication centres.  These findings are consistent with our previously-established 
vAKAP model suggesting that E1A exerts its effects on the cAMP pathway not through 
broad changes in 2nd messenger levels or PKA catalytic activity, but rather via the 
localized retasking of PKA to sites of action. While HAdV infection may provoke cAMP 
signalling, a functional vAKAP is needed to fully take advantage of these conditions.  
Notably, all E1A proteins tested also bind CBP, an important co-regulator of CREB via 
an overlapping region of the N-terminus and/or CR3, providing an additional connection 
between E1A and cAMP regulated transcriptional control (Pelka et al., 2009; Rasti et al., 
2005; Shuen et al., 2003). 
Altogether, these data suggest that E1A proteins can integrate into the cAMP signaling 
pathway to drive higher levels of cAMP-modulated gene expression, presumably in a 
localized fashion.  This also suggests the exciting possibility that E1A may be capable of 
differentially regulating the hundreds of cellular cAMP-responsive genes during 
infection.  This mechanism could contribute to enhancing the infectious cycle for HAdVs 
that have a functional E1A-PKA interaction or contribute to the different tropisms and 
disease pathogeneses of distinct HAdV species. 
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The conserved importance of PKA during infection was established by examining viral 
genome replication and progeny production in the context of siRNA-mediated PKA 
knockdowns for multiple HAdV types.  For HAdV-4, which does not bind PKA, 
knockdown of RIα and RIIα did not notably affect either viral DNA replication or 
progeny virion production.  For HAdV-3, -5, -9, and -12, which all have viral AKAPs, 
the loss of PKA regulatory subunits as targets for E1A reduced the efficiency and 
productivity of their replicative cycles.  As previously established for HAdV-5, the E1A-
PKA interaction serves to drive viral gene expression of numerous HAdV genes 
including E2, E3, and E4 (King et al., 2016a).  Many transcripts from these genes encode 
for crucial protein products involved in viral genome replication, transcription, cell cycle 
modulation, and virus-host interactions (O’Shea et al., 2005; van Breukelen et al., 2003).  
Presumably, the shortfall of these critical viral products contributes to the observed 
reduction in infectious progeny virus.  Loss of Cα or all PKA subunits in combination 
negatively affected all viruses tested, including HAdV-4, which expresses an E1A that 
does not target PKA.  This result suggests an additional, E1A-independent role for Cα in 
HAdV infection.  Cα activity was previously shown to be crucial for transport of species 
C HAdV virions to the nucleus during the establishment of infection (Scherer et al., 2014; 
Suomalainen et al., 2001).  Our results suggest other species of HAdV may also use this 
process to kick-start this early stage of their replicative cycles.  The conserved targeting 
of multiple different PKA subunits by various viral components at distinct stages of 
infection underscores the true importance of this cellular kinase for HAdV. 
E1A has been repeatedly shown to be adept at influencing various cellular scaffold and 
multiprotein complexes (Boyer et al., 1999; Glenewinkel et al., 2016; King et al., 2016a).  
To date, E1As from various HAdV species are currently the only well-characterized viral 
AKAPs; however, given the well-connected nature of cellular scaffolds like AKAPs, 
mimicry and manipulation of similar proteins is a strategy exploited by numerous viral 
pathogens (Chemes et al., 2015; Via et al., 2015).  This allows viruses to control 
macromolecular networks or nucleate protein-protein interactions to facilitate their own 
needs (Brito and Pinney, 2017).  By studying how viral regulatory proteins integrate into 
cellular signalling by mimicking scaffolds, we gain comprehension of how viruses 
overcome the daunting challenge of reorganizing their hosts into environments conducive 
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for replication.  Examining protein-protein interactions between viral and host factors 
also offers clinically-relevant insights.  For instance, the manipulation of orthologous 
cellular components within distinct host species (such as PKA) by viral proteins can 
contribute to successful cross-species transmission events.  By understanding these 
events, we learn more about disease tropism or severity.  Also, studying the molecular 
basis of these virus-host interactions provides opportunity to intervene for druggable 
targets, such as with the E1A-CDK9 interaction for various HAdVs (Prasad et al., 2017). 
In summary, we conclusively identified E1A proteins from multiple species of HAdV can 
function as viral AKAPs.  We also confirmed that they structurally and mechanistically 
resemble each other, although some flexibility exists presumably as a result of different 
evolutionary histories.  We have also advanced the understanding of the functional 
mechanism of these vAKAPs by demonstrating their ability to integrate into cAMP 
signaling-dependent transcriptional activation.  Furthermore, we demonstrate that 
vAKAPs play an important, biologically-significant role in enhancing genome replication 
and progeny production for multiple HAdV species. 
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Chapter 4  
4 General Discussion 
“One, remember to look up at the stars and not down at your feet. Two, never give up 
work. Work gives you meaning and purpose and life is empty without it. Three, if you are 
lucky enough to find love, remember it is there and don't throw it away.” 
– Stephen Hawking 
4.1 Thesis Summary 
This body of work describes my studies of the HAdV E1A proteins and the molecular 
determinants of their interaction with cellular PKA.  Specifically, I describe the 
mechanism by which this virus-host interaction occurs and its functional consequences 
during HAdV infections.  In Chapter 2 of this thesis, multiple subunits of PKA were 
shown to be targeted for binding by E1A from HAdV-5 (Figure 2.1).  Using this virus as 
a model, I carried out extensive mutagenesis to map the interaction interfaces on both 
E1A (for HAdV-5) and PKA (Figures 2.1-2.5).  Using a variety of molecular reagents, I 
showed that the manner by which E1A bound PKA strongly resembled that of cellular 
AKAPs (Figure 2.6).  I concluded that this interaction represented a novel case of viral 
mimicry and that E1A is the first known vAKAP.  Furthermore, I demonstrated that the 
interaction was functional during HAdV-5 infections as the interaction allowed E1A to 
recruit PKA into the nucleus, specifically to HAdV early gene promoters at viral 
replication centres (Figures 2.7-2.9).  E1A’s ability to act as a vAKAP enhanced viral 
transcription, protein synthesis, and infectious progeny production for HAdV-5 (Figures 
2.10-2.13).  In Chapter 3, I extended these studies to encompass representative E1A 
proteins from all seven species of HAdV (A-G).  The protein-protein interactions 
between different types of E1A with various PKA subunits (and the mechanism by which 
they occurred) were largely conserved across most species of HAdV (Figure 3.1-3.3).  
Interestingly, different E1As appeared to have a preference for one isoform of PKA R-
subunit over another, leading to different relocalization phenotypes in transfected and 
infected cells (Figures 3.4, 3.6-3.10).  Both vAKAP mimicry and relocalization of PKA 
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subunits during infection were demonstrated to be conserved requirements for full, WT-
levels of viral replication for 4 distinct HAdV species (Figure 3.13B).  I also increased 
the mechanistic knowledge of how PKA enhances the viral life cycle by showing it 
contributes both to efficient viral genome replication as well as E1A-mediated activation 
of cAMP-responsive promoters (Figures 3.5, 3.11-3.13A).  Overall, my work has 
uncovered and characterized a novel example of viral mimicry carried out by the E1A 
proteins of multiple HAdVs that repurposes a host target to benefit viral infection. 
4.2 The interaction between E1A and PKA 
The protein-protein interactions between E1A and PKA were first discovered in 2001 
(Fax et al., 2001).  Specifically, direct interactions between HAdV-12 E1A and both RIα 
and RIIα were reported, but this was only briefly explored.  PKA, already a well-
characterized kinase, was shown to have its RIIα subunit relocalized to the nucleus in 
E1A-transfected cells.  This was further shown to contribute to expression of a HAdV-12 
E2 reporter construct.  Given the ever-increasing array of genetic and molecular tools 
available for HAdV-5, we sought to further explore the E1A-PKA interaction in the 
context of this better-characterized HAdV. 
Our interaction studies began by reproducing the previously observed HAdV-12 findings 
using HAdV-5 E1A in both transfected and infected conditions.  Using siRNA-mediated 
gene silencing, we also showed that the interactions with PKA R-subunits conferred an 
indirect association with PKA’s catalytic component, Cα.  Through extensive 
mutagenesis of both E1A and PKA, the binding sites on both partners were mapped in 
fine detail.  I determined that a small portion of the N-terminus of E1A was both 
necessary and sufficient for binding PKA subunits, both in transient transfection assays 
and HAdV-5 infections.  Deletion or truncations affecting amino acids 14-28 of E1A 
abrogated the interaction whereas mutations in adjacent or downstream areas had no 
effect.  Structural modelling strongly indicated that the amino acid sequence in this 
region of E1A formed an amphipathic α-helix that resembled the analogous PKA-binding 
motifs in cellular AKAPs.  Additional deletion and point mutants designed to test this 
hypothesis (based on known PKA/AKAP structures) confirmed our prediction of 
structural mimicry to be accurate.  E1A also bound to PKA’s D/D domain, the identical 
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binding site of cellular AKAPs, further strengthening the narrative of viral AKAP 
mimicry. 
All experiments in this thesis utilized the α-isoforms of PKA subunits (RIα, RIIα, and 
Cα) encoded by the human PRKAR1A, PRKAR2A, and PRKACA genes, respectively 
(Canaves and Taylor, 2002; Skalhegg and Tasken, 2000; Søberg et al., 2013; Turnham 
and Scott, 2016).  An interaction with the β-subunit isoforms was briefly explored both 
by our lab and the previous HAdV-12 group, but no interaction with either HAdV-5 or 
HAdV-12 E1A species was observed (Fax et al., 2001; King et al., 2016).  This does not 
rule out the possibility that E1As from the other species of HAdV are able to bind and 
manipulate PKAβ, but this was not examined.  A γ isoform of the catalytic subunit also 
exists in humans, but is only expressed in the testis (not a tissue site typically infected by 
HAdVs) (Berk, 2013). 
4.3 Mimicry of cellular AKAPs by E1A 
Given both the sequence and putative structural similarities of E1A’s AKAP-like motif, I 
hypothesized that E1A was also capable of functioning like a cellular AKAP.  This was 
investigated using both transfection- and infection-based experiments.  Because HAdV-5 
E1A can bind to both type-I and –II regulatory subunits of PKA, it is potentially a ‘dual-
specificity’ AKAP (Carlson et al., 2006; Gold et al., 2006).  We first examined if the 
PKA-binding motif (aa14-28) in E1A could functionally complement a binding defect in 
a known dual-specificity AKAP, D-AKAP1.  Indeed, a deletion mutant of D-AKAP1 that 
lacked its PKA-binding ability was rescued back to WT levels when aa14-28 of HAdV-5 
E1A were cloned in its place.  Next, high-affinity, in silico-designed peptide inhibitors of 
AKAP-PKA interactions were pitted against E1A in transfected conditions to test for 
their ability to similarly disrupt E1A-PKA binding.  As with cellular AKAPs, RIAD and 
sAKAPis specifically blocked E1A binding to RIα and RIIα respectively.  Finally, in 
HAdV-5-infected cells, I showed that WT E1A expression outcompeted endogenous, 
dual-specificity AKAP7 for binding PKA subunits whereas a mutant virus lacking E1A’s 
AKAP-like motif could not.  Collectively, these experiments established new molecular 
tools for probing PKA and AKAP complexes in the context of HAdV infection.  
Additionally, reagents previously used exclusively to study cellular AKAPs are 
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demonstrably useful for examining viral AKAPs as well.  While E1A was functionally 
analogous to 2 tested AKAPs (D-AKAP1 and AKAP7), there are over 30 cellular AKAPs 
variably expressed in human cells (Taylor et al., 2012; Welch et al., 2010; Wong and 
Scott, 2004).  How E1A may or may not compete against these other endogenous PKA 
scaffolds remains to be elucidated.   
The mimicry of AKAPs by E1A caused a relocalization of PKA regulatory subunits from 
the cytoplasm to the nucleus in both transfected and infected cells.  This served to bring 
PKA proteins into closer proximity with viral replication centres and caused an E1A-
mediated increase of the catalytic Cα subunit on the promoters of HAdV-5 early genes.  
The retargeting of PKA to specific sites of action is the hallmark of AKAP functionality.  
Given that not all PKA protein is trafficked into the nucleus by E1A, it remains to be seen 
if E1A-PKA interactions serve functions at other cellular loci or compartments.  
Furthermore, the stoichiometric nature by which E1A acts as a scaffold to concurrently 
bind multiple components of the cAMP signaling pathway is unclear.  E1A’s interactions 
with p300/CBP have been well-studied, and it has also been shown to potentially bind 
cAMP-regulated transcription factors, such as CREB and ATFs (Eckner et al., 1994; Fax 
et al., 2000; Ferrari et al., 2014, 2008; Liu and Green, 1994).  Including PKA, many of 
these interactions take place on E1A’s N-terminus.  If at least some of these interactions 
occur concurrently, it’s possible that these multiple, related interactions affect regulation 
of each other by either enhancing or occluding binding.  However, these precise details 
have yet to be determined.  Novel HAdVs encoding mutant E1As that specifically lack 
binding to one (or more) of these targets could shed light on which downstream functions 
result from independence or cooperation of these overlapping interactions. 
4.4 Viral retasking of PKA to enhance infection 
The physiological consequences of E1A’s ability to usurp PKA were examined to gauge 
how they might benefit HAdV infection.  Overall, E1A’s role as a vAKAP was required 
for multiple aspects of the HAdV life cycle including WT levels of viral transcription, 
genome replication, protein synthesis, and progeny production.  For HAdV-5, viral genes 
that displayed recruitment of Cα to their promoters in an E1A-dependent manner 
experienced enhanced transcription from these loci.  This largely correlated with what 
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was subsequently observed at the protein level.  Ultimately, the production of both viral 
genomes and infectious progeny virus were reduced in the absence of an E1A-PKA 
interaction.  It’s likely that the lack of expression from the HAdV-5 E2 gene (which 
encodes viral genome replication machinery) contributes to this reduction in viral DNA 
levels (Challberg and Kelly, 1979; Levine et al., 1976; van der Vliet and Levine, 1973).  
It’s also possible PKA may have a more direct role in viral DNA synthesis at viral 
replication centres as has been shown for cellular DNA replication, but this has not been 
investigated (Costanzo et al., 1999).  The overall lack of progeny production is likely due 
to the shortfall of crucial viral proteins that are under-expressed in the absence of E1A 
being able to repurpose PKA. 
Various mechanistic details of PKA’s role in the HAdV life cycle remain unclear, 
however both HAdV-5 and E1A’s ability to alter the catalytic activity of Cα was briefly 
explored.  HAdV infection was capable of globally enhancing cellular cMAP levels and 
PKA kinase activity.  The phosphorylation status of PKA targets (such as CREB) appears 
directly affected by E1A’s interaction with PKA, suggesting that its vAKAP function 
allows HAdV to take advantage of stimulation of cellular cAMP signaling post-infection.  
It would be also be of interest to test if the phosphorylation status of other PKA-regulated 
TFs is altered at viral promoters and if this was dependent on E1A’s role as vAKAP.  
Furthermore, the phosphorylation status and downstream functional consequences for 
other classes of PKA substrates has yet to be examined.  It is possible the relocalization 
of Cα’s kinase activity affects both nuclear and non-nuclear processes unrelated to gene 
expression.  Lastly, PKA may be a suitable drug target for inhibiting viral infections as 
inhibition of broad-specificity kinases has been successfully utilized in the past for 
ablating virulence of HAdV (Prasad et al., 2017).  Given that PKA is utilized by the virus 
at multiple stages of its life cycle (Bremner et al., 2009; King et al., 2016; Scherer et al., 
2014), PKA disruption (by either catalytic or anchoring inhibitors) may slow or abrogate 
the infection more potently than typical single-target drugs (provided there is no general 
toxicity to the infected host).   
Another unanswered question pertaining to the E1A-PKA interaction is whether or not 
E1A is a substrate for the kinase.  Phosphorylated forms of HAdV-5 E1A and the 
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targeted residues have been studied in detail.  Phosphorylation is limited largely to serine 
residues, particularly Ser-89, -132, -185, -188, -219, and -231 in HAdV-5 E1A (Dumont 
et al., 1993; Dumont and Branton, 1992; Mal et al., 1996; Whalen et al., 1997, 1996).   
E1A is considered to be modified in this fashion predominantly by cyclin-dependent 
kinases (Cdk), MAPK, and casein kinase II (CKII).  However, Ser-219 is a strong 
substrate for the DYRK1A kinase as well, and this PTM confers a downstream 
interaction with the FOXK1/2 transcription factors (Glenewinkel et al., 2016; Komorek et 
al., 2010).  Therefore, E1A’s phosphorylation status is important to understand, as it 
affects binding to several key partners (including Rb) and has been shown to affect its 
transforming ability (Dumont et al., 1993; Mal et al., 1996).  Whether PKA itself can 
phosphorylate Ser or Thr residues on E1A has not been tested.  However, we can 
speculate that it is unlikely given that alternatively-migrating bands were consistently not 
observed in protein gels from experiments where Cα was either over- or under-expressed.  
Additionally, there are only two sites in HAdV-5 E1A that somewhat resemble the PKA 
consensus site; one surrounding Thr-164 and the other encompassing Thr-218 (although 
neither of these sequences are conserved across any other HAdV species) (Avvakumov et 
al., 2004; Jones et al., 2007).  Threonine is a much lower-affinity substrate than Ser for 
PKA catalysis, however, and these sites also lack the adjacent hydrophobic residue 
typically found in PKA substrates (Masterson et al., 2010; Shabb, 2001). 
4.5 Conservation of viral AKAPs 
Conservation of the E1A-PKA interaction was briefly examined in Chapter 2 but the 
majority of experiments in that chapter focused only on E1A from HAdV-5.  In the 
follow-up study to these findings (Chapter 3), similar experimental approaches were 
utilized to examine the N-terminus of E1A from all 7 HAdV species.  This portion of 
E1A was necessary and sufficient to bind RIα, RIIα, and Cα for 5 of 7 HAdV types 
tested: HAdV-12, -3, -5, -9, and -40 (representing species A, B, C, D, and F respectively).  
E1A from HAdV-4 and -52 (representing species E and G) did not associate with any 
PKA subunit.  The interaction between PKA and HAdV-40 E1A was also notably weaker 
in CoIP assays.  The overall conservation of the E1A-PKA interaction across highly 
divergent HAdVs potentially indicates importance and the observed differences between 
176 
 
 
species likely stem from the distinct evolutionary histories of each virus.  Indeed, E1As 
which did not bind or bound weakly (from species E, F, and G) are more closely related 
to simian adenoviruses or arose as cross-species recombinants (Dehghan et al., 2013; 
Jones et al., 2007).  These E1A proteins from those viruses are not predicted to contain 
the same level of helical structure in their N-terminus, likely explaining their lack of 
interaction with PKA’s D/D domain.  Consequently, these E1As were incapable of 
relocalizing PKA subunits in either transfected or infected cells.  Also, viral genome 
replication and progeny production for HAdV-4 was not affected by siRNA-mediated 
silencing of RIα and RIIα expression.  These HAdV species may not have evolved the 
means or need for manipulating human PKA subunits to enhance their viral life cycles.  It 
is unlikely that related SAdV E1A proteins are capable of binding simian PKA proteins 
given the lack of predicted structure in the E1A N-terminus of these viruses.  Amino acid 
sequences of PKA R-subunits are incredibly well-conserved among primates (99% 
identity between humans and macaques, for example) as is the structural basis for 
AKAPs binding to PKA D/D domains (Carlson et al., 2006; Gold et al., 2006; Kannan et 
al., 2007; Taylor et al., 2012).  It is therefore more likely that the ability for some HAdV 
E1As to act as vAKAPs arose from extended coevolution with humans as a result of 
providing some selective benefit for the virus within this host.  
For HAdVs that did bind and relocalize PKA subunits, they required PKA for viral 
genome replication and progeny production, as well as E1A-mediated transactivation of a 
cAMP-responsive gene.  Interestingly, a distinct preference for affecting either RIα or 
RIIα was observed.  Specifically, HAdV-5 and -9 relocalized RIα to the nucleus, whereas 
HAdV-3 and -12 relocalized RIIα.  Preference for one PKA isoform over another is a 
common feature of cellular AKAPs (Welch et al., 2010; Wong and Scott, 2004), which is 
evidently also the case for viral AKAPs.  This preference could be altered and swapped 
within different E1As using targeted mutagenesis of critical residues (predicted in silico), 
suggesting the AKAP-like helix in E1A is an evolutionarily flexible motif.  The 
biological significance for preferring either R1α or RIIα is unknown.  It may simply be an 
artefactual byproduct of divergent evolution between these viruses.  Alternatively, it may 
contribute to virulence in different cells or tissues where PKA subunit expression profiles 
differ (Skalhegg and Tasken, 2000).  Along these lines, in cells lacking RIα protein 
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expression, HAdV-5 E1A was able to switch and relocalize RIIα.  It may be that being 
able to bind both RIα and RIIα to some degree is a redundancy that ensures the crucial 
downstream association with Cα, no matter what the availability of PKA proteins is. 
4.6 Usurping PKA to alter host cell transcription 
Significant amounts of research on both E1A and PKA have focused on their respective 
abilities to regulate cellular gene expression.  I focused most of my attention towards 
effects on viral transcription and the downstream consequences on HAdV replication 
(Chapters 2 and 3).  However, given the amount of relocalized PKA observed during 
HAdV infection, it seems extremely likely that its interaction with E1A also affects host 
genes in a manner similar to viral ones.  There have been numerous studies which 
separately surveyed the effects of either E1A or PKA on the human transcriptome, 
although no published dataset yet exists that examines E1A’s effects specifically on 
PKA-regulated genes (Ferrari et al., 2014, 2008; Horwitz et al., 2008; Radko et al., 2015; 
Zhang et al., 2005).  This is an attractive area of future study as both E1A and PKA can 
potentially regulate thousands of host genes on their own and E1A has been previously 
shown to synergize with cAMP signalling to affect transcription (Brockmann and Esche, 
2003; Engel et al., 1991, 1988; Hardy and Shenk, 1988; Lee and Mathews, 1997; Müller 
et al., 1989).   
Using NGS, the Mymryk laboratory previously produced a dataset of differentially-
regulated genes in primary cells infected by a variety of HAdV-5 mutants (Appendix A).  
Additionally, information from publicly available datasets was extracted and queried 
across the entire human genome for cAMP response elements (CRE) in their promoters 
(Zhang et al., 2005).  To gain a foothold into understanding the potential impact of E1A 
on PKA-regulated genes during HAdV infection, we cross-referenced these data together.  
Using Python (Appendix B) a subset of genes was selected whose expression was altered 
more than 2-fold up or down in cells infected with WT HAdV-5 (dl309) versus ΔE1A 
HAdV-5 (dl312).  These candidate genes were then trimmed to include only those 
containing a verified CRE (as a surrogate marker for possible PKA-regulation) in either 
their proximal (<300bp from TSS [transcriptional start site]) or distal (>300bp from TSS) 
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Figure 4.1.  Host cell genes potentially regulated via E1A’s interaction with PKA. 
(A)  Workflow of the analyses.  Raw NGS data from the Mymryk laboratory was 
converted into tabular format and information on CREs in human gene promoters was 
extracted from publicly available datasets (Zhang et al., 2005).  All data were 
subsequently processed using the Python programming language.  Host genes that were 
up- or down-regulated at least 2-fold in WT-infected cells versus ΔE1A-infected cells 
were selected for further analysis.  These candidates were then trimmed to include only 
those with verified CREs in their upstream regulatory regions.  (B)  Results of 
comparison of differentially-expressed genes in WT- versus ΔE1A-infected cells and 
genes with CREs in their promoters.  The number of candidate genes of interest that met 
all criteria in these analyses (and are therefore potentially modulated by the E1A-PKA 
interaction) is highlighted in the overlapping region of the Venn diagram.  (C)  Lists of 
significantly impacted KEGG pathways and GO terms based on candidate genes. 
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promoter regions.  After removing duplicated or outlier genes that had low read numbers, 
we obtained a set of putative PKA-regulated host genes was obtained whose expression 
may be altered by E1A (Figure 4.1).   
A total of 888 candidate genes were identified, with 557 being upregulated and 331 being 
downregulated.  As a positive control, a previously-validated gene (proliferating cell 
nuclear antigen [PCNA]) was found amongst the list of upregulated genes (Lee and 
Mathews, 1997).  This dataset of differentially-expressed genes was then analyzed in the 
context of pathways obtained from the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) (Kanehisa et al., 2002; Kanehisa and Goto, 2000) and gene ontology from the 
Gene Ontology Consortium database (Ashburner et al., 2000).  Both these analyses were 
facilitated by the Database for Annotation, Visualization, and Integrated Discovery 
(DAVID) website (Huang et al., 2009, 2008).  The most significantly affected KEGG 
pathways were those involved in cell cycle, viral infections, and various cancers.  
Similarly, the most significantly enriched GO terms impacted cellular processes such as 
transcription, DNA replication, and cell cycle control.  These hits strongly align with 
E1A’s known functions during HAdV infection (Bayley and Mymryk, 1994; Berk, 2005; 
Pelka et al., 2008).  They also suggest that an interaction with PKA may contribute to the 
ability of E1A to fine-tune transcription in infected cells to establish an environment 
more favourable for HAdV replication.   
These analyses should not be used as license to start inefficiently testing individual genes, 
but rather as a general representation of the likelihood and scale of E1A’s ability to 
modulate cAMP-responsive genes.  How E1A uses PKA to modulate host cell 
transcription to affect downstream processes such as cell cycle or DNA replication 
remains an exciting and open area of investigation.  Using my mapping studies, 
construction of HAdV mutants encoding E1A that cleanly lack binding to only PKA 
would be powerful tools aiding future work of this nature.  Genome-wide RNAseq 
experiments on primary cells infected by such viruses would yield powerful results and 
could validate which hits from these preliminary analyses are real and reproducible.  
Additional ChIPseq experiments would shed light on which genes showed the presence 
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of E1A, PKA, or phosphorylated targets of PKA (such as CREB) to their promoters.  It’s 
possible that E1A may be inducing a global deregulation of cellular cAMP signaling to 
modulate hundreds of cellular genes, but this will need to be thoroughly investigated. 
4.7 Contribution of E1A-PKA interaction to oncogenic 
transformation 
HAdV E1A (and oncoproteins from other DNA tumour viruses) have repeatedly served 
as powerful tools for discovering cancer-relevant genes (Rozenblatt-Rosen et al., 2012).  
E1A’s role in oncogenic transformation stems primarily from its ability to drastically 
rewire host protein-protein interactions (Bayley and Mymryk, 1994; Pelka et al., 2008).  
Interestingly, the same N-terminal portion of E1A protein that binds PKA is also required 
for its transformation activity (Chinnadurai, 2011; Jelsma et al., 1989; Subramanian et al., 
1988; Whyte et al., 1988).  This has been largely linked to E1A’s crucial interaction with 
p300/CBP (Egan et al., 1988; Howe et al., 1990; Howe and Bayley, 1992; Wang et al., 
1993).  However, many of the mutants used in such studies contain large deletions or 
point mutations which affect multiple E1A binding partners in this promiscuous portion 
of the protein (Boyd et al., 2002; Loewenstein et al., 2006; Rasti et al., 2005) (Figure 
1.8).  Also, some mutants which retain binding to p300 in vivo still have reduced 
transforming ability, confirming that other N-terminal binding partners are involved in 
E1A-mediated transformation.  Therefore, a potential role for the E1A-PKA interaction 
would need to be thoroughly and cleanly investigated.   
While PKA is not typically considered an oncogene or tumour suppressor, it has been 
studied in the context of several cancer types or as a molecular component in cancer-
relevant pathways (Gold et al., 2013; McKenzie et al., 2011; Palorini et al., 2016; 
Pattabiraman et al., 2016).  One way the E1A-PKA interaction could contribute to 
transformation is through effects on host gene expression (discussed above).  
Alternatively, E1A-mediated relocalization of PKA to different cellular compartments 
could affect phosphorylation status of targets unrelated to transcription (such as those 
involved in DNA synthesis or cytoskeletal remodeling).  E1A would of course be 
valuable as a tool to probe this hypothesis and enhance molecular knowledge of these 
biological pathways.  Specifically using mutants lacking PKA-binding ability, 
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transformation assays on either baby rat kidney or even human cells would yield clear 
evidence of a role for this host factor in the transformation process (Massimi and Banks, 
2005; Vijayalingam et al., 2016). 
4.8 Prevalence of cellular scaffold mimics in the viral 
universe 
Mechanisms that regulate the spatial and temporal control of proteins involved in cellular 
signaling offer an appealing target for viral manipulation.  Cellular scaffold or adaptor 
proteins typically bind multiple components of signaling pathways (including residue-
modifying enzymes and their cognate substrates) and localize them to distinct subcellular 
loci (Taylor et al., 2012; Welch et al., 2010; Wong and Scott, 2004).  These highly-
connected hubs thus nucleate the formation of signalosomes that more efficiently perform 
pleiotropic functions in various signal transduction pathways.  Hijacking a host’s 
interaction network by altering or mimicking cellular scaffolds is widespread among 
viruses, indicative of it being a broadly beneficial strategy (Davey et al., 2011). 
In addition to AKAPs, many cellular scaffolds have been shown to be targeted for 
manipulation or mimicry by a range of diverse viruses such as Epstein-Barr virus (EBV), 
vaccinia virus (VACV), measles virus (MeV), Kaposi’s sarcoma-associated herpes virus 
(KSHV), HIV, IAV, mumps virus (MuV), and even walleye dermal sarcoma virus 
(WDSV).  These host targets include KSR1 (kinase suppressor of ras; which assembles 
components of the RAS-ERK pathway) (Lee et al., 2008), NLRPs (NACHT, LRR and 
PYD domains-containing protein; helps assemble the inflammasome) (Gerlic et al., 2013; 
Gregory et al., 2011; Komune et al., 2011), RACK1 (receptor of activated protein C 
kinase; tethers components of protein kinase C [PKC] signaling) among numerous others 
(Baumann et al., 2000; Daniels et al., 2008; Demirov et al., 2012; Gallina et al., 2001; 
Kubota et al., 2002; Mondal et al., 2017).  E1A itself has been shown to use the cellular 
adaptor, DCAF7 (DDB1- and CUL4-associated factor 7), to gain access to DYRK1A and 
HIPK2 kinases (Glenewinkel et al., 2016); E1A has also been reported to bind RACK1 
itself (Sang et al., 2001).  Clearly, the manipulation of host scaffold proteins is ubiquitous 
among viruses and offers a large window into examining virus-host interactions at the 
protein level.   
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While E1A proteins from various HAdVs are described here as the first (and only) known 
viral AKAPs, it would not be surprising to discover other functionally analogous viral 
mimics (Brito and Pinney, 2017; Chemes et al., 2015; Via et al., 2015).  Newly-refined 
bioinformatics tools have recently demonstrated an increased ability to predict and 
discover AKAPs and PKA-binding motifs (Carlson et al., 2006; Gold et al., 2006).  One 
study was able to translate these in silico predictions into the discovery of a new, bona 
fide human AKAP (Burgers et al., 2015).  It would be interesting use similar 
methodology to probe the proteomes of viruses to potentially uncover vAKAPs outside 
the HAdV family.  Additionally, my work has enhanced the knowledge of how flexible 
AKAP-like motifs can be, increasing the number of undiscovered sequences potentially 
capable of binding PKA. 
4.9 Concluding remarks 
HAdV E1A continues to prove itself as an excellent molecular tool for studying protein-
protein interactions between viruses and hosts.  Investigations into these interactions has 
contributed greatly to our collective understanding of numerous processes in both viral 
and cellular biology.  These include (but are not limited to) transcription, splicing, cell 
cycle, innate immunity, nuclear import, transformation, and cancer (Berk, 2005; Cohen et 
al., 2014; Fonseca et al., 2012; Pelka et al., 2008; Rozenblatt-Rosen et al., 2012).  My 
work described in this thesis advances this research by providing new insights into the 
molecular biology of both E1A and one of its cellular binding partners, PKA.  
Mechanistic studies of how this interaction occurs revealed a novel example of viral 
mimicry by HAdV, and the tools generated have laid the groundwork for future studies to 
search for other viral AKAPs.  Furthermore, my work demonstrated previously-unknown 
roles for PKA in HAdV biology, including early gene transcription, protein synthesis, 
genome replication, and progeny production.  This was also examined across all seven 
species of HAdV, revealing new insights into the evolutionary histories of E1A proteins 
from these viruses.  Moving forward, my data have identified potential roles for PKA in 
E1A-mediated regulation of host gene expression and cellular transformation, which 
could be the subject of follow-up projects.  Therefore, despite over 30 years of intense 
genetic and biochemical characterization, the E1A protein of HAdV still has much more 
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to provide for scientists yearning to understand the molecular biology of both viruses and 
cells. 
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Appendices 
Appendix A:  Methods for generating high-throughput RNAseq tabular dataset. 
Global cellular gene expression was examined during infections with a variety of HAdV 
mutants.  These experiments were carried out in primary human lung fibroblasts (IMR-
90) at a multiplicity of infection (MOI) of 25, 48 hours post-infection.  This represents a 
relatively early timepoint post-infection in primary cells.  Library prep from total RNA 
and high-throughput sequencing was performed on the Ilumina HISeq 2500 at the UCSD 
Genomics Centre.  Sequences returned were aligned against the human hg19 reference 
genome (genome reference consortium human build 37) using the ELAND software.  
Initial data analysis, including normalization of sequencing reads and changes in gene 
expression, was performed using the HOMER software suite.  This pilot experiment was 
performed only once using 6 unique viruses/conditions: (mock-infected IMR-90 cells, 
wild-type HAdV-5, ΔE1A HAdV, and 3 additional E1A point/deletion mutants targeting 
specific sites for E1A-binding partners).  In total, data on 36640 unique transcripts were 
returned. 
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Appendix B:  Python scripts used to analyze RNAseq and human promoter datasets. 
""" 
This script takes a tab-delimited .txt file containing the normalized RNAseq results data and extracts the data 
columns of interest. 
""" 
import sys 
input = sys.argv[1]  # call script on filename of choice 
  
handle = open(input, 'rU') 
_ = handle.readline() 
outfile = open('output1.csv', 'w') 
  
# extract 3 desired data columns 
for line in handle:  
    items = line.strip('\n').split('\t') 
    accession = items[0] 
    annotation = items[7] 
    annotation_edited = annotation.replace(',', '') # removes some problematic commas from within annotation field 
    foldchange = items[34] 
    outfile.write(','.join([accession, annotation_edited, foldchange]) + '\n') # data is now comma-delimited like other 
files 
  
handle.close() 
 
""" 
This script takes the output from script1.py (output1.csv) containing our 36640 transcripts of interest and excludes 
all transcripts with uninteresting or negligible changes in expression 
""" 
handle = open('output1.csv', 'rU') 
outfile = open('output2.csv', 'w') 
  
# trim down results to genes with at least 2-fold change in expression  
for line in handle: 
    items = line.strip('\n').split(',') 
    foldchange = items[2] 
    if foldchange.startswith('0'): 
        continue # ignore results that have a positive logFoldChange less than 2-fold 
    elif foldchange.startswith('-0'): 
        continue # ignore results that have a negative logFoldChange less than 2-fold 
    outfile.write(line) 
  
handle.close() 
 
""" 
This script takes a .csv-formatted list (CREpredictions.csv) of computationally-predicted fucntional cAMP 
response elements (CRE) on promoters of human RefSeq genes and extracts the data columns of interest. 
""" 
import csv  # easier handling of csv files 
import sys 
  
input = sys.argv[1]   # call script on filename of choice 
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with open(input) as handle: 
    reader = csv.reader(handle) 
    outfile = open('output3.csv', 'w') 
    _ = next(reader) 
    for line in reader:  # extract desired data columns 
        accession = line[2] 
        cre_prediction = line[5] 
        outfile.write(','.join([accession, cre_prediction]) + '\n') 
  
handle.close() 
 
""" 
This script takes the output from script3.py (output3.csv) containing our 20769 gene promoters of interest and 
excludes all that have no predicted CRE. 
""" 
import csv  # easier handling of csv files 
  
with open('output3.csv') as handle: 
    reader = csv.reader(handle) 
    outfile = open('output4.csv', 'w') 
    for line in reader: 
        accession = line[0] 
        cre_prediction = line[1] 
        if 'others' in cre_prediction:  # remove all genes that don't have a predicted CRE 
            continue 
        outfile.write(','.join([accession, cre_prediction]) + '\n') 
  
handle.close() 
 
""" 
This script takes the data columns filtered from the two starting files and combines their contents using a 
dictionary. 
"""  
import csv  # easier handling of csv files 
outfile = open('output5.csv', 'w') 
  
dictionary = {} 
  
reader1 = csv.reader(open('output2.csv')) 
for row in reader1: 
    key = row[0]  # establish accession numbers as keys 
    if key in dictionary: # avoid repeating keys, just in case 
        continue 
    dictionary[key] = row[1:]  # establish values as a list of other data values 
  
reader2 = csv.reader(open('output4.csv')) 
for row in reader2: 
    if row[0] in dictionary:  # check for existing keys (accession numbers) 
        dictionary[row[0]].append(row[1])  # if key found, append dictionary with CRE prediction! 
  
# write out dictionary to comma-delimited format  
for key, value in dictionary.items(): 
    data = ','.join(str(datum) for datum in value) 
    outfile.write(','.join([key, data]) + '\n') 
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outfile.close() 
 
""" 
This script performs final edits and formatting to the output from script5.py (output5.csv). 
""" 
handle = open('output5.csv', 'rU') 
outfile = open('rna_cre_combined_final.csv', 'w')  # final output file name 
  
for line in handle: 
    items = line.strip('\n').split(',') 
    if len(items) > 3:  # get rid of entries which don't contain all 4 desired data values 
        outfile.write(','.join(items[0:4]) + '\n')  # get rid of any remaining duplicates of CRE data column 
    else: 
        continue 
  
handle.close() 
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